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ABSTRACT
RNA polymerase II (pol II) synthesised RNAs encode fo r proteins (mRNA), aid in 
splicing and telomere maintenance (snRNPs), and down-regulate gene expression 
(microRNAs). Therefore, pol II can be a critical target fo r modulating differential gene 
expression. Understanding mechanisms that underlie the various stages of transcription 
will elucidate origins of gene misexpression, which can give rise to  a host of human 
diseases. Eleven-nineteen lysine-rich in leukaemia, (ELL), affects pol II transcription. The 
ELL gene was initially identified as a gene translocation fusion partner of the mixed lineage 
leukaemia (MLL) gene in patients with acute myeloid leukaemia (I). ELL interacts with pol 
II in vitro, increasing the rate at which it elongates nascent transcripts (2). Two ELL- 
associated factors, EAFI and EAF2, bind ELL family members and act as strong positive 
regulators of their transcription activities (3).
Although ELL and EAF orthologs have been identified in metazoan organisms, 
previous attempts to  identify similar elongation factors in lower eukaryotes had been 
unsuccessful. This thesis describes the identification of tw o genes in the yeast 
Schizosaccharomyces pombe, ell I and eafl, that share some sequence similarity to  highly 
conserved regions in ELL and EAFI/EAF2 (4). Biochemical characterisation of these gene 
products, SpELL and SpEAF, shows that they have similar activities to their metazoan 
counterparts in vitro. Using a whole genome approach, I identified genes that are likely 
direct targets fo r regulation by SpELL/SpEAF in cells. Notably, ELL and EAF functions have 
not been studied previously at a genomic level. One SpELL/SpEAF target, sme2, was used 
as a model gene to  investigate how the SpELL/SpEAF complex is recruited to  chromatin.
Together with results of in vitro binding assays, these results suggest the SpELL/SpEAF 
complex is recruited to pol II via the SpELL subunit.
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CHAPTER 1. INTRODUCTION
1.1 Regulating gene expression
In lower eukaryotes cells perform different functions at different times during the 
cell cycle and survive by responding appropriately to  different environmental situations.
In higher organisms different types of cells perform specialized functions. Different 
complements of proteins are needed at different times and in different cells from the 
same organism for survival. Correct orchestration of gene expression is achieved in 
multiple ways; protein production can be regulated during all stages o f gene transcription 
(initiation, elongation and termination), during RNA processing and transport, during 
translation of mRNA into protein and through the process of protein degradation. The 
earliest stages of protein production involve DN A directed synthesis of RNA transcripts 
by the enzyme RNA polymerase II (pol II) and offer key opportunities fo r regulating gene 
expression. This introduction w ill examine the functions of pol II in transcribing RNA, 
discuss the transcription elongation factor ELL, and introduce S.pombe as a model system 
fo r answering questions about the function of ELL in cells.
1.2 RNA polymerase II transcription
In eukaryotes, there are three nuclear enzymes capable of catalysing the 
polymerisation of ribonucleic acid (RNA) chains from the more stable D N A templates 
used to  store information in cells. Pol I and pol III are largely responsible fo r synthesis of 
the structural RNAs used to  translate messenger RNAs into proteins (pol I synthesises 
the large ribosomal RNAs (rRNA), pol III the smaller 5S rRNA and translation RNAs
(tRNAs))1. Pol II transcribes precursors of messenger RNA (mRNA), many small nuclear 
RNAs (snRNAs), and micro RNAs (miRNAs) used to  control gene expression (6). As in 
other eukaryotes, the S. pombe pol II is composed of twelve subunits. Structurally, it may 
more closely resemble human pol II than its counterpart in baker’s yeast, in particular in 
features related to  transcription factor interaction and start site selection (7). This section 
of the introduction will examine the function of pol II as a catalyst and then follow the 
various roles of pol II through the transcription cycle.
1.2.1 RNA polymerase II as a molecular machine
RNA polymerase II functions to  catalyse the addition of ribonucleotides to  an RNA 
transcript in a D N A template dependent manner (Figure I - 1):
NTP + RNAn ^  RNAn+i + PP,
This reaction, though reversible, is usually driven in the direction o f nucleotide 
addition in cells as inorganic pyrophosphate is removed from the reaction by 
pyrophosphatase. A  magnesium ion (Mg2+) at the active site positions the incoming 
nucleotide by interacting with the cc-phosphate of the NTP. A  second metal ion more 
loosely associated with pol II interacts with, and is possibly removed with, the inorganic 
pyrophosphate of the NTP. The positioning of the NTP by the tw o metal ions enables
1 In addition pol III synthesises a number of o ther types o f RNA including U6 snRNA, a component o f the 
spliceosome (5).
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Figure 1-1 A transcribing ternary complex.
Figure is from (10) ©  Roger Kornberg reprinted with permission. Cross sectional diagram showing 
some structural features of the elongating RNA polymerase II enzyme important for its function. As 
pol II transcribes from left to right, the downstream DNA is unwound and the template strand shown 
in blue is positioned near the 3’ end of the growing RNA chain (red) and the active site magnesium 
ions (pink). Polymerisation of the RNA chain occurs in a template dependent manner as 
nucleotides access the active site via the “funnel” and “pore” . As each nucleotide is added, a 
change in conformation of the bridge helix causes a translocation of the enzyme with respect to the 
DNA / RNA positioning the new 3’ end o f the RNA chain at the active site ready for further 
nucleotide addition. The RNA chain is separated from the template by the rudder and guided 
towards the exit channel. During transcript elongation the enzyme remains stably associated with 
the DNA and RNA; downstream DNA is gripped by a pair o f “jaw s” (only one of which is shown 
here) and nucleic acids are also restrained by a flexible “clam p” which closes over the DNA and 
RNA hybrid during formation of the transcribing complex (9).
nucleophillic attack by the 3’ OH of the RNA transcript, resulting in formation of a 
phosphodiester bond, addition o f the nucleotide, and release of inorganic pyrophosphate 
(8, 9). In vitro, the reverse reaction is favoured when concentrations of PP; are high and 
nucleotide concentrations are low.
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In addition to  this straightforward polymerisation reaction, in which RNA 
polymerase II elongates a transcript that has already acquired sufficient length to  form a 
stable complex, pol II needs to  be able to perform other functions. For example, pol II 
needs to be able to  catalyse the formation of the first phosphodiester bond between tw o 
nucleotides in the absence of a polynucleotide transcript (initiation) and then to  proceed 
through early stages of elongation, where the RNA transcript has not grown long enough 
to occupy the RNA exit channel and stabilize the complex. Pol II also has to  be able to 
remove nucleotides in an attempt to  restart the elongation reaction should the 3’ end of 
the transcript become misaligned w ith the active site (a stalled complex). Finally pol II 
needs to be able to  terminate the elongation reaction and release the transcript at a 
suitable site.
1.2.2 Initiating transcription
The process of forming a stable complex capable of elongating an RNA transcript 
starting from  an appropriate place on the D N A  template is called initiation. The barriers 
to successful initiation depend on the nature of the D N A template presented to  pol II and 
provide ample opportunities fo r regulating gene expression. For example, pol II is capable 
of accurate initiation w ithout the need for accessory factors when presented w ith a 
“ naked “ double stranded piece of D N A to which a single stranded tail has been added to  
the complimentary strand. In this simple in vitro reaction, pol II initiates at the junction 
between the single and double strand. More problematic, and more physiologically 
relevant, is the requirement to initiate from a position within a section of double stranded 
DNA. Here, regulatory DN A sequences such as the TATA box and other core regulatory 
elements direct pol II to  begin transcription at the appropriate site, and a set of general
4
transcription factors is required to  help position pol II, unwind the D N A and form the 
first phosphodiester bonds.
The first step of this process is the formation of a pre-initiation complex (PIC) at 
the promoter. For promoters containing the TATA box, the TBP (Tata Binding Protein) 
subunit o f the general transcription factor TFIID binds to, and bends the DNA, most 
commonly at the sequence 5’-TATAAAA-3\ This serves as a platform fo r the assembly 
of other factors, TFIIA and TFIIB. TFIIA, which is not essential for initiation from TATA 
box containing promoters in vitro (I I), stabilises the interaction between the D N A and 
TBP while TFIIB recruits a pol ll/TFIIF complex and directs transcription to  begin at a 
defined start site downstream of the TATA box (reviewed in I I) .  The heterodimer TFIIF 
was originally identified as a mammalian RNA pol II interacting factor consisting of 
subunits RAP74 and RAP30 and shown to be essential fo r accurate initiation (12). The 
Drosophila factor 5 (TFIIF) was also shown to  stimulate the rate of transcription 
elongation on oligo(dC) tailed templates (13), and this activity will be discussed later. As 
well as targeting pol II to  the PIC, TFIIF also functions to  reduce non-specific interactions 
between pol II and D N A at initiation (14, 15). It has also been proposed that TFIIF 
dependent bending of D N A  within the PIC may facilitate unwinding of promoter DNA 
(16). TFIIH is recruited to  the PIC by TFIIE (17-19).
Once the cast of factors is in place at the prom oter and PIC formation has been
completed, energy from the hydrolysis of ATP is used to  unwind the DN A to  form an
open but unstable complex in preparation fo r transcription initiation (20). The XPB
subunit of TFIIH, a 3 ’-^5 ’ D N A helicase, unwinds the prom oter D N A to  form the open
complex and prevent premature arrest of early elongation complexes (21). It has been
proposed that in S. cerevisiae RNA pol II scans the template D N A  for an initiator 
   —    5
sequence (22); recent structural studies have suggested that start site selection may be 
determined by sequence specific interactions between the D N A template strand and the 
B-reader loop and B-reader helix regions (together also designated the B finger) of TFIIB 
(23, 24). Pol II is now in a position to  begin catalysing the polymerisation of nucleotides, 
but, in the absence of a sufficiently long RNA transcript occupying the enzyme and with 
pol II still tethered to the initiation factors assembled at the promoter, the complex 
remains unstable in the early stages of elongation.
Additional barriers serve to  lim it pol II access to  D N A template in cells. Here the 
DN A is not naked but bound to  nucleosomes. The various mechanisms that are known 
to provide pol II access to  D N A packaged in this way will be discussed later.
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1.2.3 Early stages of elongation
Figure 1-2 TFIIB binds to RNA pol II and blocks the RNA exit channel.
A cutaway view of RNA pol II (grey) with key features highlighted and residues nearer the viewer 
removed. The RNA exit channel (white arrow) which lies between the wall (dark blue) and the lid 
(yellow) is blocked by the B finger domain of TFIIB (bright green). For orientation, other features 
include the bridge helix (red), the active site (purple) and the pore (light blue). The image has been 
produced by highlighting structural features in the file 3K1F.pdb (24) using the UCSF Chimera 
structural package (supported by NIH grant P41 RR-01081) (25) and the final image was 
processed and rendered in Autodesk Maya.
RNA exit
During the early stages of elongation, there are a number of distinct steps that lead
to the formation of a stable ternary complex (reviewed in (26)).
I. The Initially Transcribing Complex (ITC). The start of transcription involves the
formation of the first phosphodiester bond, after which the elongating pol II is 
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referred to  as the initially transcribing complex (ITC). During polymerisation of 
the first 4-5 ribonucleotides, the B-finger of transcription factor TFIIB remains in 
the RNA exit channel and helps to  stabilise the binding of short transcripts to  pol 
II (23, 26). The ITC is unstable, and a number of short transcripts may be 
generated w ithout the initiation complex disengaging from the DN A in a process 
known as abortive initiation. Abortive initiation may be caused by interference 
between the growing RNA and the TFIIB B-finger (Figure 1-2) (24). In eukaryotes 
there is a decrease in abortive initiation after the third phosphodiester bond has 
been formed (27), and the complex has been described as being committed to  
escape from the prom oter (reviewed in (26)).
Figure 1-3 A backtracked pol II bound to TFIIS.
A cross sectional representation o f pol II is shown in a reverse translocated or backtracked state 
with the 3’ end of the RNA transcript (red) misaligned with the active site (purple). A domain of 
TFIIS (green) is inserted into the pore/funnel region of pol II and stimulates cleavage of a 
dinucleotide at the 3 ’ end o f the transcript. Other features included for viewer orientation are the 
wall (dark blue), lid (yellow) and DNA template strand (light blue). The image has been produced 
by highlighting structural features in the file 3GTM.pdb (28) using the UCSF Chimera structural 
package (supported by NIH grant P41 RR-01081) (25) and the final image was processed and 
rendered in Autodesk Maya.
2. Promoter Clearonce. Kostrewa and co-workers describe a model fo r promoter
clearance (escape) in which the nascent RNA triggers the release of TFIIB and
binds stably to pol II, after which the transcribing unit is referred to  as the early
elongation complex (EEC) (24, 29). Early elongating complexes are no longer
susceptible to  abortive initiation, and the energy from ATP hydrolysis is no longer
required fo r transcript elongation. The EEC is not as stable as a fully functional 
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ternary complex and is liable to  transcript slippage (until about +23) o r 
backtracking (until about +30), which results in transcriptional arrest as the pol II 
active site becomes misaligned with the 3’ end of the transcript. The transcription 
factor SI I (TFIIS) can induce pol II catalysed transcript cleavage to form a new 3’ 
end properly aligned at the active site allowing elongation to continue (Figure I -3) 
(28,30,31).
3. CTD phosphorylation during initiation. A  number of proteins contain largely
unstructured protein tails, which can be modified in different ways by reactions 
involving, fo r example, phosphorylation or methylation of different amino acid 
residues. This provides a system for the temporally ordered recruitment of 
factors that would catalyse a series of events in sequence. The C terminal domain 
of pol II subunit Rpb I consists of a series of tandem repeats of the heptapeptide 
consensus sequence YSPTSPS, the number of repeats ranging from 52 in humans 
to 29 in S. pombe and 27 in S. cerevisiae (6, 26). The functional unit may be a 
heptapeptide pair, since recruited proteins may bind to  more than one CTD 
repeat (32). The primary targets fo r modification are serine 2 and serine 5, 
although other modifications include phosphorylation of serine 7, glycosylation of 
the serines and threonines and isomerisation of the proline residues (reviewed in
(33)).
The ordered phosphorylation and dephosphorylation of Ser2, Ser5, and Ser7 
is catalysed by a series o f kinases and phosphatases. The phosphorylation of Ser5 
marks the presumptive initiating / early elongating form of pol II, whereas 
phosphorylation of Ser2 is associated with productively elongating pol II (34). 
During the sequence of events at initiation, Cdk7, a subunit of TFI1H,
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phosphorylates Ser5. This phosphorylation reaction begins on formation of the 
PIC and may continue through the early stages of elongation (35). Cdk8, a subunit 
of the mediator complex, can also phosphorylate both Ser5 and Ser2. During the 
progression to  elongation, Cdk9, a subunit o f P-TEFb, phosphorylates Ser2. The 
TFIIF associated phosphatase FCPI binds to  a pol II sub module composed of 
subunits Rpb4 and Rpb7 and can dephosphorylate both Ser2 and Ser5. The 
modified CTD provides a platform fo r recruiting capping, splicing, cleavage and 
polyadenylation machinery in a timely manner. For example the RNA capping 
enzyme is recruited to pol II during early elongation (+20 to  +30) (36). Complexes 
may be recruited to  the CTD either though contacts with the phosphorylated 
repeats and / or repeats with altered structure (33).
4. Pausing in the promoter proximal region. Transcriptionally engaged polymerase is 
susceptible to  controlled pausing in the region +20 to +40 (26). The pausing 
factors DSIF and NELF cooperate to induce prom oter proximal pausing, possibly 
by binding of NELF to the nascent RNA. The repressive effects of DSIF and NELF 
can be relieved by the CTD kinase P-TEFb (Positive Transcription Elongation 
Factor b), allowing the transcribing pol II to  enter the phase referred to  as 
productive elongation. Early pausing may provide a mechanism to  allow the RNA 
transcript to  be capped (37).
1.2.4 Transient pausing during productive transcript elongation
Experiments with yeast RNA polymerase III suggest that elongation cannot be 
modelled simply as a sequence of pseudo-first order reactions (38). Instead, observations 
are consistent w ith a model in which pol III can switch between a rapidly stepping 
“ celerous” state, s i, and a slowly stepping “ slothful”  state, s2, during elongation (38). A
plausible model is that the slothful state, e2, results from a modest dislocation of the 3’ 
end of the transcript relative to  the catalytic site. Realignment of the 3’ end of the 
transcript w ith the active site converts the complex to state s I allowing transcription to  
resume (38).
One can envision at least two kinds of mechanisms that could lead to  transient 
pausing. First, limitations in the amount of nucleotides available fo r elongation could lead 
to  pausing, since the rate of nucleotide addition is slowed at positions where a limiting 
nucleotide must be incorporated. Indeed, in vitro pausing patterns can be altered by 
changing nucleotide concentrations (38, 39). Importantly, however, pausing is not 
eliminated at saturating nucleotide concentrations, arguing that pausing is not solely due 
to substrate limitations. Second, pausing can be strongly influenced by template sequence. 
As the ternary complex engages in productive elongation, the exact nature of the 
polymerase / nucleic acid complex changes as different sequences' of D N A and RNA 
become threaded through the enzyme (Figure I - 1). Each of these may provide slightly 
different conditions that could influence conversion of the complex to  the more slowly 
stepping state and thereby could influence the time taken fo r the catalytic addition of a 
nucleotide. Although some sequences may act to  promote transcription termination, 
many others cause pausing by the elongating ternary complex but do not favour 
termination (40). Studies w ith E. coli polymerase have demonstrated that such pausing 
occurs at many sites along a D N A template during transcript elongation in vitro, and
I Structural studies indicate tha t in S. cerevisiae there are eleven base pairs o f unwound D N A  w ith in the pol
II “ jaws” , three bases o f unwound template downstream of the active site and nine base pairs o f D N A  - 
RNA hybrid (9) suggesting a minimum of 423 = 7.0 x  I0 13 possible unique ternary complexes due to  the 
different possible sequences o f nucleic acid which may be associated w ith  transcribing polymerase.
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pause sites have been mapped fo r a number of D N A templates (39, 41). Although it is 
possible to determine pause sites empirically in this way, systematic prediction of pause 
sites from primary sequence has not been reported.
Pausing at some sites has been found to  be dependent on the RNA transcript 
upstream of the pause site; when polymerase transcribed in the presence of ITP (inosine 
triphosphate) rather than GTP, pausing was reduced at some sites (39). Because ITP base 
pairing with CTP is less stable than GTP with CTP, it has been suggested that RNA base 
pairing may cause pausing at some sites. Consistent with this idea, predicted RNA hairpin 
structures were found just upstream of a number of pause sites where substitution of ITP 
fo r GTP reduced pausing (39). Adding an oligonucleotide complimentary to  part of the 
hairpin also suppresses pausing at sites with RNA hairpin structures (42).
N o t all pausing depends on the nature of the RNA transcript upstream of the pause 
site. Pausing at some sites has been shown to  be dependent on D N A sequences 
downstream of the pause site, and pausing at these sites was insensitive to  substitution of 
GMP with IMP in the transcript. Interestingly, pausing influenced by downstream DNA 
sequences is not thought to  depend on the ease of melting the D N A template as GC rich 
sequences inserted downstream of a pause site failed to  enhance pausing (43). Recent 
studies indicate that contacts between the “ jaw” region of pol II and downstream DNA 
sequences may be involved in pausing at some sites; mutations in the “ jaw” region of E. 
coli RNA polymerase II suppresses pausing at a site fo r which pausing depends in part on a 
downstream sequence (44).
In conclusion, although there is a possibility o f conversion of the ternary complex 
from a “ celerous to  a “ slothful”  state at any point during transcription, the probability of
pausing is greater at certain sequences. This may be due to base pairing in the RNA 
transcript, interactions between pol II and the downstream D N A template, o r a 
combination of both. The change in the ability of the ternary complex to catalyse the 
addition of the next nucleotide may be due at least in part to  the 3’ end of the transcript 
becoming misaligned with the pol II active site.
1.2.5 Increasing the overall rate of transcript elongation by reducing 
transient pausing
Several transcription elongation factors that reduce transient pausing on naked 
D N A templates in vitro have been described.
1. In addition to  its role in promoter-specific initiation, TFIIF can interact with 
transcribing pol II and stimulate the rate of elongation. Structure function studies 
identified regions of RAP 30 essential fo r elongation activity including an N- 
terminal region that binds RAP74 and a central region that binds to  pol II (45, 46). 
The role of TFIIF as an elongation factor in vivo remains unclear. Recent chromatin 
immunoprecipitation studies found TFIIF present at promoters but not in coding 
regions (47). TFIIF elongation function may be limited to  the early stages in 
transcription. Studies by Yan and co-workers found that a TFIIF mutant selectively 
lacking elongation activity was unable to  suppress abortive initiation (16). TFIIF 
might increase the processivity of early elongation complexes and prevent 
premature release of short, unstable transcripts ( 16).
2. Elongin consists of an active subunit, Elongin A, and tw o regulatory subunits, 
Elongin B and Elongin C (48). The Elongin complex can also form an E3 ubiquitin 
ligase and may be responsible fo r the polyubiquitination and degradation of Rpbl
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in response to  D N A  damage in yeast and human (49-51). Elongin A is not 
essential fo r cell viability but disruption of Elongin A  leads to  slow growth of 
mammalian cells (52) and defective development in Drosophila (53).
3. ELL is the focus of this thesis and will be discussed in the third section of this 
introduction.
4. The Cockayne syndrome group B protein, CSB, has been shown to have both 
chromatin remodelling activity and to  stimulate pol II elongation on naked DNA. 
CSB can interact directly with double stranded D N A and histones and uses the 
energy from ATP to  remodel nucleosomes in vitro (54) and in vivo (55). CSB can 
also stimulate transcription elongation on naked D N A templates in vitro, probably 
through direct interaction with elongating pol II (56). In addition to  these two 
activities CSB is also required fo r transcription-coupled D N A repair and may be 
recruited to  pol II stalled at D N A damage sites.
It is not known how these factors reduce transient pausing. As TFIIF, Elongin, ELL 
and CSB all stimulate elongation in the presence of only D N A  template, pol II and 
ribonucleotides in highly purified, reconstituted transcription systems, it seems likely that 
stimulation is the result of interaction with some element of the ternary complex (DNA 
template, RNA transcript, pol II o r some combination of these three) (2, 57).
Three lines of evidence suggest that these elongation factors may reduce the 
number of pol II molecules in the slothful state, s2, by helping to  keep the 3’ end of the 
nascent transcript properly aligned with the active site:
I . Maintaining alignment between the 3’ end of the transcript with the active site 
should prevent pausing o r arrest caused by backward movement of pol II relative
to the transcript, which could either result in pausing o r arrest. TFIIF has been 
shown to reduce the probability that pol II complexes will arrest at DN A 
sequences that function as strong arrest sites (58).
2. The elongation factor Sll stimulates endonucleolytic cleavage near the 3’ end of 
non-arrested transcripts in vitro by the polymerase active site. This reaction would 
presumably require the active site to  have become aligned with the cleavage site 
rather than the 3’ end of the transcript. TFIIF, ELL and Elongin inhibit this Sll 
mediated transcript cleavage (59).
3. RNA pol II can catalyse template directed addition of nucleotides to  the 3’ ends 
of duplex D N A  in vitro in a reaction that seems to  mimic transcription elongation 
(60). In doing so, pol II binds to  the 3’ OH terminus of one strand of the D N A as 
if it were the 3’ OH end of a nascent transcript. The reaction is strongly 
stimulated by TFIIF, ELL and Elongin, and these observations are consistent with 
the idea that these elongation factors promote the alignment of the 3’ terminus of 
the D N A  w ith the pol II active site.
1.2.6 Processing the RNA transcript
Early in the process of transcribing a gene, eukaryotes begin to process the RNA
transcript, adding a 7-methylguanosine cap at the 5’ end, splicing out introns, and
polyadenylating the 3’ end of the transcript p rio r to  transcription termination and export
of the transcript from the nucleus (reviewed in (6 1)). Many of the proteins needed for
these events have been defined and, as with transcription, the reactions have been
investigated using purified proteins in vitro. The evidence outlined below suggests that
RNA processing factors are recruited to  the transcribing complex and that RNA
processing and transcription are coordinated.
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RNA capping. Capping the 5’ end of the nascent transcript serves both to protect 
the RNA from degradation by exonucleases and to  enhance export of the 
transcript from the nucleus to  the cytoplasm. Capping of many transcripts occurs 
as the RNA begins to  emerge from pol II. Capping enzyme binds to poll II CTD 
that has been phosphorylated at serine 5 during early elongation. Capping enzyme 
may also be allosterically activated by binding the CTD (61). Pet I, a 
triphosphatase that converts the 5’ end of a transcript from a triphosphate to a 
diphosphate, and Peel, a guanylyltransferase that caps the 5’ end of the transcript 
w ith a GMP moiety, are recruited to  the pol II CTD in fission yeast. Experiments 
with synthetic CTD peptides have shown that phosphorylation of serine 5 but not 
serine 2 is required fo r recruitment of capping enzyme in vitro, and in vivo 
interactions between capping enzymes and the CTD in a two hybrid assay require 
12 o r 14 YSPTS repeats (62). Both Pet I and Peel also bind to the Spt5 subunit of 
elongation factor DSIF, and Pctl binds to  the Cdk9 subunit of the elongation 
factor pTEFb, suggesting that coordination between capping and control of early 
elongation could be a mechanism used to prevent productive elongation of 
uncapped transcripts (37, 63).
Pre-mRNA Splicing. Introns are removed from transcripts during transcription by 
the spliceosome, a complex consisting of snRNPs (small nuclear 
ribonucleoproteins) and other proteins (non-snRNPs) including members of the 
SR family. Hyperphosphorylated pol II coimmunoprecipitates with both snRNPs 
and SR proteins suggesting a physical interaction between pol II and the 
spliceosome (64). Expression of Rpbl lacking a CTD in Xenopus oocytes results in
inefficient capping, splicing and polyadenylation of pre-mRNA, suggesting a 
functional role fo r the CTD in these processing activities (65).
3. 3 ’ end processing. Before transcription terminates, RNA cleavage and
polyadenylation machinery is recruited to the hyperphosphorylated pol II CTD. 
The precise location of transcript cleavage is determined by D N A  sequences 
including the hexanucleotide sequence AATAAA in higher eukaryotes and less 
well characterised sequences in S. pombe (66). Cleavage is catalysed by CPSF, 
which binds to the body of pol II and may then scan fo r the cleavage and 
polyadenylation hexamer (AAUAAA) on the transcript. Recognition of the 
polyadenylation hexamer triggers pol II to  pause, and CPSF can then catalyse 
cleavage of the transcript 10-30 nucleotides downstream (67). Pausing does not 
require the pol II CTD but the CTD is required fo r cleavage and termination. 
CPSF may be transferred from the body of pol II to  the CTD after the pause by 
the cleavage stimulation factor CstF (67). Polyadenylation of the cleaved transcript 
by polyadenylate polymerase, which binds CPSF, serves to  protect the 3’ end of 
the transcript from degradation and aids RNA export and translation. The 
polymerase continues to  transcribe after transcript cleavage until directed to  
terminate but the resulting RNA is quickly degraded.
1.2.7 Transcribing the correct genes in cells
D N A in cells needs to  be tightly packaged into chromatin and this has an overall 
repressive effect. For genes to be transcribed, the D N A needs to  be made accessible and 
the transcriptional machinery recruited to  the appropriate promoter. A  host of 
chromatin remodelling complexes and histone modifying enzymes are recruited by DNA 
binding regulatory proteins (activators and repressors), and modulate access to
chromatin, while some DN A binding regulatory proteins recruit coactivators such as the 
mediator complex that are responsible fo r assembly and control of RNA pol II and the 
general transcription machinery (reviewed in (68, 69)).
Where does transcription occur? The nucleus is not uniform, and areas of condensed, 
repressive heterochromatin are distinguishable from less condensed euchromatic regions 
where transcription occurs. There is evidence that transcription occurs in nanostructures 
called “ transcription factories” where active polymerases are localised at discrete sites 
(70-72). Some models fo r transcription factories suggest that pol II might remain 
immobilised as the template moves through it. Recently, 87nm, lOMDa structures that 
are rich in nitrogen (protein) but low in phosphorous (nucleic acid) have been observed 
associated with labelled nascent RNA, leading to the suggestion that transcription 
factories consist of a protein rich core with the D N A templates and RNA transcripts 
attached to  the surface (73).
Unpackagin? the DNA template. The D N A template needs to  be accessible to  the 
transcription apparatus throughout the transcription cycle. Chromatin remodelling 
involves the rearrangement of nucleosomes on D N A allowing transcriptional processes 
to  occur. Although nucleosomal D N A is somewhat accessible to  D N A binding 
transcription factors, chromatin remodelling complexes can increase transcription factor 
binding (reviewed in (68)). Once bound, activators recruit chromatin-remodelling 
complexes and histone modification enzymes that make nucleosomal D N A  more 
accessible to  the general transcription factors. In vitro, transcription on templates 
containing nucleosomes exhibits enhanced sequence specific pausing during elongation, 
and pol II is unable to  achieve physiological rates of gene transcription on chromatin 
templates, even in the presence o f elongation factors (74, 75).
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Histone modifications associated with gene activation include Acetyl-Co-A 
dependent acetylation by histone acetyltransferases (HATs), such as SAGA and NuA4, 
and methylation by methyltransferases including Set I and Set2. SAGA and NuA4 can 
stimulate recruitment of the chromatin remodelling complex SWI/SNF in vivo (76). More 
recently Carey and co-workers investigated transcription elongation on nucleosomal 
templates in vitro. They found that another ATP dependent chromatin remodeler, RSC, 
stimulates elongation through nucleosomes, and that RSC’s effect on elongation was 
stimulated by either SAGA or NuA4 (77, 78). Methylation of histones at H3K4 by Set I 
and at H3K36 by Set2 occurs in the coding regions of actively transcribed genes (68, 79). 
The H3K36 mark may function to  control histone acetylation by helping to  recruit Rpd3S, 
a histone deacetylase. The recruitment of this HDAC is thought to  be important because 
although histone acetylation enables remodelling of chromatin, which in turn enhances 
transcription elongation, it also allows D N A sequences within transcribed regions to 
become exposed to  transcription initiation machinery resulting in spurious intergenic 
transcription (80).
In addition to  chromatin remodelers moving histones along the DNA, transcription 
can also be enhanced by removing histones o r by replacing them w ith histone variants 
using histone chaperones. The histone chaperone complex FACT enhances productive 
transcription elongation on chromatin templates in vitro (81) and is localised to  actively 
transcribed pol II genes on Drosophila polytene chromosomes (82). FACT removes 
histone H2A / H2B dimers from nucleosomes leaving “ hexasomes” and may also help 
redeposit the dimers after the passage of pol II (83, 84).
Activating transcription. In addition to  controlling gene expression by modifying 
chromatin structure and making the D N A  accessible, expression is controlled by actively
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recruiting the transcription machinery to a gene. Pol II and the general transcription 
factors are not recruited directly to  DN A binding activators but require additional 
cofactors. Mediator is a multisubunit complex first isolated from yeast. It binds directly to  
both DNA binding transcriptional regulators and to  pol II to  control both activation and 
repression of genes (85, 86). The mediator complex is conserved from yeast to  man and 
is thought to  be required for all activated transcription (87). Interestingly, mediator has 
also been reported in the coding regions of genes, perhaps indicating a role for mediator 
in transcription elongation (88). Mediator subunit Med 13 interacts with transcription 
elongation factor Sll (TFIIS) (89), and the ELL / EAFI complex binds to  Med26 (CASB and 
TariJ Parmely unpublished data).
1.3 The role of the ELL gene product
1.3.1 Discovery of the human ELL gene through its link with leukaemia
The ELL gene was first identified as a fusion partner with the MLL (mixed-lineage 
leukaemia) gene in the translocation t ( l  I ; 19)(q23;p13 .1) in cells taken from the bone 
marrow of a patient w ith acute myeloid leukaemia. The gene resulting from this 
translocation encodes a protein in which the C terminus of ELL (aa 148-621) is fused to 
the N terminus of MLL (aa I - 1527) (I, 90). The MLL-ELL chimera causes immortalisation 
when introduced into haematopoietic progenitor cells. Transplantation into mice of cells 
immortalised by the MLL-ELL chimera causes acute myeloid leukaemia (9 1). In humans, 
ELL (eleven-nineteen lysine-rich leukaemia) is a 621 amino acid protein with a C-terminal 
domain homologous to  the C terminus of occludin, a membrane protein that localises to  
tight junctions. ELL also includes regions required fo r binding to proteins called ELL- 
associated factors (EAFs) and regions that have been found to  inhibit transcription
initiation o r stimulate transcription elongation (Figure 1-4). Two paralogues of ELL have 
been identified in humans, ELL2 (92) and ELL3 (93). Deletion of ELL in Drosophila (dELL or 
“ suppressor of triplo-lethal” ) is recessive lethal, and ELL mutations cause embryonic 
segmentation defects (94).
Chromosomal rearrangements involving MLL translocations occur in a number of 
acute or therapy induced leukaemias and to  date 50 translocation partner genes (TPGs) in 
addition to  ELL have been identified (95). The MLL gene product, a homolog of Drosophila 
trithorax (trx), is a histone methyltransferase that positively regulates gene expression 
during development and is known to  target Hox genes (96, 97). The N terminus, which is 
retained in the MLL fusion proteins, has domains, including an AT hook motif and a CpG 
region similar to the D N A binding domain of D N A methyltransferase, that are expected 
to be able to  bind D N A and that may help target MLL to  genes. The C terminal domain 
contains regions that may modulate the accessibility of chromatin leading to  gene 
activation. These include an H3K4 methyltransferase SET domain, and a transactivation 
domain that can recruit the histone acetyltransferase CBP (96-98). In the MLL-ELL 
translocation, the carboxy terminal region of ELL, equivalent to  amino acids 497-621 of 
the human protein, is necessary and sufficient for immortalisation of primary murine 
haemopoietic cells; MLL-ELL(l-373), which includes the transcription elongation domain 
but lacks the C terminal occludin domain, does not cause immortalisation (99). There has 
been speculation that recruitment of the EAFI protein to  MLL-ELL might be necessary fo r 
immortalisation, as the C terminus of ELL binds EAFI, and murine primary cells 
transfected with an MLL-EAFI chimera become immortalised (although there has been no 
evidence of MLL-EAFI induced leukaemias in humans) (100). Overexpression of the ELL 
protein alone has been reported to  cause transformation of rat primary embryo
contains regions involved with 
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contains regions required for initiation inhibition (1-373)
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Figure 1-4 The human ELL gene product.
The locations of the regions indicated in the figure are described in the following publications: ELL 
full length gene, lysine rich region and translocation breakpoint (1), regions required for inhibition of 
transcription initiation or for stimulation of transcription elongation (103), occludin like domain (104), 
regions involved in EAF1 and EAF2 binding (105).
fibroblasts (with transformation dependent on the lysine rich region o f ELL); however, in 
a subsequent study ELL overexpression did not transform primary haemopoietic cells in 
mice (9 1, 10 1). Very recently, a number of common MLL-fusion proteins including MLL- 
ELL have been reported to  form complexes that include AFF4 (AF4/FMR2 family, member 
4) and other translocation partner genes (102).
1.3.2 ELL localization
ELL shows broad tissue distribution in humans; transcripts have been detected by
Northern blotting in peripheral blood leukocytes, skeletal muscle, placenta and testis and
many major organs (I). ELL is conserved across metazoa (mammals, chicken, frog and 
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fish ( I)  and fly (106)) but prior to  this study had not been identified in lower eukaryotes. 
Early in murine development, RNA transcripts are diffusely expressed until about day 16, 
when high levels become evident in the liver and gut. In adult mice, transcript levels are 
most pronounced in the liver and gastrointestinal tract (107). The ELL associated factor 
EAF2 is localised to  the tissues of the nervous system during mouse embryogenesis (108).
W ithin cells, both ELL and EAFI colocalise with Cajal bodies, nuclear compartments 
that contain components of the RNA processing machinery (109). In contrast tw o other 
elongation factors, Elongin and TFIIF show diffuse nuclear localisation. Colocalisation with 
Cajal bodies is dependent on transcription, with ELL/EAF appearing dispersed throughout 
the nucleus in cells treated with a-amanitin, a potent inhibitor of pol II transcription. It 
has been suggested that Cajal bodies may be sites for preassembly of complexes 
containing both transcriptional and RNA processing machinery, which are subsequently 
transported to  the genes to  be transcribed ( I 10).
1.3.3 ELL interacts with pol II and can function as a transcription 
elongation factor
ELL interacts with RNA polymerase II. Coimmunoprecipitations using purified factors 
show that ELL binds directly to  pol II in vitro both in mammals and in flies ( 103, 106). 
Although the presence of the pol II CTD is not required fo r ELL function or binding in 
vitro, CTD phosphorylation has been implicated in ELL recruitment in vivo. Knockdown of 
Cdk9 (the kinase subunit o f P-TEFb) in flies resulted in reduced CTD phosphorylation and 
decreased chromosome binding of dELL suggesting that CTD phosphorylation might be 
required fo r dELL recruitment ( I I I ) .  W hether recruitment involves a direct interaction 
between pol II CTD and ELL is not known.
ELL stimulates transcription elongation in vitro. Shilatifard and co-workers originally 
identified ELL as a transcription elongation factor by purifying an activity from rat liver 
nuclear extracts over several chromatographic steps by its ability to  stimulate 
transcription elongation by purified pol II on naked D N A templates in vitro (2). The 
activity copurified w ith a single protein, which was identified as a rat homologue of the 
62laa human ELL protein (2). Analysis of recombinant human ELL deletion mutants 
showed that sequences required fo r stimulation of elongation were contained in the 
regions aa 60-200 and aa 300-373 (Figure 1-4) (103). In addition to  its elongation activity, 
ELL also inhibits the activity of the elongation factor Sll -in vitro. The transcription 
elongation factor Sll (TFIIS) acts to reactivate pol II that has become stalled by stimulating 
a pol II ribonuclease activity that hydrolytically cleaves a misplaced transcript at the active 
site1 resulting in a complex competent to  continue elongation (M3).
RNAn + H20  RNAn-m + RNAm
Sll accesses the pol II active site via the funnel and pore (I 12) (Figure 1-3). The 
inhibition of this reaction by ELL could result from ELL preventing Sll access to  the active 
site o r from ELL maintaining the position of the 3’ end of the transcript in alignment with 
the pol II active site so as to  prevent cleavage (59).
1 The different RNA pol II activities share the same active site which is “ tuneable” to  catalyse either 
elongation / pyrophosphorolysis o r hydrolytic cleavage (I 12).
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Indirect evidence for a role o f ELL as an elongation factor in vivo. Studies with drosophila 
ELL (dELL) have provided evidence that ELL functions during transcription elongation in 
vivo. Like cdk9 (P-TEFb) and Spt5 (DSIF), dELL colocalises with phosphorylated pol II on 
polytene chromosomes at transcriptionally active puff sites and relocalises to  heat shock 
genes on heat shock (106, I 14). The association with elongating pol II in flies only 
requires an N terminal domain of dELL homologous to  Hs. ELL aa 1-373. Eissenberg and 
co-workers have suggested that dELL may be preferentially targeting large genes. 
Mutations in dELL cause misexpression of Scr (23kb), Notch (35kb) and cut (65kb) but do 
not affect the smaller rudimentary ( 13kb) and white (5.9kb) (94).
1.3.4 ELL associated factors EAF1 and EAF2
Two homologous proteins that interact directly with human ELL have been 
identified (105, I 15). These ELL associated factors EAFI and EAF2 positively regulate ELL 
elongation activity in vitro (3). Binding to  the EAF proteins is achieved through regions in 
both the N and C termini of ELL (EAFI) or through the N terminus only (EAF2) (Figure 
I -4). Activation of ELL activity by EAF I requires not only the transcription elongation 
domains in ELL but also the firs t 45 N terminal ELL amino acids, which overlap an 
EAFI/EAF2 interaction domain. Activation can occur in the absence of the C terminal 
EAFI binding domain, suggesting that the binding of ELL to  EAFI is not sufficient for 
stimulation of ELL activity. Upregulation of ELL elongation activity requires only the N 
terminal l l8  aaofEAFI (CASB unpublished data). As well as stimulating ELL activity, the 
C terminus of EAFI contains an acidic transactivation domain that when fused to a GAL4 
D N A binding domain, will stimulate transcription from templates containing GAL4 binding 
sites in whole cell extracts (I 15).
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In addition to  the ELL Associated Factors (EAFs) already described, ELL has been 
found to copurify as a complex with three proteins designated EAP20, EAP30 and EAP45. 
The association of the EAPs with ELL does not appear to  affect the ability of ELL to 
stimulate elongation (116-118).
1.3.5 ELL interacts with transcription factor p53
The C terminal domain of p53, a transcription factor that can function as either an 
activator o r a repressor, interacts with the ELL transcription elongation domain (I 19). 
This interaction negatively regulates ELL stimulated transcription from oligo(dC) tailed 
templates, and it has been proposed that p53 could repress general transcription at least 
in part by targeting ELL, while activating promoters containing p53 responsive elements 
by other, ELL-independent mechanisms (I 19).
1.3.6 ELL2 affects pre mRNA processing
ELL2 has recently been shown to  regulate pre mRNA processing in plasma cells, in 
which alternative splicing and polyadenylation of the Igh gene results in synthesis of 
mRNAs encoding either the secreted o r the membrane-bound form of the 
immunoglobulin heavy chain (120). ELL2 and the polyadenylation factor CstF-64 normally 
co-localise w ith pol II on the Igh locus. Reducing levels of ELL2 with ELL2 specific shRNA 
was found to  decrease levels of ELL2 and CstF-64 to  the locus. Depletion of ELL2 also 
results in a reduced proportion of the shorter secretory-specific transcripts (implying a 
decreased use of a weak prom oter proximal polyA site), and an increase in longer 
transcripts (requiring use of a weak splice site) (Figure I -5).
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Figure 1-5 ELL2 influences Igh pre mRNA processing.
B cells, in which ELL2 expression is low, favour production of the membrane specific form of 
immunoglobulin heavy chain mRNA, whereas plasma cells, which express higher levels of ELL2, 
produce a secretory specific form of the mRNA.
It is thought that slowing of elongation near a weak splice site might help its 
recognition by allowing time for the splicing machinery to assemble. Conversely, rapid 
elongation promoted by ELL2 could decrease recognition of this weak alternative splice 
site, which is 5’ to the weak polyA site, thereby favouring use of the weak polyA site 
rather than continued transcription and splicing. Indeed, one model fo r “ exon skipping” , 
in which a weak splice site is ignored, suggests that transcription elongation factors might 
help favour exon skipping as the increase in the rate of pol II elongation decreases the 
likelihood that a weak 3’ splice site will be used (Figure I -6) ( 12 1). Interestingly 
expression of ELL2 in non-plasma cells, where ELL2 is normally in low abundance, has 
been shown to increase exon skipping or to increase use of a weak polyA site in different 
reporter constructs transfected into cells (120).
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Figure 1-6 Rate of transcription elongation might regulate alternative splicing.
This illustration is based on figure 3 in (121). This model suggests that an increase in the rate of pol 
II elongation, possibly by factors that m ight reduce pausing and result in high pol II processivity, 
leads to an increase in exon skipping. In genes that contain weak alternative 3’ splice sites (light 
blue) a high elongation rate favours transcription through the altenative exon (red) resulting in use 
o f a stronger 3’ splice site (dark blue) and removal of the alternative exon. Lower elongation rates 
favour inclusion of the alternative exon.
1.3.7 ELL role in development
ELL is necessary fo r the timely expression of some genes during development. 
Although deletion of ELL in mice results in viable heterozygotes (ELL+/-), intercrossing 
heterozygotes fails to generate homozygote mice (ELL-/-), with nearly a quarter of 
embryos exhibiting degenerative changes during early embryogenesis (122). Mutations in 
Drosophila ELL (dELL) cause misexpression of several genes during development (including 
Scr, cut and Notch), causes segmentation defects, and results in late embryonic lethality 
(maternally loaded dELL mRNA is present early in development) (94).
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ELL associated factors have also been shown to be necessary fo r controlling 
developmental processes. W nt-4, via the noncanonical W n t signalling pathway, controls 
neural differentiation. EAF2 is a target fo r W nt-4  signalling, is essential for proper eye 
development in Xenopus laevis, and functions by regulating transcription of the eye specific 
Rx gene (123). In these experiments Maurus and coworkers demonstrated that EAF2 
controls levels of Rx mRNA but not control (Pax-6) RNA suggesting that ELL / EAF2 
function might be gene specific.
1.3.8 Summary
ELL stimulates transcription elongation in vitro by binding to RNA pol II and
suppressing transient pausing o f the enzyme at many sites along the DNA. Pausing may be
caused by conversion of the ternary complex from an actively elongating (celerous) state
to a slowly stepping (slothful) state that results from the misalignment of the 3’ end of the
transcript and the pol II active site, and ELL might function at least in part by helping to
maintain proper alignment. There is evidence that ELL functions together with elongating
pol II in vivo and that the state of pol II CTD phosphorylation may affect recruitment of
ELL either directly o r indirectly. Knockdown of an ELL homologue leads to  mislocalisation
of a polyadenylation factor, an increase in exon skipping, and altered use of
polyadenylation sites but it remains unclear whether this is due to a direct function of ELL
(such as an altered rate of pol II elongation) o r an indirect effect (such as a change in
recruitment o r function of the splicing and polyadenylation machinery). It is intriguing that
ELL has a C terminal domain that appears to  have a function independent of transcription
elongation. The homology with the membrane-distal cytoplasmic domain of the
membrane bound protein occludin, which is a target fo r modification and binds to  several
proteins, suggests that the ELL occludin domain may act as a docking site fo r other 
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factors including EAFI (124). Finally, ELL has been shown to  be essential fo r proper
development and may be targeted to specific developmental genes.
1.4 Scope of this thesis
1.4.1 Using fission yeast as a model system to explore the role of ELL in
cells
Previous attempts to  find homologues of ELL had not identified it in lower 
eukaryotes, and there is no apparent homologue of ELL in S. cerevisiae. In this thesis, I will 
describe the identification and in vitro characterisation o f homologues of ELL and EAF in 
the fission yeast S. pombe. I will then address questions about the function of these 
proteins, designated SpELL and SpEAF, in cells. Fission yeast is a valuable model system, 
having the advantages that it is easy to  manipulate genetically and that some cellular 
processes are remarkably similar to their counterparts in Metazoa ( 125). S. pombe also 
uses some enzyme systems o r components of systems that are not present in S. cerevisiae, 
fo r example RNA interference and parts of the spliceosome ( 126).
1.4.2 Questions to be addressed
This thesis begins by demonstrating that ELL and EAF do exist in a single celled 
eukaryote, identifing the coding regions of the ell I and eafl genes, and demonstrating a 
physical interaction between the SpELL and SpEAF proteins. I then ask whether the in vitro 
activities of the human ELL/EAF complex are shared by SpELL/SpEAF and look at how 
they interact with pol II in vitro. I recently collaborated w ith Stephanie Kong to 
demonstrate that human ELL appears to function as a dimer with EAF in stimulating 
transcription elongation (3) and so, having confirmed that they function this way in S. 
pombe, wanted to  ask whether they appeared to function together on chromosomes in
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vivo. It has not previously been clear whether ELL is involved w ith regulating a specific 
subset of genes or whether its function is more general, nor has there been information 
about what properties SpELL regulated genes might share. Using a whole genome 
approach, I have attempted to define the most likely candidates fo r direct regulation by 
SpELL/SpEAF, and I have used one of these candidate genes to begin to  answer 
mechanistic questions about how the SpELL/SpEAF complex might be recruited to  genes 
in cells.
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CHAPTER 2. MATERIALS AND METHODS
2.1 Materials
Unlabeled ultrapure ribonucleoside 5’-triphosphates and [a-32P]CTP (400 
mCi/mmol; I Ci = 37 GBq) were purchased from Amersham Pharmacia Biosciences. 
Recombinant RNasin ribonuclease inhibitor was obtained from Promega. Anti- FLAG 
(M2) monoclonal antibodies, anti-Myc (C-3956) rabbit polyclonal antibodies, anti-FLAG 
(M2)-agarose, and anti-FI_AG peptide were purchased from Sigma. Light chain-specific 
anti-mouse antibodies were from Bethyl laboratories and labelled with Alexa Fluor 680 
(Invitrogen) according to  the manufacturer’s instructions.
2.2 Cloning of S. pombe elll and eaf1 genes
The SMART™ RACE cDNA Amplification system (Clontech) was used according 
to manufacturer’s instructions to identify the 5’ ends of each gene using the gene specific 
primers: 5’-GGGTGGAAGGCAAGGATTGCGGAGGAGA-3’ (ELL) o r
5’-TGCTGGCCGTTTGGGATACTGTAGAGGG-3’ (EAF).
RACE products were cloned into pCR®2.1-TOPO® and the inserts were 
sequenced to  identify the 5’ end of each gene and to  confirm the positions of introns. 
Sequences corresponding to  the coding regions of the mRNA were then subcloned into 
pBacPAK8 using primers overlapping consecutive exons to  remove introns from S. pombe 
genomic D N A  sequences.
2.3 Strain construction
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pFA6a kanMX6
Promoter kanamycin Terminator
ORF
Figure 2-1 Construction of gene deletion strains.
PCR primers (indicated by arrows) were used with the pFA6a kanMX6 plasmid as template to 
generate a PCR product w ith 80 bp of homology to regions flanking the sequence to be deleted 
as indicated. Electroporation of the PCR product into S.pombe cells resulted in replacement of the 
target sequence with a kanamycin resistance cassette under the control o f promoter and term inator 
sequences from Ashbya gossypii. Transformed cells were plated on YES containing 100 mg/l 
G418 / geneticin. G418 resistant transformants were streaked to isolation. Deletion of the target 
sequence and insertion o f the resistance cassete at the correct locus were both confirmed by PCR.
The S. pombe strains used are listed in appendix A. S.pombe cells were grown at
32°C in rich medium (YES) supplemented with adenine, histidine, leucine and uracil (225
pg/ml) or minimal medium (EMM) with the supplements indicated. The gene deletion
strains were generated by replacing the coding region of the ell I gene with the kanMX6
marker as described (127) (Figure 2 -1). Epitope tagged strains were generated by
replacing the stop codon of the target gene with the 13myc natMX6 cassette ( 127, 128)
(Figure 2-2). I constructed strains containing both a gene deletion and an epitope tagged 
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pFA6a 13myc natMX6
*
Terminator [Promoter13myc nourseothricinr
ORF STOP
Figure 2-2 Construction of epitope tagged strains.
The target gene is indicated as the ORF (black) including the stop codon (red). PCR primers were 
designed with 80 bases of homology to the region immediately upstream of the stop codon (5’) and 
a region 20-200 bp downstream of the stop codon (3 ’). These were used to generate a PCR 
product using the pFA6a 13myc nat MX6 plasmid as a template. This includes 13 tandem repeats 
coding for the c-myc epitope with a transcription term ination sequence from the S. cerevisiae ADH1 
gene (blue) followed by a nourseothricin antibiotic cassette. The PCR product was used to 
generate recombinant strains as described in Figure 2-1 .
gene by crossing two strains w ith a single disruption. A mating m ixture of the two stains 
on malt extract (ME) plates was incubated at 28°C fo r three days and dilutions of cells 
were then plated on media containing both geneticin and nourseothricin (clonNAT). An 
ell I rescue strain was constructed by inserting the ell I gene into the leu I locus of the 
ell IA  strain using the pDUAL system as described (129).
2.4 Analysis of Proteins Associated With FLAG-tagged SpELL 
and SpEAF in S. pombe
cDNAs encoding SpELL o r SpEAF with N-terminal FLAG epitope tags were 
subcloned into a modified version of pNMT-TOPO (Invitrogen), which carries a thiamine 
repressible promoter, and transformed into S. pombe strain PPI38. Cells were grown in
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EMM supplemented w ith 10 p,M thiamine and 225 jig/ml each of adenine, histidine, and 
uracil. Once they had reached a density of ~ 5 x l0 6 /ml, cells were washed in EMM 
supplemented w ith adenine, histidine, and uracil alone to  release thiamine repression and 
grown for an additional 18 hours. Cultures were harvested by centrifugation at 3,000 x g, 
washed in cold H20 , and then washed in an extraction buffer containing 0.2 M Tris-HCI 
(pH 7.5), 0.39 M (N H 4)2S 04, 10 mM MgS04, I mM EDTA (pH 8.0), 20% (v/v) glycerol,
0.28 |ig/ml leupeptin, 1.4 pg/ml pepstatin A, 0.17 mg/ml PMSF, and 0.33 mg/ml 
benzamidine. Cells were pulverized under liquid nitrogen by m ortar and pestle, thawed, 
and resuspended in extraction buffer. W hole cell extracts were clarified by centrifugation 
at 150,000 x  g before immunoprecipitation. FLAG-tagged SpELL or SpEAF and associated 
proteins were purified from whole cell extracts as described below under Purification of 
Recombinant Proteins. FLAG-immunopurified complexes were analyzed by MudPIT mass 
spectrometry as described previously (130-133).
2.5 Expression of Recombinant Proteins in Insect Cells
cDNAs encoding wild-type SpELL and SpEAF containing N-terminal FLAG o r c-
Myc epitope tags, as well as an SpEAF deletion mutant lacking the first 59 amino acids,
were subcloned into pBacPAK8. Recombinant baculoviruses were generated with the
BacPAK expression system (Clontech) using pBacPAK6 viral D N A prepared as described
(134), and stored in 50 ml centrifuge tubes spray-painted black to  prevent exposure to
light during storage (135). The tite r of recombinant baculoviruses was determined using
the immunological assay developed by Kitts and Green (136). Sf21 insect cells were
cultured at 27°C in Sf-900 II SFM (Invitrogen). Flasks containing I x 108 Sf21 cells were
infected with the recombinant baculoviruses. Forty-eight hours after infection, cells were
collected and lysed in 15 ml of ice-cold buffer containing 50 mM Hepes-NaOH (pH7.9), 
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0.5 M NaCI, 5 mM MgCI2, 0.2% Triton-X-100, 20% (v/v) glycerol, 0.28 jig/ml leupeptin,
1.4 jJig/ml pepstatin A, 0.17 mg/ml PMSF, and 0.33 mg/ml benzamidine. Lysates were 
centrifuged 100,000 x g fo r 30 min at 4 °C.
2.6 Purification of Recombinant Proteins
FLAG-tagged proteins were purified from Sf2l cell lysates by anti-FLAG agarose 
immunoaffinity chromatography. Lysates from I x I08 cells were incubated w ith 0.5 ml 
anti-FLAG (M2) agarose beads overnight at 4°C. The beads were washed three times 
with Tris-buffered saline (TBS, 25 mM Tris-HCI (pH 7.4), 137 mM NaCI, 2.7 mM KCI), 
and bound proteins were eluted from the beads w ith TBS containing 10% (v/v) glycerol 
and 0.3 mg/ml FLAG peptide. W here indicated, anti-FLAG agarose eluates prepared from 
Sf2l cells expressing both recombinant FLAG-SpELL and Myc-SpEAF were further 
purified by anion exchange HPLC. Eluates were adjusted to  a conductivity equivalent to 
that of 0.05 M KCI and applied to  a 0.6 ml TSK DEAE-NPR HPLC column (Tosoh-BioSep) 
equilibrated in Buffer A  (40 mM Tris-HCI (pH 7.9), I mM EDTA, I mM DTT, 10% (v/v) 
glycerol) containing 0.1 M KCI. The column was eluted w ith a 6 ml linear gradient from 
0.1 to  0.5 M KCI in Buffer A, and 0.2 ml fractions were collected. Concentrations of 
eluted proteins were estimated by using ImageQuant TL software (G. E. Healthcare) to  
compare the relative intensity of Coomassie Blue stained bands corresponding to full- 
length protei'ns to  the intensity of bands corresponding to  BSA standards after 
SDS/PAGE.
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2.7 Preparation of RNA Polymerase II
Mammalian pol II was purified from rat liver nuclei as previously described (14), 
except that a TSK DEAE 5-PW HPLC column was used in place of TSK DEAE-NPR. Pol 
II from S. pombe was a kind gift from Henrik Spahr, which he purified as described (4).
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1. Pulse: add RNA pol II, ATP, GTP, [a32P]CTP
135bp 
U-less cassette
2. Rem ove nucleotides
3. Chase: continue transcrip tion by adding ATP, GTP, CTP and UTP (and elongation factors)
GAGCAAGG G
labeled transcript
AAGAAAAAGCAAACCG. . .
AAGAAAAAGCAAACCG. . GAGCAAGGCGTTTCGGGGAAGAAAAAGCAAACCGCAGAGGGAAGCCAACCCCAGAAGAG 
ITT CTTTTT CGTTT GGCGTCT CCCTTCGGTTGGGGT CTT C TC,
AAGAAAAAGCAAACCG
transient pausing
. GAGCAAGGCGTTTCGGGGAAGAAAAAGCAAACCGCAGAGGGAAGCCAACCCCAGAAGAG. 
. CTCGTTCCGCAAAGCCCCTTCTTTTTCGTTTGGCGTCTCCCTTCGGTTGGGGTCTTCTC.
4. S top Reaction
Figure 2-3 Pulse chase assay.
The oligo(dC) tailed pAdGR220 template contains a U-less cassette (red) to allow the formation of 
paused ternary complexes. (1) On the addition of the nucleotides indicated, RNA pol II will start 
transcription at the junction between the single and double strands of the template w ithout the need 
for additional factors to initiate transcription and will pause at +135 bp from the start site in the 
absence of UTP. The 135 nucleotide transcript is labeled with [aP32]CTP. (2) Ternary complexes 
can then be purified free of nucleotides. This enables lower concentrations of unlabeled 
nucleotides to be used during the chase phase (3). The RNA pol II continues transcription 
elongation until the reaction is stopped.
2.7.1 Oligo(dC)-tailed Template Transcription Assays
Oligo(dC) tailed pAd-GR220 was prepared as described (137). 60 pi transcription 
assays were carried out in the presence of 20 mM Hepes-NaOH (pH 7.9), 20 mM
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Tris -HCI (pH7.9), 60 mM KCI, 2 mM DTT, 0.5 mg/ml BSA, 3% (w/v) polyvinyl alcohol 
(average molecular weight 30,000-70,000 Da), 3% (v/v) glycerol, 8 units of RNasin, 8 mM 
MgCI2, -100 ng oligo(dC)-tailed pAd-GR220, -25  ng pol II, and ribonucleoside 
triphosphates and transcription factors as indicated in the figure legends. The pulse chase 
assay used in Figure 3-4 is outlined in Figure 2-3. Reactions were preincubated fo r 5 min 
at 28 °C before the addition of ribonucleoside triphosphates. Reactions were stopped by 
the addition of 60 pi stop buffer (10 mM Tris -HCI, pH 7.2 / 0.5 mM EDTA / 0.3 M NaCI / 
0.4% SDS) after incubation at 28 °C fo r the times indicated in the figures, and 
transcription products were resolved on 6% polyacrylamide gels containing 7 M urea, 45 
mM Tris-borate, and I mM EDTA (pH 8.3) and detected with a Molecular Dynamics 
Typhoon Phospholmager.
2.8 Preparation of Paused RNA Polymerase II Elongation 
Complexes
Paused pol II elongation complexes were assembled on oligo(dC) tailed pAd-GR220
by performing transcription reactions (scaled up 10 fold) in the presence of 50 pM ATP,
50 pM GTP, 2 pM CTP and 10 pCi [a-32P]CTP fo r 30 minutes at 28 °C. Two
Sephadex G-50 spin columns were prepared by inserting a 5ml syringe (with the plunger
removed) into a 15ml centrifuge tube, pushing a small amount of polyester aquarium filter
fibre into the bottom  of the syringe, and filling the syringe w ith Sephadex G-50 gel slurry
(prepared as described (138)) equilibrated in buffer containing 20 mM Hepes-NaOH
(pH7.9), 20 mM Tris -HCI (pH7.9), 50 mM KCI, I mM DTT, 0.5 mg/ml BSA, 2% (w/v)
polyvinyl alcohol, 3% (v/v) glycerol, and 5 mM MgCI2. The columns were allowed to  drain,
spun at 2000 x  g to  remove excess buffer and inserted into fresh centrifuge tubes. Free
ribonucleoside triphosphates were then removed by applying -600 pi of the reaction 
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mixture to  two sequential Sephadex G-50 spin columns. The columns were spun fo r 5 
min at 2000 x g in a swinging bucket rotor, and 60 pi of eluant/reaction mixture was used 
in further experiments.
2.9 Chromatin Immunoprecipitations (CHIPs)
Chromatin immunoprecipitations were carried out essentially as described (139) 
with modifications:
2.9.1 Preparation of Chromatin Extracts
S. pombe strains were grown in 100 ml YES to  an OD600 between 0.9 and I . I . Cells 
were crosslinked by adding formaldehyde to  a final concentration of \% fo r 15 minutes at 
room temperature'. The crosslinking reaction was quenched w ith the addition of 5 ml of
2.5 M glycine. Cells were harvested by centrifugation and the cell pellets were washed 
twice with ice-cold Tris-buffered saline (TBS) containing protease inhibitors (0.28 pg/ml 
leupeptin, 1.4 pg/ml pepstatin A, 0 .17 mg/ml PMSF, and 0.33 mg/ml benzamidine). Cells 
were resuspended in 800 pi FA lysis SDS buffer (50 mM HEPES/KOH pH 7.5, 150 mM 
NaCI, I mM EDTA, I % T riton X-I00, 0. \% sodium deoxycholate, 0.2% SDS, 0.28 pg/ml 
leupeptin, 1.4 pg/ml pepstatin A, 0 .17 mg/ml PMSF, and 0.33 mg/ml benzamidine) and 
aliquoted into four 1.5 ml microfuge tubes. A fter the addition of 200 pi acid washed glass 
beads (Sigma G8772), cells were disrupted by vortexing using a Vortex-Genie® 2 w ith a 
Turbomix™ attachment fo r 15 minutes at 4°C. Lysates were recovered from the beads 
by piercing the bottom of each tube w ith a 2 1G needle, placing each tube over a clean 1.5
1 No attempt was made to  optim ise crosslinking conditions.
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ml centrifuge tube and centrifuging both tubes fo r 30 seconds at 3000 x g. Lysates were 
combined in a 15 ml centrifuge tube and the total volume increased to  approximately 2 
ml with FA-lysis SDS buffer. Lysates were sonicated at 4 °C using a Bioruptor™ 
(Diagenode) on setting “ high” (7 cycles 30 seconds on, 60 seconds off) to  generate 
chromatin fragments in the range 200-1000 bp. For ChlP-qPCR experiments lysates were 
sonicated more extensively to generate smaller chromatin fragments of average size 
~200bp in order to  improve the resolution of ChIP peaks (140). For this more extensive 
chromatin fragmentation, lysates were sonicated fo r 20 minutes (30 seconds on 60 
seconds off), centrifuged at 4000 x g fo r 5 minutes at 4 °C, and the supernatant sonicated 
fo r a further 20 minutes (30 seconds on 60 seconds off). Cellular debris was removed by 
centrifuging the sonicated extracts in 1.5 ml microfuge tubes at 4 °C fo r 20 min at 14000 
rpm.
2.9.2 Preparation of Input DNA
An aliquot of chromatin extract was used to  prepare D N A to  check the degree of 
chromatin shearing. 60 pi of chromatin extract was combined with 140 pi TE, pH 8.0 (10 
mM Tris-HCI, I mM EDTA), 2 pi proteinase K (20 mg/ml New England Biolabs) and 200 
|il proteinase K buffer (50 mM Tris-HCI, 12.5 mM EDTA, 300 mM NaCI, 1% SDS), and 
incubated at 55 °C for I hour and then at 65 °C overnight to  reverse the crosslinks.
A fter addition of 6.2 pi 5 M NaCI, D N A was purified by phenol/chloroform extraction 
and ethanol precipitation using 2 pi GlycoBlue™ (Ambion) as a carrier. Contaminating 
RNA was removed by treatment with 2 pi RNaseA (5 mg/ml Epicentre Biotechnologies), 
followed by phenol/chloroform extraction and ethanol precipitation. DN A was 
resuspended in TE to  a final volume of 100 pi, 10 pi of which was run out on a I % 
agarose gel. The majority of D N A fragments were between 200 bp and 1000 bp.
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2.9.3 Chromatin Immunoprecipitations
300 pi chromatin solution was mixed with 900 pi FA-lysis buffer (50 mM 
HEPES/KOH pH 7.5, I mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate) 
containing 150 mM NaCI, 9 pi lOOx protease inhibitors (28 pg/ml leupeptin, 0.14 mg/ml 
pepstatin A, 17 mg/ml PMSF, and 33 mg/ml benzamidine), and 60 pi 20% sarkosyl. A fter 
centrifugation at 21000 x g fo r 30 minutes, supernatants were transferred to  fresh tubes. 
Extracts were incubated with 2 pi goat polyclonal anti-Myc antibody (Abeam ab9l32) fo r 
2 hours at 4 °C and then fo r a further 2 hours with 100 pi protein G dynalbeads 
(Invitrogen) pre-equilibrated in FA-lysis buffer containing 150 mM NaCI. Beads were 
concentrated with a magnetic particle concentrator, the supernatant removed and the 
beads washed with:
• FA lysis buffer (150 mM NaCI) fo r 10 minutes
• FA lysis buffer (I M NaCI) for 5 minutes
Beads were transferred to  clean tubes and further washed:
• FA lysis buffer (500 mM NaCI) fo r 10 minutes
• TEL buffer (0.25 M LiCI, 1% NP-40, 1% sodium deoxycholate, I mM EDTA, 10 
mM Tris-HCI pH 8.1) fo r 10 minutes
• TE pH 8.0 fo r 5 minutes twice
Bound complexes were eluted from the beads by incubating with 200 pi of elution 
buffer (10 mM TRIS-HCI pH 8.1, I mM EDTA, 250 mM NaCI, 1% SDS) at 65 °C fo r 30 
minutes. The elution was repeated and the combined eluates digested with 2 pi 
Proteinase K (10 mg/ml) fo r I hour at 55 °C. A fter reversing the crosslinks by incubating 
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overnight at 65 °C, DNA was purified by phenol/chloroform extraction followed by 
ethanol precipitation with 2 pi GlycoBlue™ (Ambion) as a carrier. D N A pellets were 
resuspended in 50 pi TE and analysed by real time PCR.
2.10 ChlP-chip analysis
Three biological replicate ChlPs were prepared fo r each tagged strain together with 
three control ChlPs using the wild type untagged strain. 40 pi was submitted (80%) of 
immunoprecipitated DN A from each ChIP sample to  Karin Zueckert-Gaudenz in the 
microarray core facility fo r amplification, labelling and hybridisation to  GeneChip® S. 
pombe Tiling I .QFR Arrays (Affymetrix). 10 pi from each sample was retained to  compare 
original ChIP D N A with amplified ChIP DNA. This was to  ensure that less abundant DNA 
sequences were not significantly amplified relative to  more abundant sequences. Samples 
were processed according to the manufacturer’s protocols, and Madeline Gogol analysed 
the scanned array data using the MAT algorithm to  generate a MAT score together with 
an associated p-value for each probe on the array ( 14 1). The p-value indicates the 
probability that a result would be obtained by chance. Genes with a ChIP signal with a p- 
value less than 0.05 within the annotated region were classified as being enriched by the 
bait protein (for a lists of SpELL and SpEAF enriched genes refer to  Appendix C).
2.11 Preparation of RNA
RNA was prepared either by hot phenol extraction (larger quantities) o r using 
Epicentre® MasterPure™ yeast RNA purification kits (142). For hot phenol extractions 
200 ml cultures were grown to  early log phase (OD600 = 0.2-0.4), harvested on ice and
centrifuged at 3000 x g fo r 5 minutes at 4 °C. Pellets were washed in DEPC treated 
ddHzO and resuspended in 6 ml TES (10 mM Tris pH 7.5, 10 mM EDTA pH 8 and 0.5% 
SDS) in phenol / chloroform resistant Oak Ridge centrifuge tubes (Nalgene
#3114 with sealing cap assemblies #DS3 131)1. A fter addition of 6 ml acidic (pH 4.3 - 4.7) 
phenokchloroform 5:1 (Sigma P I944), samples were vortexed fo r approximately 5 
seconds in a fume hood and incubated at 65 °C in a hybridisation oven fo r at least I hour, 
vortexing fo r 10 seconds every 10 minutes. Samples were incubated on ice fo r 4 minutes, 
vortexed fo r 20 seconds and centrifuged at 4000 x g fo r 20 minutes. Approximately 5 ml 
from the upper phase was transferred to  a 50 ml phase-lock tube (5 Prime) containing 5 
ml acidic phenokchloroform and 5 ml chloroform, mixed by inversion and centrifuged at 
4000 x  g fo r 10 minutes. Samples were then washed by adding 5 ml of chloroformiisoamyl 
alcohol (24:1) to  the same tube, centrifuged as beforeh and RNA precipitated from the 
aqueous phase ethanol and sodium acetate pH 5.2 using standard procedures. 100 pg of 
the RNA was purified further using an RNeasy mini spin column (Qiagen) according to 
the manufacturer’s instructions.
2.12 Analysis of RNA from deletion strains using spotted arrays
For each analysis I prepared purified RNA enriched fo r polyadenylated RNA 
(polyA+ RNA) from three biological replicates of both the deletion strain and the wild 
type parental strain. I prepared the polyA+ RNA from I mg of total RNA using the 
Oligotex D irect mRNA Mini Kit (Qiagen). Brian Fleharty in the microarray facility
' Obtaining tubes that can withstand vortexing hot phenol is critical fo r this protocol.
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processed the samples according to the protocol described in ( 143), hybridising labelled 
cDNA w ith 70mer S.pombe spotted arrays designed by Chris Seidel. The scanned data 
was analysed by Chris Seidel to  generate lists of genes with significant changes in RNA 
levels between wild type and deletion strains essentially as described (144). Lists of genes 
with greater than 1.40 fold changes in RNA levels in the deletion strains can be found in 
Appendix C.
2.13 Preparation of cDNA
Except where otherwise noted, I prepared all cDN A from I pg of total RNA in 20pl 
reactions using iScript reverse transcriptase (Bio-Rad) and an oligo(dT) primer according 
to the manufacturer’s instructions. Reaction products were diluted l:50 fo r qPCR 
analysis.
2.14 Real time Polymerase Chain Reactions
Quantitative real tim e polymerase chain reactions (qPCR) were prepared w ith iQ 
SYBR Green Supermix (Bio-Rad) in 96 well plates sealed with Microseal “ B” sealing film 
(Bio-Rad). Typically 5 pi of diluted template was used in each 25 pi reaction to  avoid 
pipetting errors associated with using smaller template volumes. Reactions were cycled 
on MyiQ thermocyclers (Bio-Rad) and results were analysed with iQ5 analysis software 
(Bio-Rad) according to  the manufacturer’s instructions. Quantitation of gene expression 
was done either w ith reference to  a standards curve o r by the AACt method w ith the 
final analysis done w ith the iQ5 software. ChIP samples were analysed with reference to  a 
standards curve produced from 10 fold serial dilutions of genomic DNA. Values for 
“ relative quantity” were then exported to  excel fo r final analysis.
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2.15 Northern Analysis of RNA
Probe preparation. Single stranded radiolabeled RNA probes were prepared by in 
vitro transcription using the MAXIscript® kit (Ambion) according to  the manufacturer’s 
instructions. D N A template fo r the in vitro transcription was generated by PCR 
amplification of the region 26-547 of the sme2 gene using an antisense primer containing 
the T7 prom oter sequence (5* TAATACGACTCACTATAGGG 3’) at the 5’ end. 
Unincorporated nucleotides were removed with NucAway® spin columns (Ambion).
Northern blotting. 30 kug of total RNA per lane was resuspended in NorthernMax® 
formaldehyde loading dye (Ambion) and incubated at 65 °C fo r 15 minutes. Samples were 
fractionated in gels containing I % agarose, 2.2 M formaldehyde and IX  MOPS running 
buffer (40 mM MOPS pH 7.0, 10 mM sodium acetate and I mM EDTA) run at 5 V/cm in 
Ix MOPS running buffer. RNA was transferred onto BrightStar-Plus nylon membranes 
using 20x SSC buffer (3 M NaCL, 0.3 M Na3citrate-2H20  pH 7.0) and immobilized by 
exposure to  120 mj/cm2, 254 nm ultraviolet light in a CL-1000 UV crosslinker (UVP).
Blots were prehybridised fo r 30 minutes at 60 °C in ULTRAhyb buffer (Ambion), 
hybridised overnight at 60 °C in ULTRAhyb buffer containing single stranded radiolabeled 
RNA probes (~ 106 cpm/ml), washed twice fo r 5 minutes at room temperature in 2x 
SSC/0.\%  SDS, and washed twice for 15 minutes at 60°C in 0 .Ix  SSC/0.1%SDS. Signals 
were detected w ith a Molecular Dynamics Typhoon Phospholmager.
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2.16 Analysis of 3’ RNA ends
In order to analyse the 3’ ends of both polyadenylated and non-polyadenylated RNA 
species in samples of total RNA, total RNA samples were incubated in reactions with or 
w ithout poly(A) polymerase and the RNA products then analysed by 3’ RACE.
Polyadenylation. 2.5 pg total RNA was incubated with o r  w ithout 5 units poly(A) 
polymerase at 37 °C for 30 minutes in 20 pi reactions in buffer containing 40 units RNase 
Inhibitor (NEB), I mM ATP, 50 mM TRIS-HCI pH 7.9, 250 mM NaCI, and 10 mM MgCI2.
Reverse Transcription. Reaction volumes were increased to  50 pi with the addition of:
2.5 pi dNTP mix (10 mM)
5 pi 3-CDS primer A  (0.5 pM) 
3’-AAGCAGTGGTATCAACGCAGAGTAC(T30)VN-5’
I pi (40 units) RNase Inhibitor
I pi (200 units) SMART™ MMLV reverse transcriptase (Clontech)
2.5 pi DTT (0 .1 M)
10 pi TRIS-HCI pH 8.3 (250 mM), KCI (375 mM), MgCI2 (30 mM)
8 pi nuclease free ddH20 .
Reactions were incubated at 42 °C fo r 60 minutes and then at 72 °C fo r 7 minutes. 
Following the addition of 5 units RNAseH (NEB) reactions were incubated at 37 °C for 
30 minutes.
PCR amplification. cDN A products were amplified by polymerase chain reaction over
25 cycles using a gene specific forward primer and a reverse primer complimentary to  3’
CDS primer A  and with an annealing temperature o f 68 °C. Amplified products were
resolved by electrophoresis on 1.5% agarose TBE gels. Major bands were excised and the
D N A purified using QiaQuickgel extraction kits (Qiagen). D N A fragments were cloned 
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into the pCR®2.1TOPO® vector (Invitrogen) according to  the manufacturer’s 
instructions and plasmid DNA preps from approximately 10 colonies were sequenced to  
confirm the identity of the cDNA 3’ ends.
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CHAPTER 3. IDENTIFICATION AND CHARACTERISATION 
OF THE SpELL/SpEAF COMPLEX1
3.1 Introduction
The human ELL gene was first identified as a fusion partner of the M IL gene in the 
(I 1: 19)(q23;p13.1) translocation in some patients w ith acute myeloid leukemia (I, 145). 
ELL was later purified from rat liver nuclear extracts based on its ability to  activate the 
rate o f transcript elongation by RNA polymerase II (pol II) in vitro. Mechanistic studies 
showed that ELL interacts directly with transcribing pol II in vitro and functions by 
suppressing transient pausing by the enzyme at many sites along the D N A (2, 103). Two 
additional ELL family members, designated ELL2 and ELL3, as well as a single Drosophila 
melanogaster orthologue, have been identified through searches of sequence databases. 
These proteins all function similarly to  activate the rate of elongation by pol II in vitro (92, 
93, 106). Yeast two-hybrid screens fo r ELL-interacting proteins led to  the identification of 
two closely related proteins EAFI and EAF2 (105, I 15). EAFI colocalises with ELL in the 
nucleus of mammalian cells in Cajal bodies, nuclear structures that are enriched in factors 
involved in transcription and mRNA processing (109). Subsequently, we showed that 
EAFI and EAF2 bind directly to  ELL family members and function as strong positive 
regulators of ELL transcription activity in vitro (3).
It is unclear what role the ELL/EAF complex plays in regulating transcription in 
vivo. The Drosophila ELL homolog, dELL, is encoded by the Suppressor of Triplo-lethal
' This w o rk  has been published (J. Biol Chem 282, 57 6 1-9, 2007) and was featured as “ paper o f the week”
(4).
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[Su(Tpl)] locus and is essential fo r viability in flies. Mutations in Su(Tpl) may preferentially 
affect synthesis of some long transcripts and it is possible that some Su(Tpl) mutations 
suppress lethality resulting from overexpression of the Tpl gene by impairing synthesis of 
Tpl mRNA (94). dELL also colocalises with hyperphosphorylated (elongating) pol II on 
polytene chromosomes, consistent with a role fo r ELL in controlling transcript elongation 
in vivo (106). In Xenopus laevis, the EAF2 protein is specifically expressed in the eye and 
functions to activate transcription of the eye-specific Rx gene during development (123).
Although many components of the pol II transcription machinery are highly 
conserved across species from mammals to yeast, until now attempts to  identify 
orthologs o f the ELL and EAF proteins in fungi have been unsuccessful. It has been 
suggested that elongation factors like ELL might have evolved after the emergence of 
multicellular organisms, where genes can be many tens of kilobases long, and fine-tuning 
of the transcriptional program is expected to  be particularly important fo r differentiation 
and development (94).
Using a bioinformatics approach, Ron Conaway and Arcady Mushegian had 
previously identified tw o genes annotated in the S.pombe genome (ellI and e a fl) that 
appeared to  encode proteins similar to  ELL and EAF. These genes are found in S. pombe 
and several other fungi w ith completely sequenced genomes, but not in Saccharomyces 
cerevisiae.
I began by confirming the sequence of ell I and eafl mRNA and demonstrating that 
eafl has a sequence at the N terminus which was missed in the original genome 
annotation. Like the ir counterparts from larger eukaryotes, S. pombe ELL and EAF (SpELL 
and SpEAF) interact w ith one another to  form a stable heterodimer that potently
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activates transcription elongation by pol II in vitro. In common with yeast strains bearing 
mutations in several other components of the pol II elongation machinery, S. pombe 
lacking the gene encoding ELL exhibit a 6-azauracil-sensitive phenotype, suggesting that 
ELL could play an important role in transcriptional regulation even in simple, unicellular 
organisms (4).
3.2 Identification of ELL and EAF Orthologs in S. pombe
The predicted SPBP23AI0 .14c ORF was identified by Ron Conaway and Arcady 
Mushegian as a possible S. pombe orthologue of ELL It codes fo r a 533 amino acid protein 
specified by a gene with 3 exons on S. pombe chromosome II. Sequencing of a cDNA, 
which I generated by 5’-RACE, confirmed the predicted SPB23A10 .14c ORF. Multiple 
sequence alignments indicate that the sequence similarity between SPBP23AI 0.14c 
product and ELL orthologues from higher eukaryotes extends throughout the entire 
length of the protein, with the highest similarity concentrated in three predicted globular 
regions: an N-terminal all-beta domain, a central region that includes a predicted all-alpha 
region, and the previously defined C-terminal occludin-like domain (Figure 3-1 A). The 
gene encoding the SPBP23AIO.I4c ORF has been designated e lll, and the ell I gene 
product as SpELL. In an attempt to  find an S. pombe orthologue of EAFI, Ron Conaway 
compared the full-length 268 amino acid human EAFI ORF to  sequence databases; 
although no highly-scoring fungal homologues were found, using the highly conserved N- 
terminal I 10 amino acids of the human EAFI protein as the query generated a low- 
scoring match to the predicted S. pombe SPCCI223.10c ORF. The predicted 
SPCC1223.10c ORF in the database is 199 amino acids long and lacks 59 N-terminal amino
acids that are highly conserved in metazoan EAF proteins. Using both 5’ and 3’-RACE, I 
was able to  isolate a full length cDN A from S. pombe total RNA that included a new first 
exon and encoded 59 N-terminal amino acids missed in the original genome annotation 
(Figure 3-1 B).
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Figure 3-1 Multiple sequence alignment of ELL family proteins.
This alignment was performed by Arcady Mushegian. Distances, in amino acids, between conserved 
sequence blocks are indicated by numbers. Conserved regions in ELL proteins: N-term inal mostly-beta 
domain (top), middle alpha-helical domain, and C-terminal occludin-like domain (bottom).Predicted 
secondary structure is shown below the alignment. Yellow  shading indicates conserved bulky hydrophobic 
residues (aliphatic I, L,V, M o r aromatic F, Y, W ), red type indicates conserved residues w ith small side 
chains o r propensity fo r main-chain turns (A, G, S, P), red-shaded green type indicates conserved residues 
w ith carboxy o r  carboxamide side chains (D, E, N, Q), blue type indicates conserved positively charged 
residues (K, R), and magenta type indicates a conserved histidine. In the secondary structure lanes, h 
indicates alpha-helix, I indicates loop and s indicates beta-sheet. Secondary structures are predicted, except 
fo r the the occludin domain structure, which that is taken from  PDB structure IX A W  (C-terminal domain 
of human occludin) ( 124). Species abbreviations are as follows: Aedae, Aedes aegypti; Arath, Arabidopsis 
thaliana; Aspni, Aspergillus nidulans; Bos, Bos taurus; Caebr, Caenorhabditis briggsae; Chagl, Chaetomium globosum; 
Dartre, Danio rerio; Drome, Drosophila melanogaster; Cibze, Giberella zeae; Maggr, Magnaporte grisea; Phano, 
Phaeospheria nodorum; Schja, Schistosoma japonicum; Schpo, Schizosaccharomyces pombe; Strpu, 
Strongylocentrotus purpuratus; Tetni, Tetraodon nigroviridis; Trica, Triboleum castaneum; Xenia, Xenopus laevis; 
Yarli, Yarrowia lipolytica.
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The sequence of this full-length eafl cDN A has been submitted to  the GenBank 
with accession number EF192607 (Appendix D).
When this extended protein sequence was compared to  the database, the first 
match, was a protein from Schistozoma japonicum (gi 29841 I 14) annotated as similar to 
Homo sapiens EAFI. When this S. japonicum sequence was used as a query, the known 
and predicted EAF homologues from various eukaryotes were detected, including SpEAF. 
EAF homologues were found in all metazoa, in higher plants, and in most fungi and 
protists, but not in S. cerevisiae. The gene encoding the extended SPCCI223.10c ORF has 
been designated as e a fl, and the eafl gene product as SpEAF.
3.3 Sensitivity of an elHA strain to 6-azauracil
Yeast strains carrying mutations in genes encoding a number of proteins implicated 
in regulation of transcription elongation grow slowly in the presence of the nucleotide- 
depleting drug 6-azauracil. To determine whether ell I o r eafl mutants are sensitive to  6- 
azauracil, I generated strains lacking ell I o r e a f l. The ell IA  and eafl A strains were both 
viable. Although the eafl A strain appeared to  grow as well as wild type S. pombe on plates 
containing 6-azauracil, the ell!A  strain exhibited a 6-azauracil-sensitive phenotype (Figure
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PP138 
e l  1 1 A  
PP138 
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Figure 3-2 6-azauracil sensitivity of S. pombe deleted for the gene encoding SpELL.
The parental strain PP138 and the elllA strain, both containing the pUR19 plasmid, were grown to 
mid log phase in rich media, washed in 1.2 M sorbitol, and resuspended in 1.2 M sorbitol at a 
density o f 1 x 108 cells/ml. 5 pi of 3-fold serial dilutions of cells were spotted onto EMM plates 
supplemented with adenine, histidine and leucine (225 pg/ml) with or w ithout 6-azauracil (300 
pg/ml).
3.4 Direct interaction of SpELL with SpEAF
To determine whether SpELL and SpEAF interact with one another in cells, I 
expressed N-terminal FLAG-tagged SpELL or SpEAF individually in S. pombe under
EMM
EMM + 6-AU
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control of the inducible nm tl promoter. I purified SpELL- and SpEAF-associated proteins 
from these strains using anti-FLAG agarose immunoaffinity chromatography and these 
were identified by mass spectrometry using multi-dimensional protein identification 
technology (MudPIT)1. As summarized in Table 3.1, epitope-tagged SpELL and SpEAF 
specifically copurified with endogenous SpEAF and SpELL, respectively, indicating that the 
two proteins interact in cells. The NSAF gives an approximate indication o f the relative 
abundance of a protein in each sample and the NSAF values here indicate that the 
amounts of epitope-tagged subunit and the endogenous partner subunit are of the same 
order of magnitude.
FLAG-SpELL FLAG-SpEAF FLAG-control
peptides spectra NSAF peptides spectra NSAF peptides spectra NSAF
SpELL 20 70 0.0094 36 179 0.0123 0 0 -
SpEAF 13 117 0.0335 32 292 0.0425 0 0 -
Table 3.1 SpELL coim m unoprecipitates with SpEAF expressed in S. pombe.
Cell lysates from S. pombe expressing FLAG-SpELL, FLAG-SpEAF, or FLAG-6His were purified 
by anti-FLAG immunochromatography and subjected to MudPIT mass spectrometry. The table 
shows the number of peptides and spectra for SpELL and SpEAF detected in samples purified 
from cells expressing either FLAG-SpELL or FLAG-SpEAF. NSAF, normalized spectral abundance 
factor. The number o f spectra for a given protein detected in a MudPIT run has been shown to be 
a function of the protein ’s size and abundance (133); hence, comparison of the spectral counts 
provides a:rough estimation of the relative abundance o f different proteins across samples. NSAF 
is the spectral count for a given protein, normalized to the protein’s length and the total number of 
spectra detected in the MudPIT run. NSAF is calculated using the equation
(A<SAF)t -  f p C IL ^ h _
^  (SpC / Length) t
where SpC is the number o f spectra detected, k denotes a specific protein, and N is all proteins 
detected.
1 The MudPIT runs and analysis were performed by Skylar M artin-Brown, Laurence Florens and Michael 
Washburn in the Stowers Institute proteomics facility.
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I next subcloned the SpELL and SpEAF ORFs into baculovirus vectors and expressed them 
in Sf2l insect cells in several epitope-tagged forms. In particular, I coexpressed FLAG-
lysate IP: FLAG
+ + + + + + myc :SpELL
+ + + ■ f: SpEAF
+ + + + + + myc: SpEAF
+ kD + + - f: SpELL
150-
100-
75- —  —  -SpELL
50-
37- ^  -SpEAF
25-
20- Coomassie
1 2  3 4 M 5 6 7 8 9 10 11 12
Figure 3-3 Interaction of SpELL and SpEAF.
Sf21 cells coinfected with baculoviruses encoding FLAG-SpELL, Myc-SpELL, FLAG-SpEAF or 
Myc-SpEAF in the combinations indicated in the figure were prepared and immunoprecipitations 
were carried out with the antibodies indicated in the figure. Bound proteins were eluted with 150 
ng/pil FLAG peptide, analyzed by SDS-PAGE, and detected by either Western blotting or staining 
with Coomassie Blue R-250.
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SpEAF with Myc-SpELL or FLAG-SpELL with Myc-SpEAF ( 
lysate IP: FLAG
+ + + + + + myc:SpELL
+ + + - f: SpEAF
+ + + + + + m y c : SpEAF
+ kD + + - f: SpELL
150-
100-
75- —  —  -SpELL
50-
37- ^  -SpEAF
25-
20- Coomassie
M 9 10 11 12
Figure 3-3 lanes I -4) and purified the resulting protein complexes using anti-FLAG 
agarose chromatography (lanes 5 -12). FLAG-SpEAF copurified with Myc-SpELL (lanes 5 
and 9) and FLAG-SpELL copurified w ith Myc-SpEAF (lanes 7 and I I). The interaction of 
SpELL and SpEAF appeared to be direct, since only very small amounts of any additional 
proteins were present in my purified preparations of SpELL/SpEAF (lanes 9 and I I).
3.5 The SpELL/SpEAF Complex Activates Transcription 
Elongation by S. pombe RNA Polymerase II
To test the effects of SpELL and SpEAF on transcription elongation by S. pombe pol
II, I assayed transcript elongation on a linearised plasmid with a single-stranded 3’
oligo(dC)-tail on its template strand. Although purified pol II is unable to initiate from a
specific location on double-stranded DN A w ithout assistance from the general 
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transcription factors TFIID, TFIIB, TFIIE, TFIIF, and TF1IH, it binds to  the single-stranded 
oligo(dC)-tail and initiates transcription at the junction between the single- and double­
stranded regions o f the template (146). On the template used in my experiments, the first 
nontemplate strand (dT) residue is 136 nucleotides downstream of the oligo(dC)-tail; 
thus, transcripts of 135 nucleotides will accumulate when transcription is initiated with 
just ATP, CTP, and GTP.
In the experiment shown in Figure 3-4, I initiated transcription by the addition of 
purified S. pombe pol II1 to  reaction mixtures containing the oligo(dC)-tailed template, 
ATP, GTP, and [a-32P]CTP. A fter a 30-min incubation to  allow accumulation of pol II 
ternary elongation complexes containing radioactively labelled, 135 nucleotide long 
transcripts, I purified the elongation complexes by gel filtration to  remove unincorporated 
ribonucleoside triphosphates (Figure 3-4 lane I). I then chased nascent transcripts into 
longer products by the addition of ATP, GTP, CTP and UTP, in the presence o r absence 
of SpELL, SpEAF, o r both (Figure 3-4, lanes 2-13). Like the mammalian ELL- EAF complex 
(3), the SpELL/SpEAF complex stimulated the rate of transcription elongation by its 
cognate S. pombe pol II, as detected by an increase in the rate that radioactively labelled 
135 nucleotide long transcript was chased into longer products when reactions included 
the SpELL/SpEAF complex. Addition of either SpEAF o r SpELL alone had a negligible 
effect on the rate of transcript elongation. Notably, SpEAF(60-251), which is the 
truncated version of SpEAF encoded by the predicted SPCCI223.1 Oc ORF and which lacks
1 The purified pol II was a kind gift from  H enrik Spahr
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Figure 3-4 SpELL and SpEAF stim ulate elongation by S. pombe pol II.
Oligo(dC)-tailed template transcription reactions were initiated by the addition of 50 pM ATP, 50 
|iM GTP, 2 (.iM CTP and 10 |iCi [a-32P]CTP (400 mCi/mmol). A fter a 30-min incubation, paused 
pol II elongation complexes were purified, and labeled transcripts were chased into longer products 
by the addition o f 2 piM ATP, 2 [iM GTP, 2 CTP and 2 pM UTP, with or w ithout 5 pmol SpELL or 
SpEAF. Reactions were stopped after 5, 10 or 30 minutes of chase. The lane marked M shows 
OX174 Hae III restriction fragm ents used as size markers.
the most highly evolutionarily conserved N-terminal region of the protein, was inactive 
even in the presence of SpELL (Figure 3-5 and data not shown).
62
SpEAFl—
SpEAF(60-251)
3 =
SpELL - + 
SpEAF - + 
SpEAF(60-251) - -
lysate
+  +
IP: FLAG
Western Western
gray box represents the 
(dC )-tailed template 
.M GTP and 10 jaCi [a- 
e or mutant SpEAF, and 
panel, FLAG-SpEAF(60- 
/ith anti-FLAG antibodies,
myc:SpELL 
f: SpEAF 
myc : SpEAF 
f: SpELL
M 8
—  -SpELL 
-SpEAF 
Coomassie 
10 11 12
63
To obtain additional evidence that the SpELUSpEAF complex possesses 
transcription activity, I further fractionated the purified SpELL/SpEAF complex by ion 
exchange HPLC and monitored copurification of SpELL/SpEAF with pol II stimulatory 
activity. I coinfected Sf2l insect cells with baculoviruses expressing FLAG-SpELL and Myc- 
SpEAF, and the resulting cell lysates were subjected to  anti-FLAG agarose 
chromatography followed by chromatography on a TSK DEAE-NPR HPLC column. 
FLAG-SpELL and Myc-SpEAF proteins co-eluted from  the TSK DEAE-NPR column at 
-160 mM KCI, w ith the majority of both proteins being detected in fractions 7, 8 and 9 
(Figure 3-6 A, lower panel).
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A purified separately
fraction L FT 3 5 7 9 11 1315171921 
f:SpELL»
myc:SpEAF
Coomassie
purified together
KCI ________
fraction L FT 3 5 7 9 11 1315171921
f:SpELL
mycSpEAF Western
f:SpELL -  -  
mycSpEAF Coomassie
B
fraction - L FT 3 5 7 9 11 13 15
135 4  — “
transcription assay
Figure 3-6 Cochromatography of stim ulatory activity with the SpELL/SpEAF complex.
FLAG-SpELL and Myc-SpEAF were expressed separately (upper panel) or together (lower panel) 
in insect cells and purified by anti-FLAG agarose chromatography. The eluate was adjusted to a 
conductivity equivalent to 0.05 M KCI and applied to a 0.6 ml TSK DEAE-NPR HPLC column pre­
equilibrated in buffer A  containing 0.1 M KCI. The column was eluted with a 6 ml linear gradient 
from 0.1 to 0.5 M KCI in buffer A, and 0.2 ml fractions were collected. A liquots o f the indicated 
fractions were analyzed by SDS-polyacrylam ide gel electrophoresis and either stained with 
Coomassie Blue R-250 or analyzed by W estern blotting with anti-FLAG (red) or anti-myc (green) 
antibodies.
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SpELL and SpEAF purified according to  this procedure were stably associated with 
one another, since SpELL and SpEAF eluted from the TSK DEAE-NPR at distinct positions 
when they were expressed and purified individually (Figure 3-6 A, upper panel). To assay 
column fractions fo r their ability to stimulate the rate of transcript elongation, I used a 
modified version of the tailed template assay, in which I measured accumulation of the 
135-nt, U-less transcript initiated from the oligo(dC)-tail on pAd-GR220 in the presence 
of only ATP, GTP and a limiting amount of CTP. During the short incubation time and 
with the limiting concentration of nucleotides used in these assays, only a fraction of pol II 
molecules are able to  complete synthesis of 135 nucleotide long transcripts in the 
absence of elongation factors unless the rate of transcript elongation is stimulated by 
elongation factors. As shown in Figure 3-7, synthesis of 135 nucleotide long transcripts 
depends on the presence of pol II and is inhibited by 5 ng/ml a-amanitin, a concentration 
that is sufficient to  inhibit purified S. pombe pol II (data not shown) but that does not 
inhibit S. pombe pol I o r pol III (147, 148).
Thus, this assay provides a reliable and more easily quantifiable alternative to  the 
pulse-chase protocol, since it measures synthesis of a single transcript, rather than a 
collection o f products w ith variable lengths. As shown in Figure 3-6 C, the SpELL/SpEAF 
complex co-eluted with pol II stimulatory activity from the TSK DEAE-NPR column, 
arguing that the SpELL/SpEAF complex possesses intrinsic transcription stimulation 
activity.
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a-amanitin - - - +
SpELL/SpEAF - + + + 
Pol II + + - +
Figure 3-7 Synthesis of 135nt transcripts by pol II.
Oligo(dC )-tailed template transcription reactions were performed in the presence of 50 pM ATP, 50 
pM GTP and 10 pCi [a-32P]CTP (400 mCi/mmol) with 3 pmoles SpELL, 3 pmoles SpEAF, 5 pg a- 
amanitin and 20 ng pol II as indicated . Reactions were stopped after 5 minutes.
3.6 The SpELL/SpEAF Complex Stimulates 
Pyrophosphorolysis.
During RNA synthesis, RNA polymerases catalyze nucleophillic attack by the 3’- 
hydroxyl group of the nascent transcript on the a-phosphate of the incoming 
ribonucleoside triphosphate, resulting in nucleotide addition and pyrophosphate release:
NTP + RNAn ^  RNAn+1 + PPj
In the presence of high concentrations of inorganic pyrophosphate, RNA 
polymerases will catalyze the reverse reaction, pyrophosphorolysis, during which the 
nascent transcript is shortened with concurrent release of ribonucleoside triphosphates.
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These reactions are thought to be carried out by the same active site in pol II. If, as has 
been proposed fo r other pol II elongation factors including mammalian TFIIF, Elongin, and 
ELL (59, I 13), SpELL/SpEAF stimulates transcription by stabilizing the active site of pol II 
in an active configuration, it would be expected to stimulate not only elongation but also 
pyrophosphorolysis. To determine whether the SpELL/SpEAF complex could stimulate 
pyrophosphorolysis, I purified pol II ternary transcription complexes free of 
ribonucleoside triphosphates and incubated them in inorganic pyrophosphate in the 
presence o r absence of the purified SpELL/SpEAF complex.
As shown in Figure 3-8, transcripts grew progressively shorter during incubation 
with pyrophosphate, and the rate of transcript shortening was greater in reactions that 
contained the SpELL/SpEAF complex. Transcript shortening was due to 
pyrophosphorolysis and not to the presence o f contaminating ribonuclease, since it was 
strictly dependent on the presence of pyrophosphate (Figure 3-8 A  and B). As observed 
for the SpELL/SpEAF elongation stimulatory activity, neither SpELL nor SpEAF alone is 
sufficient to  stimulate pyrophosphorolysis (Figure 3-8 B).
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Figure 3-8 The SpELL/SpEAF com plex stim ulates pyrophosphorolysis by paused pol II 
elongation com plexes.
Paused transcription elongation complexes containing ~135-nucleotide long transcripts were 
prepared as described in experimental procedures. (A) Purified ternary complexes were incubated 
with 0.3 mM PPi (lanes 2-7) for the times indicated in the presence or absence of an aliquot from 
the peak fraction of the TSK DEAE-NPR purified SpELL/SpEAF complex. (B) Ternary complexes 
were incubated for 5 minutes with ~5 pmoles SpELL, SpEAF or both in the presence or absence of 
0.3 mM PP,
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3.7 The SpELL/SpEAF Complex Does Not Activate Elongation 
By Mammalian RNA Polymerase II.
Previous studies have shown that metazoan ELL can bind directly to pol II in vitro 
(103, 106). Similarly, SpELL can bind directly to S. pombe pol II, as can SpELL/SpEAF;
Input ip; FLAG
+ + + + + + +  + S. pombe pol II
- + + -  . + + .  FLAG-SpELL
- - - + - - - + FLAG-SpEAF
- - + - - - + - myc-SpEAF
. , ri fc Rpb1
FLAG-SpELL
FLAG-SpEAF
myc-SpEAF
Figure 3-9 Physical interaction of the SpELL/SpEAF com plex with pol II.
~0.2 pg S. pombe pol II was mixed with ~10 pmoles of the factors indicated, in buffer containing 20 
mM Hepes-NaOH, pH7.9, 20mM TrisH C I, pH7.9, 50 mM KCI, 1 mM DTT, 0.5mg/ml BSA/2% 
(wt/vol) polyvinyl alcohol (average molecular weight 30,000-70,000 Da), 3% (wt/vol) glycerol, 5 mM 
MgCI2. Im munoprecipitations were carried out with anti-FLAG agarose, and bound proteins were 
eluted with 150 pg/ml FLAG peptide, analyzed by SDS-polyacrylam ide gel electrophoresis, and 
detected by W estern blotting.
however, free SpEAF binds only poorly to pol II (Figure 3-9). In addition, mutations in
human ELL that interfere w ith pol II binding also interfere w ith its ability to  stimulate
elongation (103). Taken together, these observations suggest that ELL increases the
elongation activity of transcribing pol II through direct interactions with the enzyme. If
this model is correct, one might expect ELL/EAF to  stimulate pol II in a species-specific 
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fashion. To determine whether the activity of SpELL and SpEAF is specific fo r S. pombe 
pol II o r whether it can also stimulate mammalian pol II, I assayed the ability of purified 
pol II from rat liver to generate 135-nt transcripts initiated from the oligo (dC)-tail on 
pAd-GR220, in the presence of recombinant SpELL/SpEAF o r both. As shown in Figure 
3-10 A, transcription by mammalian pol II was unaffected by SpELL/SpEAF, although the 
same amount of SpELL/SpEAF stimulated elongation by S. pombe pol II. Similarly, 
transcription by S. pombe pol II was unaffected by recombinant human ELL/EAFI, although 
the same amount of human ELL/EAFI stimulated elongation by rat pol II (Figure 3-10 B). 
Therefore, stimulation of elongation by ELL/EAF depends on specific interactions between 
ELL/EAF and pol II.
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Figure 3-10 Functional interaction of the SpELL/SpEAF com plex with pol II.
(A) Insect cells were infected with recombinant baculoviruses encoding FLAG-HsELL, FLAG- 
H sEA FI, FLAG-SpELL or FLAG-SpEAF. Proteins were then purified by anti-FLAG agarose 
chromatography, and 3 pmoles of each factor was assayed for its ability to stimulate transcription 
by pol II purified from rat liver nuclear extracts as indicated. Transcription reactions were initiated 
from the T-less cassette of oligo(dC)-tailed template pAd-GR220 by the addition of 50 pM ATP, 50 
pM GTP, 2 pM CTP and 10 pCi [a-3 P]CTP (400 mCi/mmol). Reactions were stopped after 5 
minutes. (B) Functional interaction of the SpELL-SpEAF complex with S. pombe pol II. 3 pmoles of 
each factor was assayed for its ability to stimulate transcription by pol II purified from S. pombe. 
Reactions were initiated by the addition o f 50 pM ATP, 50 pM GTP, and 10 pCi [a-32P]CTP (400 
mCi/mmol) and stopped after 5 minutes.
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3.8 Discussion
The SpELL/SpEAF complex is a new transcription elongation factor that shares 
structural and functional properties w ith the ELL/EAF complex found in higher 
eukaryotes. As w ith the mammalian ELL/EAF, the S.pombe SpELL/SpEAF complex can 
stimulate the rate of transcription elongation of its associated RNA polymerase (Figure 
3-4) and can positively regulate the reverse reaction, the removal of nucleotides through 
pyrophosphorolysis (Figure 3-8). Previously it had been thought that transcription 
elongation factors of this type were limited to  higher eukaryotes and may have been used 
particularly fo r transcribing genes many kilobases long. Eissenberg and coworkers 
suggested “ ELL family proteins appear to  have co-evolved with the dramatic growth in 
transcription unit lengths that accompanied the evolution of metazoan eukaryotes.” (94). 
The discovery of the SpELL/SpEAF complex in S.pombe, a single celled eukaryote with an 
average gene size o f I430bp' (150) shows that this is not the case. It is curious that ELL 
and EAF homologues exist in higher, multicellular eukaryotes and in some fungi including 
S. pombe but not in S. cerevisiae and related yeasts. S. cerevisiae is distinct in that it lacks 
the apparatus needed fo r many splicing processes and fo r RNAi. This raises the possibility 
that in vivo SpELL/SpEAF function is related to  RNA processing o r to  gene silencing.
Deletion of the gene encoding SpELL renders the cells sensitive to  growth on media 
containing the drug 6-azauracil (6AU) (Figure 3-2). Although this phenotype is seen with
1 Compare w ith the average human gene length o f 27000 bp (149).
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mutations of genes involved with other cellular processes (151), 6AU sensitivity is often 
associated with mutations in genes encoding proteins involved in transcription elongation. 
These include pol II subunits Rpbl (152), Rpb2 (153), Rpb9 (154), the transcription 
elongation factors Sll (155), Spt4 and Spt5 (similar to  human DSIF), and Spt6 (similar to a 
subunit of human FACT) (156). In cells 6AU is converted to  6-azaUMP, which inhibits 
GTP biosynthesis and 6AU might affect elongation rate by reducing the cellular pools of 
GTP ( 157).
These results provide new insight into the biochemical mechanism by which the ELL/EAF 
complex stimulates the rate of transcript elongation. Previous coimmunoprecipitation 
experiments have suggested that ELL interacts directly with pol II (103, 106). I have shown 
that the S. pombe and human ELL/EAF complexes specifically activate S. pombe and 
mammalian pol II, providing functional evidence that ELL stimulates elongation through a 
direct interaction w ith pol II (Figure 3-10). In addition, while confirming that ELL 
coimmunoprecipitates pol II w ithout the need fo r additional factors, I have shown that 
SpEAF binds pol II only very weakly o r not at all (Figure 3-9). This suggests that EAF 
might not stimulate elongation by direct interaction with pol II but instead might be 
modulating ELL activity. EAF might induce a conformational change in ELL. This could 
allow ELL to  stimulate pol II elongation activity more effectively, and/or could change the 
ELL/pol II binding affinity allowing ELL a greater probability of interacting with and 
stimulating pol II. The effect of EAF on ELL/pol II binding affinity could be investigated with 
a more quantitative assay, perhaps by using fluorescence correlation spectroscopy (FCS).
It has not previously been clear which regions of EAF are required fo r binding to  ELL and 
for elongation activity. I have demonstrated that w ithout the highly conserved N terminus 
SpEAF can neither bind to  SpELL nor can upregulate SpELL stimulation of pol II elongation
activity (
lysate IP: FLAG
+ +  
+
+ + + +
kD + +
150-
100-
75-
50-
37- -
25-
20- Coomassie
myc:SpELL 
f: SpEAF
myc:SpEAF 
f: SpELL
-SpEAF
M 5 9 10 11 12
Figure 3-3). Further investigation could reveal whether other regions of SpEAF, fo r 
example the acidic C terminus, are dispensable'.
In vitro the SpELL/SpEAF complex interacts directly with RNA pol II via the SpELL 
subunit to  stimulate the rate of transcription elongation by reducing pol II pausing. The 
next chapter will begin to investigate the role of the SpELL/SpEAF complex in cells.
1 Interaction studies w ith  truncation mutants o f human EAF I suggest that the conserved N terminal region 
is sufficient fo r binding ELL (CASB unpublished data).
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CHAPTER 4. IDENTIFICATION OF GENES REGULATED 
BY THE SpELL/SpEAF COMPLEX IN S.POMBE
4.1 Introduction
I have demonstrated that SpELL and SpEAF function as a complex to  stimulate the 
rate of pol II catalysed transcript elongation in vitro. Their role in cells could be to  function 
as a general activator of elongation or the SpELL/SpEAF complex may have evolved to 
fulfil some alternative function during transcript elongation that necessitates binding to  pol 
II (and perhaps stabilising it) in its elongating state. Previous studies have supported some 
role fo r ELL/EAF in transcription in cells. The complex is localised in the nucleus in Cajal 
bodies, perhaps together w ith other machinery involved with transcription and RNA 
processing (109). Studies in drosophila have shown that dELL and dEAF colocalise with 
pol II engaged in transcription on chromatin and may be relocalised to  genes when they 
need to  be transcribed in a timely fashion (106, 158). Furthermore, evidence from a very 
recent study suggests that human ELL/EAF, functioning as part of a large complex that 
also includes P-TEFb and several other MLL translocation partners, regulates heat shock 
and several hox genes in cells (102).
Many questions remain about what subset of a genome ELL and EAF might be 
targeting and why. Although there has been no systematic study of ELL/EAF’s contribution 
to gene regulation, a previous study of ELL function in Drosophila provided some evidence 
ELL/EAF may contribute more to  regulation of longer, intron containing genes such as 
Notch, cut and Scr (size range 23-65 kb) rather than shorter genes such as white and 
rudimentary (5.9-13 kb) (94). The existence of the complex in S. pombe, which has a mean 
gene length of 1.4 kb and no genes longer than 15 kb, suggests that the ELL/EAF complex
might have a role in the transcription of much shorter genes. Defining which genes in a 
genome are regulated by ELL/EAF will answer questions including whether the complex 
regulates all o r just some genes, whether regulation depends on some property of the 
gene (for example the presence of introns o r the gene length), o r whether specific 
pathways o r genes fulfilling a specific function are affected. In order to  define 
SpELL/SpEAF regulated genes fo r such an analysis, I have used spotted microarrays to 
investigate global changes in gene expression after deletion of either SpELL or SpEAF, 
and I sought to  define genes that colocalise w ith the complex by hybridising chromatin 
immunoprecipitations to  tiling arrays.
In addition to  defining which genes are regulated, the results address questions 
about how the complex functions at genes, fo r example to  what extent SpELL and SpEAF 
colocalise at a gene and function in concert, and whether they appear to  operate in a 
distinct region such as at the prom oter o r the 3’ end of a gene. Importantly, identification 
of a set of genes that are thought to be targeted by the SpELL/SpEAF complex provides 
candidate genes fo r further analysis,
4.2 Misregulation in ell-1 A or eaflA cells of a common set of 
genes, including a number of genes involved in cell 
separation.
In order to  determine which genes o r pathways might be regulated either directly 
o r indirectly by the SpELL/SpEAF complex, I compared RNA from either ell IA  o r eafl A 
cells with RNA from wild type cells using microarrays spotted with 70mer D N A probes 
(described in section 2 .12). Genes with a greater than 1.40 fold difference between 
mutant and wild type signals and an adjusted p-value less than 0.025 were further analysed
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Figure 4-1 Correlation between changes in mRNA levels of 36 genes in elllA  and eaflA  cells 
relative to wt cells.
Genes identified by spotted arrays whose expression changed in either the elUA or eaflA strains 
relative to wild type cells were further analysed by RT / qPCR. Reverse transcription was primed 
with an oligo(dT) primer. Levels of cDNA for each gene analysed were calculated relative to the 
level of actin cDNA for each experiment. Data points shown as open dots represent genes in the 
ace2 pathway. Error bars represent the standard deviation of three independent experiments.
by RT / qPCR and are listed in Appendix C. O f the 36 genes identified by the expression 
array analysis, 27 (75%) had a greater than 1.40 fold difference between mutant (either 
ell IA  o r eafl A) and wild type RNA levels as following analysis by qPCR. When I compared 
the changes in RNA levels in ell IA  cells relative to wild type cells with changes in RNA 
levels in eafl A cells relative to  wild type cells, I found a strong positive correlation 
(correlation coefficient 0.73 Figure 4 -1).
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Figure 4-2 Deletion of the eafl gene results in a decrease in SpELL protein.
W hole cell extracts from approximately equal numbers of cells o f the strains indicated were 
prepared as described in Chapter 2. and analysed by SDS-PAGE followed by Western blotting. 
Membranes were probed with anti-tubulin (mouse monoclonal, Sigma T9026), anti-myc (goat 
polyclonal, AbCam Ab9132) primary antibodies and IRDye®800 anti-mouse (green) and Alexa 
Fluor® 680 anti-goat (red) secondary antibodies prior to scanning with a Li-COR® Odyssey® infra 
red imaging system.
4.3 Deletion of eafl results in a change in SpELL protein levels
The correlation between global effects on RNA levels caused by the deletion of the 
ell I gene or the eafl gene could be due to the requirement for both the SpELL and SpEAF 
proteins fo r the correct expression of the genes affected by deletion of either ell I or 
e a f l . Alternatively this correlation could be the result of a direct requirement fo r only 
one subunit of the SpELL/SpEAF complex fo r proper gene regulation, but that deletion of 
the other subunit has an indirect effect on global patterns of gene expression by causing a 
change in levels of its partner subunit. In order to test whether deletion of either ell I 
affects SpEAF protein levels o r deletion of eafl affects SpELL protein levels, I analysed 
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tubulin
whole cell extracts from various strains by SDS PAGE followed by W estern blotting as 
detailed in Figure 4-2. I found a significant decrease in SpELL:l3myc in the ellhmyc eafl A 
strain compared w ith the elll:myc strain. There was a more modest effect on levels of 
SpEAF:l3myc in the absence of e l l l . W hile these results do not exclude the possibility 
that SpELL and SpEAF affect global patterns of expression of a common set of genes 
independently, they suggest that the common pattern of changes in global gene 
expression may, at least in part, be due to  reduced levels of one subunit of the 
SpELL/SpEAF complex in both the elll A and eafl A strains. Having shown that deletion of 
one subunit decreases levels of the partner subunit, I wondered whether this co­
regulation was at the transcriptional level. To test whether, fo r example, deletion of eafl 
leads to  a decrease in elll mRNA levels, I performed oligo(dT) primed reverse 
transcription on total RNA isolated from the strains indicated (Figure 4-3) followed by 
qPCR analysis of both elll and eafl cDN A levels. I did not detect a decrease in elll 
mRNA in eafl A cells (Figure 4-3 A). Similarly, deletion of elll does result in decreased 
levels of eafl mRNA (Figure 4-3 B). Taken together, these results suggest that the 
downregulation of SpELL protein in the eafl A strain (and to  a lesser extent of SpEAF 
protein in the elll A strain) is a result of events post transcription.
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Figure 4-3 Levels of elll mRNA are not reduced in eaflA  cells.
Am ounts of elll or eafl mRNA were normalised to act1 (actin). Error bars represent the range of 
three independent experiments.
4.4 Reintroducing elll at the Ieu1 locus partially rescues 
altered patterns of gene expression
To confirm that the global changes in RNA levels we had observed were due to 
disruption of the SpELL/SpEAF complex and not, fo r example, caused simply by the 
insertion of the antibiotic marker, I inserted the elll gene at the leu I locus into cells in 
which the endogenous elll gene had been deleted. This insertion included regions 
upstream and downstream of the elll coding region, which may be necessary fo r proper 
transcriptional regulation of e l l l . I then looked at the RNA levels of a number of genes 
whose expression was altered in the elll A cells to  see whether insertion of elll at the leu I 
locus could rescue the altered gene expression. The level of elll mRNA in the elll rescue 
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Figure 4-4 Rescue of altered gene expression in the elHA strain
The elll gene was cloned into the pDUAL vector (129) and inserted at the Ieu1 locus in elHA cells 
to generate the ell1+ strain. Total RNA from three independent replicates of wild type (PP138), 
elHA, and ell1+ cells was prepared by hot phenol extraction as described on page 44. 1 (.ig of total 
RNA was reverse transcribed with an oligo(dT) primer and the cDNA was analysed by qPCR. RNA 
levels were calculated relative to the levels of actin (act1) using the AACt function in the iQ5 
analysis software (Bio-RAD). Error bars represent the range of the three biological replicates.
cells (indicated as e///+) was between 70% and 90% of the level of ell I mRNA in wild type 
cells (Figure 4-4). The lower levels of elll mRNA could be due to a failure to  reintroduce 
all of the control regions required fo r proper elll transcription in the e ll l+  cells. 
Alternatively there may be a difference in the chromatin environment between leu I and 
elll loci, which could result in altered transcription of genes in these regions.
I next tested a selection of genes that were either downregulated (sme2, oce2, oce2 
regulated genes engl and adg l, and pho l)  o r upregulated ( t lh l)  in the elll A cells. The 
changes in RNA levels seen in elll A cells fo r these genes were reversed in e///+ cells 
(Figure 4-4), although in some cases, most notably fo r phol, the rescue was partial. These 
results suggest that the altered patterns of gene expression we had observed were 
primarily due to disruption of the SpELL/SpEAF complex in our deletion strains and not,
82
fo r example, to the presence o f the antibiotic cassette. In the future, it will be interesting 
to  investigate the possibility phol is particularly sensitive to  SpELL/SpEAF levels in cells.
In addition to  these rescue experiments, I have tested an additional S. pombe elll A 
strain and an S. japonicus elll A strain. I In these additional strains, I also observe the same 
changes in RNA levels, confirming that these effects are not specific to  the PPI38 parental 
strain (data not shown). The same effects are also observed when elll A cells are grown in 
minimal rather than rich media.
4.5 Chromosomal localisation of SpELL and SpEAF suggest a 
direct role in regulating of some genes downregulated in 
the elHA and eaf/A strains.
I hypothesise that genes that colocalise with the SpELL and SpEAF proteins are 
more likely to  be directly regulated by the SpELL/SpEAF complex. In order to  determine 
the chromosomal location of SpELL and SpEAF proteins, I first constructed the epitope 
tagged strains SpELL:myc and SpEAF:myc (as described in section 2.3). As previously 
described, elll A cells have a 6-azauracil sensitive growth phenotype so I confirmed that 
the presence of the epitope tag in the ellkmyc cells did not have an effect on cell growth 
on EMM media supplemented w ith the drug 6-azauracil (Figure 4-5). In addition to  the 
ellhmyc and eafhmyc strains, I generated a tagged pol II strain, rpb3:myc, and a tagged TBP 
strain, tbphmyc, to use as controls in the ChlP-chip experiments. C terminal myc epitope
1 Additional strains are ell l A (972h-) and Sje lll A  (CBS354/OYI) see appendix A. The Schizosaccharomyces 
japonicus ell I gene was identified by sequence comparison w ith  S. pombe e lll and deleted using the methods 
described fo r S. pombe gene deletion. The S. japonicus engl gene was identified by comparison w ith S. pombe 
sequences; RNA levels of S. japonicus engl w ere reduced in S. japonicus e lll A cells.
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tagged S.cerevisiae strains for TBP-myc and Rpb3-myc have been described previously 
(47, 159).
EMM EMM+6AU
PP138
ell1 A
el 11 :
Figure 4-5 ell1:myc epitope tagged cells are not sensitive to growth in the presence of 6- 
azauracil.
The strains indicated, each containing the pUR19 plasmid, were grown to mid log phase in rich 
media, washed in 1.2 M sorbitol, and resuspended in 1.2 M sorbitol at a density of 1 x 108 cells/ml.
5 fil o f cells were spotted onto EMM plates supplemented with adenine, histidine and leucine (225 
pg/ml) with or w ithout 6-azauracil (300 pg/ml).
4.5.1 ChlP-chip analysis
I performed chromatin immunoprecipitations using chromatin from strains
ellkmyc, eafkmyc, rpblim yc and tbpkm yc (as detailed in sections 2.9).
Immunoprecipitated DN A was then analysed using Afymetrix GeneChip® S. pombe Tiling
I.OFR Arrays (section 2.10). Previous studies have suggested that some regions of
chromatin, particularly transcribed regions, are coimmunoprecipitated more efficiently
than others and that different approaches to  analysing the same data can produce
different results ((160) Figure2). For these ChlP-chip analyses I have controlled fo r over 
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representing regions that might be more likely to  immunoprecipitated nonspecifically. For 
each experiment, D N A enriched with a myc antibody from cells expressing a myc-tagged 
protein was compared with D N A enriched nonspecifically from wild type (untagged) cells 
with the same antibody. Data analysis was performed by Madelaine Gogol using the MAT 
algorithm (as described (141)). The MAT algorithm generates a score based on the 
intensity value of each 25mer probe on the array. The intensity value is modified to  take 
into account probe sequence characteristics and copy-number variation (as some probes 
map to  multiple locations in the genome). The MAT score at any position is calculated 
from the modified intensity values of all probes within a 500 nucleotide window. Lists of 
genes enriched above background with an associated p-value1 below 0.05 are designated 
“ enriched genes” and are presented in Appendix C.
4.5.2 Do SpEAF:myc ChlPs enrich genes that are also enriched by 
SpELL:myc ChlPs?
There are 824 SpELL enriched genes, 490 SpEAF enriched genes with 383 genes 
enriched in both the SpELL:myc ChIP and SpEAFimyc ChIP samples (Figure 4-9). The 
probability that at least 383 genes would be enriched in these tw o  gene sets if the genes 
were selected at random can be calculated using hypergeometric distribution calculator 
http://stattrek.com/Tables/Hypergeometric.aspx2):
1 The p-value indicates the probability that a result would be obtained by chance. A  p value o f 0.05 is 
equivalent to  a w indow  w ith  a MAT score above 95% of the MAT scores in the null d istribution (estimated 
from  a sample o f 600 windows).
2 Using a population size = 5542, a sample size = 824 (all SpELL enriched genes), successes in the population 
= 490 (all SpEAF enriched genes) and successes in sample = 383 (genes that are both SpELL and SpEAF 
enriched genes).
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P (SpELL ChIP f l SpEAF ChIP > 383) = 3.24 x I O'252
That is the probability of selecting 824 genes at random from a population of 5542 genes, 
then selecting 490 genes at random from the same population o f 5542 genes, and getting 
an overlap o f at least 383 genes is ~ I0 '252« 0. This suggests that the overlap between the 
set of SpELL and SpEAF enriched genes would be unlikely to have happened by chance. In 
addition, visual inspection of the ChIP profiles of the ell I-myc and eafl-myc strains using a 
genome browser suggested that many genes classified only as a “ SpELL-myc enriched 
gene” had a ChIP signal with the eafl -myc strain just above the 0.05 p value cutoff and 
vice versa (Figure 4-6). Thus, although there are a number of genes that have been 
classified as being occupied by only SpELL o r SpEAF, there might be a number of these 
that are in fact occupied by both SpELL and SpEAF. Reduced ChIP signals fo r one of the 
two subunits could perhaps be caused by partial masking of the myc epitope tag at some 
locations.
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Figure 4-6 SpELL and SpEAF enriched genes have sim ilar ChlP-chip profiles.
ChIP profiles (myc tagged strain / untagged strain) for four genes are shown with MAT scores 
on the y axis. Annotated genes are depicted by gray boxes. Control ChlPs use strains tbp1:myc 
(green) and rpb3:myc (purple). Experimental ChlPs use strains eaf1:myc (blue) and ellhmyc 
(red). SpEAF enriched regions (calculated with a p value cutoff o f 0.05) are shown with blue 
boxes, and SpELL enriched regions with red boxes. A and B. Genes sme2 and mid2 are both 
SpEAF and SpELL enriched. C. pex7 is SpEAF enriched and not SpELL enriched. D. 
SPAC2E1 P3.05c is SpELL enriched and not SpEAF enriched. A ll four genes have reduced 
mRNA expression in the elHA and/or eaflA strains.
87
SpELLmyc fI SpEAF:myc SpRpb3:myc
311 332
-4900 other genes
Figure 4-7 Genes enriched by both RNA pol II and the SpELL/SpEAF complex. 
SpELL:m yc n SpEAF:myc describes the set of genes enriched by both SpELL:m yc and 
SpEAFim yc chrom atin imm unoprecipitations.
4.5.3 The SpELL/SpEAF complex is enriched at genes with epitope tagged 
pol II
To ask whether the set of SpELL/SpEAF genes correlate w ith genes enriched by 
immunoprecipitated RNA pol II, I used a strain in which the third largest subunit o f pol II 
was tagged w ith 13 tandem repeats of the myc epitope at the C terminus to  perform an 
Rpb3:myc ChlP-chip study. I compared the SpELL/SpEAF enriched genes with the SpRpb3 
enriched genes (Figure 4-7) and found 72 genes common to  both groups. The probability 
of 72 o r more genes being common to  these groups if the genes had been selected at 
random from the genome is 6.00 x I O'15, suggesting that the SpELL/SpEAF complex 
colocalises with epitope tagged pol II at a set of genes in cells. I use a more quantitative 
approach to  examine the relationship between SpELL/SpEAF localisation and pol II 
occupancy in sections 4.6.2 and 4.6.3.
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Figure 4-8 SpELL or SpEAF localises to a number of the genes that are downregulated in 
the elll and eaf1 deletion strains.
All genes (n = 36) which were identified by spotted m icroarrays with a change in RNA levels in the 
elUA or eaflA strains have been compared with the set genes classified as either SpELL enriched 
or SpEAF enriched genes (n=383). The change in RNA levels in deletion cells relative to wild type 
cells measured by qPCR is shown. Results are the mean of three biological replicates and error 
bars represent range.
4.5.4 Are the genes that are downregulated in the deletion strains also 
SpELL/SpEAF enriched genes?
O f the 37 genes exhibiting altered RNA levels in the elll and/or eafl deletion 
strains, 16 were either SpELL and/or SpEAF enriched genes. Among these are genes 
encoding the transcription factor Ace2 and 6 Ace2 regulated genes (Figure 4-8). The 
identities of these genes are listed in appendix C. 27 genes have reduced RNA levels in 
the elll A o r eafl A strains. O f these, 10 are also both SpELL and SpEAF enriched genes
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Figure 4-9 SpELL and SpEAF enriched genes identified by tiling arrays.
The SpELL and SpEAF enriched genes have been compared with the 26 genes identified as being 
downregulated in the ell 1 or eafl deletion arrays as well as with the sme2 gene which was not 
spotted onto the array but was later.; confirmed: t o ’be downregulated in the deletion strains by 
qPCR. N.B. there are 16 genes which are both downregulated in both the e //M a n d  eaflA strains, 
and are also either SpELL or SpEAF enriched genes. This includes sme2 in addition to the the 15 
genes fulfilling this condition in Figure 4-8.
(Figure 4-9). The probability that 27 genes selected at random from the genome would 
yield at least 10 of the 383 (SpELL H SpEAF) enriched genes can be calculated as before:
P (center of venn > 10) = 6.43 x I O'6
This suggests that the overlap between the tw o gene sets is not due to chance and 
that SpELL/SpEAF complex coimmunoprecipitates a set of genes that is downregulated in 
the absence of the complex.
SpEAF ChIPSpELL ChIP
373438 104
down in 
e lll A I eafl A -4600 
other genes
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4.6 A set of candidate genes for SpELL/SpEAF regulation
The 10 genes that are downregulated in elll and/or eafl deletion strains and have 
both an SpEAF and an SpELL ChIP signal (listed in Figure 4-8) define a set of candidate 
genes that I believe might be regulated directly by the SpELL/SpEAF complex. I will refer 
to these as “ SpELL/SpEAF candidate genes” . These include ace2 and the Ace2 regulated 
genes adgl, adg3, agnl, eng I and mid2, a glycerol phosphate dehydrogenase, gpdl, which 
is induced by osmotic stress, sme2 a non coding RNA involved in meiosis, a putative 
phosphate transporter SPBC8E4.09c, and an uncharacterised gene SPBPB7E8.01.
4.6.1 Does the SpELL/SpEAF complex preferentially regulate longer
genes?
It has been proposed that dELL preferentially affects the expression of large genes 
in the fru it fly (94). To investigate the possibility that the SpELL/SpEAF complex 
preferentially regulates longer genes, we used both a statistical one sample t-test and a 
Mann-Whitney U test to  compare the ORF lengths of our candidate genes to the mean 
ORF length o f all other S. pombe genesu (Table 4 .1). The probability that the mean ORF 
length of a random sample (candidate genes), drawn from a population of median ORF 
length I 155, would be greater than 1829 is calculated to  be 0.0583 (using one sample t-
1 I performed these tests at the suggestion o f and in parallel w ith Hua Li, a biostatistician.
2 The tw o  tests make different assumptions; the t-test assumes that the data are normally distributed while 
the Mann-W hitney test is non-parametric and does not make assumptions about the underlying distribution 
o f the data. The Mann-Whitney U test ranks all data and then compares the rankings o f one data set to  the 
rankings o f the o ther data set. It is less likely tha t the Mann-W hitney test w ill give a false positive result due 
to  outlying data points.
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SpELL /  SpEAF enriched genes
ORF length (bp) mRNA level Relative pol II occupancy
mean 1452 5488 2.55
standard deviation 1089 3976 2.01
A ll o th er genes
ORF length (bp) mRNA level Relative pol II occupancy
mean 14 16 2578 1.25
standard deviation 1 IIS 2635 1.01
Com pare SpELL /  SpEAF enriched genes to  all o th er S.pombe genes
ORF length mRNA level Relative pol II occupancy
two sample t-test p value 0.5421 <0.0001 <0.0001
Mann-Whitney U test p value 0.386 < 0.0001 <0.0001
is the SpELL/SpEAF enriched
gene mean value significandy 
greater than the mean value of 
all other genes at the 95% 
significance level?
NO YES YES
Table 4.1 Hypothesis test to determine whether SpELL/SpEAF candidate genes have 
significantly higher than average values for ORF length, mRNA level and pol II occupancy.
Values for ORF length, mRNA level and relative pol II occupancy in S. pombe have previously 
been determ ined in a study by Lacknerand co-workers (161). I used these values to perform a one 
sample t-test (using the t-test calculator at
http://www.araphpad.com/auickcalcs/OneSampleT1 .cfm?Format=SDT and a Mann Whitney U test 
(using the calculator at http://www.fon.hum.uva.nl/Service/Statistics/W ilcoxon Test.htm h. The 
sme2 gene was not included in the analysis as this gene had not been included in the study by 
Lackner et al. Values for mRNA level and pol II occupancy are in arbitrary units.
test), o r 0.0759 (using a Mann-Whitney U test). This is larger than the significance level of 
0.05 fo r both tests and the null hypothesis that SpELL/SpEAF regulated genes do not have 
larger ORF length is accepted suggesting that the evidence is not sufficient to  support the 
hypothesis that the SpELL/SpEAF complex is preferentially recruited to  longer genes 
(Table 4 .1).
As the results of a statistical analysis such as this become more valid as the
number of genes in the data set increases, I decided to repeat the analysis using the set of
383 SpELL/SpEAF enriched genes (the genes with a significant ChIP signal fo r both the
elll:myc and eafhmyc strains). Many of these genes may be regulated directly by the 
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SpELL /  SpEAF enriched genes
ORF length (bp) mRNA level Relative pol II occopancy
mean 1452 5488 2.55
standard deviation 1089 3976 2.01
All other genes
ORF length (bp) mRNA level Relative pol II occopancy
mean 14 16 2578 1.25
standard deviation I 115 2635 1.01
Compare SpELL /  SpEAF enriched genes to  all other S.pombe genes
ORF length mRNA level Relative pol II occopancy
two sample t-test p value 0.5421 <0.0001 <0.0001
Mann-Whitney U test p value 0.386 <0.0001 <0.0001
is the SpELL/SpEAF enriched 
gene mean value significantly 
greater than the mean value of NO YES YES
all other genes at the 95% 
significance level?
Table 4.2 Hypothesis test to determine whether SpELL/SpEAF enriched genes have 
significantly higher than average values for ORF length, mRNA level and pol II 
occupancy.
Values for ORF length, mRNA level and relative pol II occupancy in S. pombe have previously 
been determined (161). I used these values to perform a two sample t-test (using the t-test 
calculator at http://www.araphpad.com /auickcalcs/ttest1.cfm ?Form at=SD). and a Mann 
Whitney U test (using the calculator at
http://www.fon.hum.uva.nl/Service/Statistics/W ilcoxon Test.htm h. Genes not included in the 
study by Lackner et al were excluded from this analysis. Values for mRNA level and pol II 
occupancy are in arbitrary units.
SpELL/SpEAF complex even though there is no significant change observed in the RNA 
levels of these genes in the elll A or eafl A strains under the conditions used to  perform 
the expression array analysis. As the sample size is now significant compared with the 
population we have replaced the one-sample t-test with the two-sample t-test. The 
results of the hypothesis tests comparing the SpELL/SpEAF enriched genes to the set of all 
other S. pombe genes are shown in Table 4.2. The mean ORF length of the SpELL/SpEAF 
enriched genes (1452) is not significantly greater than the mean ORF length of all other S. 
pombe genes ( 14 16) at the 95% significance level (p<0.05).
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4.6.2 Does the SpELL/SpEAF complex preferentially regulate genes with 
high mRNA levels or genes with a high RNA pol II occupancy?
Gerber et al. have established that dELL co-localises with hyperphosphorylated 
RNA pol II on polytene chromosomes and that RNA pol II from fly extracts copurifies 
with dELL (106). Also, Shilatifard and co-workers showed that purified ELL binds pol II 
isolated from rat liver (103). In addition, I have shown that SpELL interacts physically and 
functionally with purified S. pombe pol II in v itro  (Figure 3-9 and Figure 3-10). Taken 
together, these observations suggest that ELL/EAF and pol II might be part of a common 
complex during elongation in vivo. For this reason, I decided to  ask whether SpELL/SpEAF 
occupancy correlates with RNA pol II occupancy and/or with levels of mRNA expression 
genome-wide. When I compared the mean values of both of these quantities between the 
SpELL/SpEAF candidate gene set and all other S.pombe genes I found that the candidate 
genes had significantly higher levels of mRNA compared with the average value fo r the 
genome. F-lowever, it was not clear whether pol II occupancy was greater fo r candidate 
genes as the tw o statistical tests used had different outcomes (Table 4 .1). If I compare 
the larger set of SpELL/SpEAF enriched genes with all genes in the S.pombe genome, the 
mean values of mRNA level (5488) and pol II occupancy (2.55) are clearly significantly 
greater than fo r all other S.pombe genes (2578 and 1.25 respectively)(Table 4.2).
Figure 4-10 illustrates the differences in distributions of ORF length, mRNA level 
and pol II occupancy between SpELL/SpEAF enriched genes and all S.pombe genes. Both 
gene sets have a similar distribution fo r ORF length but there is a greater proportion of 
the SpELL/SpEAF enriched gene set w ith high mRNA and pol II occupancy levels 
compared with the set of all genes. Taken together the analyses of Table 4 .1, Table 4.2 
and Figure 4 -10 suggest that the SpELL/SpEAF complex is not preferentially recruited to
--------------------------------------------------------------- ------------------------------------------. -------------     9 4
longer genes only, but is preferentially recruited to  genes with higher pol II occupancy and 
mRNA levels.
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Figure 4-10 Histograms illustrating the frequency distribution of values for ORF length, pol 
II occupancy and mRNA level for both SpELL/SpEAF enriched genes and all genes.
Values for ORF length, mRNA level and relative pol II occupancy in S. pombe have previously 
been determ ined in a study by Lackner and co-workers (161). ORF length is in base pairs. mRNA 
level and relative pol II occupancy are both in arbitrary units.
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Figure 4-11 SpELL/SpEAF enriched genes with a high pol II occupancy have a larger ORF 
length than other genes with a high pol II occupancy.
I repeated the analysis of Table 4.2 and Figure 4-10 using only genes with a pol II occupancy 
greater than 4.00 (arbitrary units). ORF length is in base pairs and mRNA level in arbitrary units. 
There are 58 SpELL/SpEAF enriched and 118 other genes with a pol II occupancy greater than
4.00 units.
4.6.3 Is the SpELL/SpEAF complex recruited to a class of longer genes 
with a high pol II occupancy?
It is possible that the SpELL/SpEAF complex is recruited to  more than one distinct 
category of genes. In particular actively transcribed genes with pause sites or regions 
where pol II moves slowly might be expected to  have a high pol II occupancy resulting 
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from pol II piling up. The SpELL/SpEAF complex might be required specifically to  help 
transcribe longer genes in this class, since longer genes could contain more pause sites 
and take a longer time to  transcribe. W ith  this in mind I analysed all genes with a pol II 
occupancy greater than 4.00 (arbitrary units) to ask whether SpELL/SpEAF might be 
recruited to  the longer genes with a high pol II occupancy. There were 58 SpELL/SpEAF 
enriched genes and I 19 other genes with a pol II occupancy greater than 4.00. The 
SpELL/SpEAF enriched genes which had high pol II occupancy had a mean ORF length of 
1433 which is significantly longer than the other genes w ith high pol II occupancy, which 
had a mean ORF length of 742 (Figure 4 -1 I). If the SpELL/SpEAF complex is promoting 
more efficient transcription of these longer genes we might expect similar levels of 
mRNA to be generated fo r the longer (SpELL/SpEAF regulated) and shorter genes. Table
3.1 suggests that there is no difference in the amounts of mRNA synthesised between 
longer and shorter genes in this class.
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Figure 4-12 Measured vs modelled distribution of gene lengths for SpELL/SpEAF enriched 
genes with a high pol II occupancy.
SpELL/SpEAF enriched (blue) or other (red) genes with a high pol II occupancy were grouped into 
5 groups according to ORF length (in base pairs) as shown in the table. The total length occupied 
by all genes within a group was calculated (in base pairs) for each group and expressed as a 
percentage o f the sum o f all genes in all groups. The expected distribution of the 58 
SpELL/SpEAF enriched genes (green) assumes that the genes are distributed among the groups 
in proportion to the sum of the lengths of all the genes within a group (i.e. the percentage of the 
total ORF length in each group).
The measured (blue) and modelled (green) distributions were compared for independence using 
the chi squared test (162), and found not to be significantly different (p = 0.30).
One possibility is that SpELL/SpEAF might be more likely to  be detected at longer 
genes simply because longer genes provide a larger target fo r colocalisation with a peak, 
and perhaps thus have a higher probability of containing pause sites. In collaboration with 
Hua Li, we asked whether the distribution of the lengths of genes with SpELL/SpEAF 
peaks and a high pol II occupancy was statistically significantly different to  the distribution 
of the lengths of these genes that would be expected assuming a random distribution of 
SpELL/SpEAF peaks along the sum total length of all of these genes. The analysis of Figure
4 -12 suggests that there is no statistical difference between the actual and modelled 
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distributions of gene lengths fo r the SpELL/SpEAF enriched genes with high pol II 
occupancy.
4.6.4 Is the SpELL/SpEAF complex is recruited to a class of longer genes 
with a high mRNA level?
I decided to  do a similar analysis to  ask whether SpELL/SpEAF might be recruited 
to a class o f genes with high associated mRNA levels. I analysed all genes w ith mRNA 
levels greater than 10000 (arbitrary units); there were 69 SpELL/SpEAF enriched and 154 
other genes in this category (Figure 4-13 A-C). The SpELL/SpEAF enriched genes which 
had high mRNA levels had a mean ORF length of I 156 which is significantly longer than 
the other genes w ith high mRNA level, which had a mean ORF length of 803. This 
suggests that of the SpELL/SpEAF enriched genes with high cellular mRNA levels are 
significantly longer than other genes with high mRNA levels.
As w ith the class of SpELL/SpEAF enriched genes with high pol II occupancy, it is 
possible that SpELL/SpEAF enriched genes w ith high associated mRNA levels are more 
likely to  be longer genes simply because longer genes offer a larger target fo r 
colocalisation with a peak. W e modelled the distribution of SpELL/SpEAF peaks among 
the genes w ith high associated mRNA levels as we had done fo r the genes with high pol II 
occupancy (Figure 4-13 D). Again there was no significant statistical difference between 
the measured and modelled distribution of genes according to  length. This suggests that 
SpELL/SpEAF might be more likely to enrich longer than shorter genes in this class simply 
because they provide a larger target fo r colocalisation. The analysis of does not eliminate 
the possibility that SpELL/SpEAF is specifically targeted to  these longer genes via a 
mechanism independent of ORF length (target size).
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Figure 4-13 SpELL/SpEAF enriched genes with a high mRNA level have a larger ORF 
length than other genes with a high mRNA level.
I repeated the analysis of Table 4.2, Figure 4-10, and Figure 4-12 using only genes with an 
mRNA level greater than 10000 (arbitrary units). ORF length is in base pairs and pol II 
occuoancv in arbitrary units. There are 69 S dELL/SdEAF enriched and 154 other aenes with a r r '
4.6.5 SpELL/SpEAF distribution across coding regions
Although previous studies have examined chromosomal localisation of the ELL at a 
resolution that allows large chromosomal regions associated with ELL to be identified (94, 
163) it is not clear how the SpELL/SpEAF complex might be distributed across genes. One 
possibility could be that the distribution of the complex might vary according to the 
nature of individual genes, perhaps depending on the distribution of intrinsic pause sites 
within the transcribed region. Another possibility could be that the complex might be 
consistently located at the prom oter o r at the 3’ end of the gene. For example one study 
demonstrated that ELL shows a higher enrichment at the 3’ end of the human c-Fos gene 
(164). To address these questions w e1 analysed the distribution of the SpELL and SpEAF 
proteins across all genes, SpELL/SpEAF enriched genes o r SpELL/SpEAF candidate genes 
as shown in Figure 4-14. The complex appears to  be distributed within the coding regions 
of genes and is not located exclusively in either the prom oter o r 3’ end regions. There is 
a slight increase in localisation of both proteins towards the 5’ end of the coding region, 
in particular in the analysis of the set of candidate genes.
1 The analysis was done in collaboration w ith Madelaine Gogol who designed a script using the 
programming language R to  process the data and generate the graphs shown.
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Figure 4-14 Distribution of SpELL and SpEAF across coding regions.
Each ORF was divided into 40 equally sized bins and upstream and downstream intergenic regions 
into 20 equally sized bins. Genes are usually annotated from the translation start codon (ATG) to 
the stop codon. ChIP signals for each gene were assigned to the closest bin and empty bins for 
each gene filled by linear interpolation between the closest surrounding bins with non zero values. 
The average bin value for all genes in the gene set being analysed is plotted as the ordinate. The 
black line represents the set o f all S. pombe genes.
4.6.6 The SpELL/SpEAF complex is not exclusively located at intron 
containing genes
In light of recent evidence that human ELL2 may influence splice site selection (120), 
I asked whether the SpELL/SpEAF complex was localised exclusively at intron containing 
genes. O f the set of 10 candidate genes, none are annotated as containing introns 
suggesting that the SpELL/SpEAF complex has roles other than (and possibly in addition 
to) regulating splicing.
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4.6.7 The SpELL/SpEAF candidate genes are enriched for genes involved 
in cell separation.
The Gene Ontology Consortium has developed a vocabulary fo r describing the 
roles of genes and their products in cells ( 165). In order to  determine whether the 
SpELL/SpEAF complex was responsible for regulating genes with a common function in 
cells I analysed the list o f candidate genes fo r enrichments in gene ontology terms as 
described in Table 4.3. I found a significant enrichment fo r genes involved in cell 
separation during cytokinesis. These included the gene encoding the transcription factor 
Ace2 and a subset of Ace2 regulated genes, agnl, eng I, mid2, adgl and adg3 (166). In light 
of the physical and functional interactions o f the SpELL/SpEAF complex with RNA 
polymerase II, it is interesting that this set of Ace2 regulated genes is also downregulated 
in cells with reduced levels of the pol II subunit Rpb4 (167), The deletion of the rpb4 gene 
in S. cerevisioe renders the cells sensitive to growth on 6-AU, and Rpb4 may have a 
distinct role in transcription elongation (168). This set of Ace2 pathway genes have also 
been shown to  be particularly sensitive to mutations in various Mediator subunits (169, 
170), including components of the head module (Med8, Med 17, Med20 and Med27) and 
Med3 I, which appears to  be at o r near the interface between the head and middle 
modules (Chieri Sato, Shigeo Sato unpublished data).
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Biological Process
GO Term P-value Sample freauency Background freauency Genes
G0:0000920 cell separation during cytokinesis 2.99E-09 5/I0 (50.0%) 36/5178 (0.7%) engl ace2adg3 agnl mid2
G0:0032506 cytokinetic process 7.97E-07 5/10(50.0%) 107/5178 (2.1%) engl ace2adg3agnl mid2
G0:0000910 cytokinesis 3.74E-06 5/10(50.0%) 146/5178 (2.8%) eng 1 ace2 adg3 agn 1 mid2
G0:0051301 cell division 6.65E-06 5/10(50.0%) 164/5178 (3.2%) eng 1 ace2 adg3 agn 1 mid2
GO:0016052 carbohydrate catabolic process 3.39E-04 3/10(30.0%) 76/5178 (1.5%) engl agnl gpdl
C e llu la r C o m p onent
GO Term P-value Sample freauency Background freauency Genes
G0:0009986 cell surface 7.60E-07 5/10(50.0%) 106/5178 (2.0%) engl adg3 agnl adgl SPBPB7E8.0I
M olecu la r Function
GO Term P-value Sample freauency Background freauency Genes
G0:0004553 hydrolase activity, hydrolyzing O-glycosyl compounds 7.54E-05 3/10(30.0%) 46/5178 (0.9%) eng 1 adg3 agn1
G 0 :0 0 16798 hydrolase activity, acting on glycosyl bonds 1.36E-04 3/10(30.0%) 56/5178 (1.1%) eng 1 adg3 agn1
Table 4.3 Gene Ontology terms enriched in the set of SpELL I SpEAF candidate genes.
The list of SpELL/SpEAF enriched genes was used as an input for the GO Term Enrichment tool 
(http://www.geneontology.org 165) with the maximum p-value setting of 0.001 and a minimum of 
three gene products.
4.7 Discussion
The SpELL/SpEAF complex appears to  function at a number of genes regulating 
different cellular processes and disruption of the complex leads to reduced levels of RNA 
associated w ith some of these genes.
I have defined sets of genes likely to be regulated by the SpELL/SpEAF complex, and 
analysis of the properties of these genes provides insight into how the complex might 
function in cells. W hole genome analyses necessarily identify a range of signals varying 
across the genome requiring an arbitrary cut off to  be selected to  classify genes as 
belonging to a particular gene set. Thus, the gene sets do not define those genes and only 
those genes that are SpELL/SpEAF regulated rather sets of genes that are most likely to 
be SpELL/SpEAF regulated.
I have previously shown that SpELL and SpEAF function as a stable complex in vitro 
(Figure 3-6). In cells, a common set of genes is misregulated by the deletion of either 
subunit (Figure 4 -1), and deletion of one subunit results in a decrease in the protein 
levels, but not mRNA levels, of the other subunit (Figure 4-2 and Figure 4-3). Together,
these findings provide further support for the idea that SpELL and SpEAF function 
together as a complex in vivo. It is possible that the reduced levels of SpELL protein in 
eafl A cells might be the result of a decrease in stability of the SpELL in the absence of its 
partner subunit. Alternatively, SpEAF might be needed fo r proper processing or 
translation of elll mRNA.
Studies with purified proteins in vitro have demonstrated that the SpELL/SpEAF 
complex functions through a direct interaction w ith pol II (Figure 3-9,Figure 3-10), and 
drosophila ELL colocalises with active pol II on polytene chromosomes (106). Consistent 
with these observations, I have shown that the SpELL/SpEAF complex is located at a 
significant number of genes w ith both high levels of pol II occupancy and high mRNA 
levels (Table 4.1, Table 4.2, and Figure 4-10). Consistent with this, SpELL/SpEAF complex 
is distributed throughout the coding regions of genes (Figure 4-14).
As ELL/EAF functions to stimulate the rate of transcription elongation in vitro, it has
been proposed that the complex might be used fo r the timely transcription of longer
genes (94). The function(s) of the SpELL/SpEAF complex are not limited to  enabling
transcription of longer genes, as such genes are not overrepresented in the SpELL/SpEAF
gene sets (Table 4 .1, Table 4.2). The histogram showing the distribution of the
SpELL/SpEAF enriched genes ranked by ORF length, mRNA level and pol II occupancy
illustrates that genes with high pol II occupancy and high mRNA levels are
overrepresented in the SpELL/SpEAF enriched gene set but that longer genes are not
(Figure 4-10). It has also been suggested that ELL/EAF might be specifically required for
transcribing intron containing genes (4, 94). However, the set of SpELL/SpEAF candidate
genes does not contain any genes with introns, suggesting that the SpELL/SpEAF complex
does not exclusively control splicing. 
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There is a possibility that SpELL/SpEAF complex may be involved with regulating 
more than one class of genes, including longer genes w ith high pol II occupancy. Zeitlinger 
and co-workers recently considered this possibility in analysing CHIP-chip data sets 
investigating pol II binding to  drosophila chromosomes and found three distinct classes of 
genes including a class o f transcribed genes with pol II binding across the gene and a class 
of genes with pol II stalled near the prom oter poised fo r activation (171). Analysing 
subsets of the SpELL/SpEAF enriched gene dataset, limited to  only the genes with a high 
pol II occupancy o r high associated mRNA level, shows a correlation between such genes 
and ORF length (Figure 4-11-  Figure 4 -13). I cannot exclude the possibility that this 
correlation may result, at least in part, from a greater probability of a peak overlapping a 
longer gene; longer genes provide a larger target and would be more likely than shorter 
genes to  coincide with randomly distributed peaks. Hence the SpELL/SpEAF complex may 
be important fo r regulation of longer, highly transcribed genes in addition to  other classes 
of genes (perhaps those that are of mixed length but need to  be transcribed quickly at 
certain times), but is not clear why this might be true. This could be either due to  specific 
recruitment of SpELL/SpEAF to this set of longer genes o r could simply due to  an 
increased probability of SpELL/SpEAF occupancy as the length of any contiguous DN A 
sequence increases.
It is interesting that most o f the genes in the set of candidate genes do seem to be 
used only at a distinct period during the cell cycle. There are six genes that are part of the 
Ace2 pathway and are downregulated in elll A and eafl A strains, are 
coimmunoprecipitated by both SpELL and SpEAF, and whose products are required fo r 
cell separation during cytokinesis (Figure 4-9 and Table 4.3). These include oce2, adgl, 
adg3, agnl, engl and mid2. Interestingly, these genes have been identified as being 
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mis regulated in strains expressing low levels of the pol II subunit Rpb4 (172), which has 
also been suggested to  be important fo r proper transcription elongation ( 168). These 
Ace2 pathway genes are also misregulated in cells with mutations in a variety of mediator 
subunits. Taken together these findings suggest a jo in t role fo r pol II, mediator and the 
SpELL/SpEAF complex in the control of a pathway of genes required fo r the proper 
completion o f cell division. In the future, it will be of interest to  explore a potential role 
for Mediator in recruiting and/or regulating the function of SpELL/SpEAF in S. pombe.
The complex may not function at every gene. 942 of the ~5000 genes in S. pombe 
were coimmunoprecipitated by either SpELL or SpEAF (Figure 4-9), and, of the genes 
associated w ith pol II, most were not also associated w ith both SpELL and SpEAF (Figure
4-7). Alternatively the complex could function at many more genes under different 
growth conditions. Notably, only a m inority of genes were associated with pol II, 
suggesting that a proportion of the genome was not actively transcribed in the majority of 
cells at the time of the experiment; thus, many of these genes may use the SpELL/SpEAF 
complex when they are transcribed.
The results of this whole genome study are consistent with a role of SpELL/SpEAF 
acting in concert w ith pol II to stimulate transcription of a set of genes in vivo, although 
additional roles fo r the complex cannot be excluded. In addition, the study has identified a 
number of genes that are likely to  be regulated by SpELL/SpEAF and provides models that 
can be used in more targeted analyses to  investigating the mechanism of SpELL/SpEAF 
function in vivo.
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CHAPTER 5, RECRUITMENT OF SpELL AND SpEAF 
SUBUNITS TO THE sme2 LOCUS
5.1 Introduction
Using whole genome approaches, I have identified genes that are enriched and likely 
to be regulated by the SpELL/SpEAF complex. By using a targeted approach to  study a 
gene found to  be highly occupied by SpELL/SpEAF, I have been able to  characterise in 
more detail the recruitment o f SpELL and SpEAF to  regions within a candidate transcribed 
gene.
The biochemical studies described in Chapter 3 have shown that free SpELL binds 
to  pol II and that free SpEAF does not (Figure 3-9, Figure 3-I0). These observations 
predict that SpELL might localise to  transcribed genes in the absence of SpEAF by binding 
directly to  pol II and that SpEAF localisation might require SpELL. To test this hypothesis,
I used SpELL- and SpEAF-dependent chromatin immunoprecipitations analysed by qPCR 
to  study the recruitment of SpELL and SpEAF to  the sme2 gene.
The sme2 gene in particular provides a suitable target fo r investigating recruitment
fo r three reasons. First, the peak MAT scores within the SpELL and SpEAF ChIP profiles
associated w ith sme2 were the largest of all genes tiled on the arrays. Second, the profile
of each peak appears well resolved, with no other significant peaks in the surrounding
genomic regions thus reasonably accurate information about the presence and location of
each peak is possible (Figure 5-1). This is especially important in a model system such as S.
pombe, where the average gene size is considerably smaller than fo r higher eukaryotes
and is close to  the same order of magnitude as the sizes of sonicated chromatin fragments
produced fo r chromatin immunoprecipitations. Third, the sme2 gene can be induced in 
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Figure 5-1 SpELL and SpEAF colocalise at the sme2 locus.
The SpELL and SpEAF proteins coim m unoprecipitate chromatin that is enriched for sequences 
within the sme2 gene on chromosome 2. Ordinate values for each ChlP-chip profile indicate MAT 
scores (141) based on three biological replicate experiments. Experimental ChlPs were with strains 
containing myc epitope tagged SpELL or SpEAF. Control ChlPs using the same myc antibody and 
the wild type strain were used as a reference to normalise signals. The transcribed region of sme2 
is indicated; the decrease in the height o f this region corresponds to the low amounts of longer 
species of sme2 transcript (discussed in 5.2)
response to a readily manipulated transcription signal such as oxidative and heat stress 
and nitrogen starvation.
5.2 Characterisation of sme2 transcripts
Sme2 codes fo r a non-coding RNA, meiRNA, that is transcribed by pol II and is 
subsequently polyadenylated. It functions by binding to the me/2 gene product during 
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meiosis and promotes its translocation to  the nucleus. It can be induced in response to  
heat shock or oxidative stress as well as in response to  conditions, such as nitrogen 
starvation, that promote meiosis in S. pombe. Before investigating the localisation of pol II, 
SpELL and SpEAF on the sme2 gene, I wanted to confirm which regions of the gene were 
being transcribed either under conditions where sme2 is expressed at basal levels o r in 
cells exposed to  oxidative stress, which results in the accumulation of larger amounts of 
sme2 transcript. Data from Lackner et al. suggests that this accumulation is not due to  a 
decrease in RNA transcript degradation but rather due to  an increase in transcription, 
since whole genome experiments showed no significant reduction in sme2 transcript 
levels after cells were treated w ith I, 10-phenantholine1 (161).
The sme2 gene, as characterised previously by Watanabe and co-workers (173), 
has a putative TATA box ~30 bp upstream of the tw o major transcription start sites at 
T l and A2. In addition, it has and several poly(A) sites. Northern analysis of the sme2 
transcript after induction by nitrogen starvation showed two doublets, w ith the majority 
of transcripts in the lower doublet corresponding to  products that are 439/440 and 
507/508 nucleotides long. Although the lengths of the transcripts in the second, upper 
doublet were not determined in this paper, they appeared to  be ~ 1200 nt in length. The 
authors suggest that the less abundant, longer transcripts probably reflect read-through 
products that overlap with the shorter products ( 173).
1sme2 transcrip t levels were reduced to  93% (standard deviation = 10%) 28 minutes after transcription was 
blocked by 300 jxg/ml 1,10-phenanthroline. 1, 10-phenantholine at 100 pg/ml reduces transcription to  10% of 
normal levels.
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Figure 5-2 Identification of the 3 ’ ends of sme2 transcripts by RACE
A. The 3 ’ ends of sme2 transcripts were identified by sequencing 3’ RACE products generated from 
cDNA prepared from wild type, elHA or eaflA cells incubated for 30 minutes with or w ithout 6 mM 
H20 2 (described in section 2.16). In order to identify both polyadenylated and non-polyadenylated 
species o f transcripts, RNA was initially incubated in reactions with or w ithout poly(A) polymerase. 
Reverse transcription was with the “lock docking” oligo(dT) primer described in materials and 
methods. cDNA was amplified using an sme2 specific forward primer (sme2 +26) and a reverse 
primer complim entary to the 5’ end o f the prim er used for reverse transcription.
B. Summary of data from this study and from the study by W atanabe and co-workers (173) 
characterising the sme2 transcripts. Note the transcription start site (T1/A2), non-polyadenylated 
transcript at +340 (red arrow), majority of transcripts polyadenylated at +438 to +442, 
polyadenylated transcript at +508, and longer transcripts which may or may not be polyadenylated 
at +748/+751 (blue arrow) and transcripts detected by Northern blot which are ~1200 nt long (green 
arrow)
5.2.1 Identification of the 3’ ends of sme2 by 3’ RACE
To confirm the poly(A) sites for the shorter transcripts described by Watanabe et
0 /. and to  define the positions of the poly(A) sites of the longer doublet, I amplified 3’
RACE products generated with an internal sme2 forward primer at +26 nt and a modified 
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“ lock docking” oligo(dT) reverse primer ( 174) that anneals to  the 5’ end of the poly(A) 
sequence during reverse transcription. 3’ polyadenylation sites were mapped by 
fractionating RACE products generated from wild type and ell IA  cells by agarose gel 
electrophoresis, cloning the D N A from individual gel bands, and sequencing the cloned 
DNA. In addition to  the reported poly(A) sites at +440 and +508 (relative to  the T l at 
the transcription start site), I identified additional polyadenylation sites at +438, +442, 
+746 and +751. Treatment of cells with 6 mM H20 2 resulted in an increase in the 
intensity of the band that resolved just below the 500 bp marker. The majority of sme2 
sequences represented transcripts polyadenylated at between +438 and +442 suggesting 
that these poly(A) sites are used when the gene is induced (Figure 5-2). There was no 
apparent difference between wild type and ell IA  in the exact choice of polyadenylation 
site. Only I of the 28 sme2 sequences represented a transcript polyadenylated at +508.
Pre-treatment of RNA w ith polyA polymerase resulted in an additional band 
indicative of a prevalent non-polyadenylated species of transcript whose 3’ end was at 
+340. The band representing these transcripts can be seen in all samples pre-treated with 
polyA polymerase in Figure 5-2 A, although the bands are fainter relative to background 
fo r the experiment comparing wild type and ell IA  cells. This is probably due to  slight 
variation in per amplification between the w t/e lllA  samples and the w t/e a flA  samples. 
Subsequent experiments using nested primers for per amplification confirmed the 
presence of the 340 nt transcripts in all samples. It is not clear whether this transcript 
represents a prematurely terminated transcript, a transcript associated with paused pol II, 
o r is the result of some alternative process.
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Figure 5-3 Northern analysis of sme2 transcripts
30 ug o f total RNA prepared from either wild type, elUA or eaflA cells incubated at 
32 °C for 30 minutes with or w ithout 6 mM H20 2 was fractionated on a 1% 
agarose gel, and sme2 transcripts were detected by Northern blotting as described 
in section 2.15. Single stranded radiolabeled RNA probes contained a sequence 
complim entary to the region +26 to +545 o f the sme2 gene.
Analysis of RACE products by PCR is semi-quantitative. To confirm that -440 nt 
sme2 transcripts were the main species generated in response to  treatment of cells with 6 
mM H20 2, I analysed samples of total RNA by Northern blotting (Figure 5-3). I was 
unable to  detect sme2 transcripts transcribed at basal levels in the absence of H20 2. In 
contrast, stressed cells contained detectable levels of sme2 transcript, which appeared as 
a single diffuse band. Taken together w ith the results of Figure 5-2, these results suggest 
that the majority of RNA products generated on exposure of cells to stress in Figure 5-3 
are greater than 500 nt and less than 800 nt long and probably represent polyadenylated 
species of the dominant 438/442 nt transcripts characterised by 3’ RACE.
5.3 Co-localisation of SpELL, SpEAF and pol II at the sme2 
gene
Having characterised the transcripts synthesised at the sme2 gene, I wanted to  see if 
there was a correlation between the localisation of SpELL, SpEAF and pol II under 
conditions where the gene is expressed at basal levels o r induced.
ChIP qPCR primers 
poly(A)
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Figure 5-4 Location of primers for ChIP qPCR across the sme2 locus.
Sequences for appropriate primer pairs were generated by using approximately 400 bp genomic 
DNA sequences as an input for PrimerQuest software (IDTDNA). Primer Quest was used with the 
default settings for generating prim er sequences for real-time PCR and generated lists of 
suggested prim er pairs with a PCR product range 80-200 bp from which the most appropriate 
primer pairs were selected. Primer sequences are listed in Appendix B. Arrows indicate the poly(A) 
sites at +438 to +442 nt (thick arrow) and +508nt (thin arrow).
In order to better characterise the distribution of the SpELL/SpEAF complex in and 
around the sme2 locus, I designed a series of qPCR primer sets covering a region from 
1407 bp upstream to  1928 bp downstream of the transcription start site. This region 
overlaps the tw o neighbouring ORFs (Figure 5-4). In addition, I used an amplicon within 
the K region as a control. The K region is a transcriptionally silent locus that has been 
used previously as a control for ChIP assays in S. pombe (79). Appropriate primer pairs 
were selected from a list generated by PrimerQuest software (ID TDN A 
www.idtdna.com). In initial experiments I used sonication conditions that generated 
chromatin in the range 200-1000 bp as suggested in the Affymetrix® ChIP assay protocol
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and by Lee and Young (175). These conditions produced unacceptable variation and very 
broad peaks. More recent studies carried out by Fan and Struhl (140) found that 
extensive chromatin fragmentation increases enrichment of binding sites relative to 
control regions. Likewise, I was able to  get more reproducible data with greater 
resolution by increasing sonication time to generate chromatin fragments with an average 
size of 200 bp (data not shown).
5.3.1 SpELL enriches chromatin within the transcribed region of sme2
In agreement with the microarray analysis (Figure 5 -1), qPCR analysis of chromatin 
fragments coimmunoprecipitated with SpELL revealed an enrichment of sequences near 
the polyA sites of the shorter smel transcripts relative to  the surrounding regions and a 
distant control region (the K region) as shown in Figure 5-5 A. Control chromatin 
generated from the parental strain w ithout epitope tagged SpELL was less efficiently 
immunoprecipitated with the myc antibody and did not produce a significant enrichment 
of sequences within the sme2 gene relative to  the surrounding regions. To control fo r 
experimental variation, I have normalised all experimental ChIP signals to  the K region 
control ChIP signal (Figure 5-5 B and following figures).
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Figure 5-5 SpELL enriches sequences within the sme2 region.
A Chromatin immunoprecipitations (ChlPs) were performed with antibodies specific for the myc 
epitope using a strain with the elU gene modified to encode 13 tandem repeats of the myc epitope 
at the C terminus. As a negative control ChlPs were performed with myc antibodies and chromatin 
extracts prepared from wild type cells. ChlPs were performed as described in section 2.9 with an 
increased sonication time which resulted in sheared chromatin with a reduced average size of 
~200 bp. ChIP signals show enrichment of DNA in the immunoprecipitated sample relative to the 
input DNA expressed as a percentage. All data points are the mean of three biological replicates. 
Error bars represent range.
B The data represented in Figure 5-5 A with experimental ordinate values divided by the K region 
ordinate value. All data points are the mean of three biological replicates. Error bars represent 
range.
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5.3.2 Is there a correlation between the localisation of SpELL, SpEAF and 
RNA pol II at the sme2 locus?
The results o f Figure 3-6 suggest that the SpELL and SpEAF proteins function as a 
complex in vitro, and the ChlP-chip analysis (Figure 5-1) suggests co-localisation of SpEAF 
with SpELL at the sme2 gene in cells. Consistent w ith this, a comparison of Figure 5-6 A  
(red line) w ith Figure 5-6 B (red line) shows that myc-antibody-mediated chromatin 
immunoprecipitations from S. pombe strains encoding either SpEAF-myc or SpELL-myc 
give similar profiles when analysed by qPCR.
If the SpELL subunit is recruited to chromatin as a result of an interaction between 
SpELL and pol II bound to  the chromatin, one might expect pol II to  be present on the 
chromatin in the same location as SpELL. To test this, I immunoprecipitated pol II with 
the antibody 8WG 16, which recognises the pol II CTD sequence YSPTSPS. Like SpELL 
and SpEAF, pol II coimmunoprecipitated genomic sequences that were enriched for 
region D (Figure 5-6 A to  C red line).
5.3.3 The effect of a transcription signal on SpELL and SpEAF and pol II 
recruitment to the sme2 locus
As oxidative stress induces sme2, it may also cause changes in the landscape of pol II, 
SpELL and SpEAF occupancy across the sme2 region. To characterise these variations, I 
performed chromatin immunoprecipitations using antibodies against the 
hypophosphorylated pol II C-terminal domain, the CTD phosphorylated on serine5, the 
CTD phosphorylated on serine 2 and epitope tagged SpELL and SpEAF, and compared 
occupancy levels during normal logarithmic growth and after 30 minutes exposure to 
hydrogen peroxide. Initiating pol II o r pol II engaged in early elongation is characterised by
---------------------------------------------------------------------------  _ l  |3
phosphorylation of serine 5 in the YSPTSPS repeats within the CTD of the Rpb I subunit 
of pol II, while productively elongating pol II is characterised by phosphorylation of serine
2. Consistent with sme2 gene induction, exposure o f the cells to  H20 2 resulted in a 
significant increase in sme2 sequences enriched by antibodies to  the hyperphosphorylated 
pol II CTD. Notably, oxidative stress caused a marked increase in initiating RNA 
polymerase II phosphorylated at serine 5 in the prom oter region (Figure 5-6 D amplicon 
C), as well as productively elongating pol II, which is phosphorylated at serine 2, in the 
body of the sme2 gene (Figure 5-6 E amplicons C and D).
SpELL and SpEAF occupancy also increased significantly under sme2-inducing 
conditions (Figure 5-6 A  and B). Although SpELL and SpEAF function with elongating pol II 
in vitro, the ChlP-qPCR profiles o f these proteins do not parallel those of CTD-phospho- 
serine 5 nor CTD-phospho-serine 2. This suggests that there is not a direct relationship 
between pol II phosphorylation state and the presence of SpELL o r SpEAF. [This is 
consistent with previous data that suggest that ELL can stimulate transcription elongation 
by pol II lacking a CTD in vitro (JWC personal communication)].
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Figure 5-6 Co-localisation of SpELL, SpEAF and RNA pol II at the sme2 gene.
Chromatin extracted from cells o f the strains indicated treated with (green) or w ithout (red) 6 mM 
H20 2 was immunoprecipitated using the following antibodies: anti myc (abeam ab9132) (A, B, C to 
E controls), pol II 8WG16 (C), pol II CTD phospho S5 (abeam ab5131) (D), pol II CTD phospho S2 
(abeam ab5095) (E). All ChIP signals have been normalised to the K region as before. All data 
points are the mean of three biological replicates. Error bars represent range.
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Figure 5-7 SpEAF enrichment at the sme2 region depends on SpELL
Chromatin immunoprecipitations were performed with antibodies specific for the myc epitope using 
chromatin extracts from the strains indicated. Deletion of the eaf1 gene results in reduced levels of 
the SpELL-m yc protein (as shown by Western blot (inset B)). To account for these differences in 
levels o f SpELL-myc protein in different strains, ChIP signals have been normalised. Values on the 
y axis are enrichm ents in immunoprecipitated DNA (ChIP / Input) normalised to enrichm ent at an 
amplicon within the transcriptionally silent K region. All data points are the mean of three biological 
replicates. Error bars represent range.
5.4 SpEAF enrichment at the sme2 locus depends on SpELL
To begin to explore how the SpELL/SpEAF complex is recruited to  the sme2 gene, I 
decided to  investigate the contribution o f each subunit to complex localisation. As my 
previous studies have suggested that SpELL interacts physically with pol II in vitro in the 
absence of SpEAF (Figure 3-9), I wanted to  ask whether the SpELL subunit was recruited 
to the sme2 gene in the absence of SpEAF in S.pombe cells. To test this possibility, I used a
12 1
strain with the eafl gene deleted and with a sequence coding fo r thirteen tandem copies 
of the myc epitope inserted before the ell I stop codon. Even though the strain lacking the 
eafl gene has reduced levels of SpELL-myc protein, ChlPs with elll-myc eafl A cells enrich 
for sequences within the sme2 locus. This suggests that SpEAF is not required for 
recruitment of SpELL to  sme2 in vivo (Figure 5-7 B). It is not clear why the enrichment 
relative to  the K region is larger in the eafl A strain. This may reflect lower background at 
the K region due to  the very low expression of SpELL in eafl A-cells. Alternatively the 
myc epitope tag on SpELL may be partially masked by SpEAF. Importantly the profiles of 
the tw o peaks shown in Figure 5-7 B are qualitatively similar.
To test the model that SpEAF is recruited to  chromatin by SpELL in vivo, I used a 
strain with the ell I gene deleted and w ith a sequence coding fo r thirteen tandem copies of 
the myc epitope inserted before the eafl stop codon. Consistent with the ChlP-chip 
assay (Figure 5-1), I found that SpEAF-myc coimmunoprecipitated sequences enriched for 
a region within the sme2 transcribed region, w ith the peak enrichment detected by 
primer set D (sme2 301-473) (Figure 5-7 C red line), a region coincident with the 
location of peak enrichment by SpELL-myc cells (Figure 5-7 A  and B). In the absence of 
the ell I gene there was no chromatin enrichment by the SpEAF-myc protein above 
background levels w ith respect to the surrounding regions (Figure 5-7 C blue line). As 
there is only a relatively small decrease in SpEAF-myc proteins when ell I is deleted 
(Figure 4-2), and I have normalised to the K region to  account fo r changes in protein 
levels in lysates, these observations suggest that SpELL is required fo r localisation of 
SpEAF within the sme2 gene.
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5.5 Quantification of different species of sme2 transcript in
elUA or eaflA  strains
Taken together, evidence from the 3’RACE and Northern analysis indicate that 
induction of the sme2 gene in response to oxidative stress causes an increase in pol II 
transcription of sme2, which results in the production of transcripts polyadenylated at 
between +438 and +442 nt relative to  the transcription start site. To test the possibility 
that there is a change in the level of these transcripts in cells in which the SpELL/SpEAF 
complex has been disrupted, I used tw o complementary assays, in which RNA from wild 
type, ell IA  o r eafl A cells was reverse transcribed and the resulting cD N A analysed by 
qPCR. In the first assay, I used an oligo(dT) primer fo r reverse transcription to  enrich for 
cD N A generated from polyadenylated transcripts, and, in the second assay, I used a series 
of gene specific primers fo r reverse transcription to  detect both polyadenylated and non- 
polyadenylated transcripts.
5.5.1 Quantification of sme2 transcript in elUA or eaflA strains using
oligo(dT) primed RT-qPCR
To determine whether levels of the shorter sme2 transcripts were altered in cells 
w ith either the ell I o r  eafl genes deleted, I used oligo(dT) primed reverse transcription 
to  generate cDNA complimentary to  polyadenylated RNA from wild type, ell IA  o r eafl A 
cells treated with o r w ithout 6mM H20 2. The cDN A samples were then analysed by 
quantitative PCR (qPCR) using primer pairs to amplify sequences containing either region 
C o r region L as indicated in Figure 5-8 A. All correctly initiated transcripts longer than 
105 nt should be detected by primers that amplify region C, whereas only transcripts
longer than +535 nt should be detected by the primers that amplify region L. I detected 
reduced levels of cDNA containing the region C sequence (sme2 26-105) in eafl A cells 
treated with H20 2 compared to wild type cells and only slightly reduced levels in ell IA
cells treated with H20 2 (Figure 5-8 B).
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Figure 5-8 Reverse Transcription qPCR at sme2.
Cells were incubated at 32 °C with or w ithout 6 mM H20 2 for 30 minutes and total RNA extracted 
with acidic phenol as described in section 2.11. 1 jig of total RNA was reverse transcribed with an 
oligo(dT) primer and the resulting cDNA was analysed by qPCR with the indicated primer pairs and 
a primer pair specific to the coding region o f the act1 gene (actin). Signals relative to genomic DNA 
standards are normalised first to actin then to wild type untreated cells. Error bars represent the 
ranqe of three bioloqical replicates.
The majority of transcripts identified by the primer set 26-105 in cells subjected to 
oxidative stress are likely shorter transcripts (polyadenylated at 439, 443 or 508) and not 
the longer ~ 1.2 kb transcripts detected by Watanabe and co-workers. The primers
124
amplifying region L (sme2 448-535) did not indicate a significant amount of the longer 
transcripts in cells whether or not they were treated with H20 2.
5.5.2 Quantifying transcription across sme2
As not all sme2 transcripts identified by 3’ RACE appeared to  be polyadenylated, I 
wanted to use an assay that did not depend on the use of an oligo(dT) primer fo r reverse 
transcription to  quantify the relative amounts both polyadenylated and non- 
polyadenylated transcripts. Gullerova and co-workers recently described an assay to 
assess transcription patterns across genes using only gene specific primers (176). In a 
similar assay, I performed separate reverse transcription reactions fo r each RNA sample 
using a series of primers located across sme2 as indicated in Figure 5-9 A. Following 
reverse transcription, cDN A samples were analysed by qPCR with the reverse primer 
used for reverse transcription and a corresponding forward primer as indicated (Figure 
5-9 A). I confirmed that levels o f sme2 transcripts that include the region sme2 +26 to 
+ 105, were lower in ell IA  o r eafl A cells than in wild type cells under conditions where 
the sme2 gene is induced by oxidative stress Figure 5-9 B. All correctly initiated 
transcripts longer than 105 nt include the region sme2 +26 to  +105 and are detected by 
amplicon C. Interestingly, under conditions where sme2 is transcribed at basal levels we 
did not detect a decrease in levels in transcripts containing the +25 to  +105 region as we 
had done when specifically analysing polyadenylated transcripts using the oligo(dT) primer 
fo r reverse transcription (compare Figure 5-8 B w ith Figure 5-9 B). This may be due do 
the presence of non-polyadenylated transcripts containing the sme2 +26 to  +105 region 
which are not significantly reduced in the mutant strains.
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Figure 5-9 Transcription across the sm e2 locus
This assay is essentially as described by Gullerova and co-workers (176). 1 ^ig o f total RNA from 
wild type, elUA or eaflA cells, incubated for 30 minutes with or w ithout 6 mM H20 2, was reverse 
transcribed in four separate reactions (B to E) with the reverse primer corresponding to the regions 
B-E within the sme2 gene as indicated, [together with a reverse prim er corresponding to an 
amplicon within the actin gene (act1).] The resulting cDNA was analysed by qPCR using the 
reverse primer used for reverse transcription together with its corresponding forward primer. 
Signals relative to genomic DNA standards have been normalised to actin. Results from three 
separate experiments are shown with error bars representing the range.
5.6 Discussion
The major goal of the experiments described in this chapter was to  define some of 
the basic requirements for recruiting SpELL/SpEAF to specific chromosomal locations. 
Although deletion of ell I o r eafl had only a very modest effect on the accumulation of 
sme2 RNA, the sme2 locus stood out as the gene with the highest apparent SpELL/SpEAF 
occupancy in initial screens fo r candidate genes using tiling arrays. Accordingly, I chose to
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use sme2 as a model gene to address questions about how SpELL and SpEAF are 
recruited to  genes.
sme2: A complex locus with multiple polyadenylated species.
In order to use sme2 as a model gene it was important first to define more 
completely the nature of the transcripts initiated at the sme2 prom oter under basal and 
inducing conditions. As discussed in the results section, a prior study (173) concluded that 
there are tw o  major classes of transcripts: short ones, with major poly A  sites at ~440 nt, 
and long ones, which hadn’t  been characterised and which were proposed to  result from 
read-through of the upstream polyA sites. Consistent with previous studies, I found that 
there are major polyA sites at +438, +440 and +442 nt corresponding to  the short 
products previously reported by Watanabe et al. w ith an additional, less frequently used 
polyA site immediately downstream at +508 nt. Although I did not detect polyadenylation 
sites at +1.2 kb, I identified cDNAs that appeared to  correspond to  transcripts 
polyadenylated at +746 and +751 nt. The 3’ ends of these are immediately upstream of 
runs of T-residues in the template strand, thus, templated runs of As in the transcript 
could allow oligo(dT) priming from sites that do not correspond to  bona fide 
polyadenylation sites. All basally transcribed sme2 products were also detected under 
inducing conditions by qPCR with a significant increase in amounts of the shorter, 
polyadenylated transcripts. Although Northern blot analysis could detect only RNAs from 
cells treated w ith H20 2, these RNAs migrated as a diffuse band of intermediate size, and 
this band would be consistent w ith the presence of the +438 to  +442 nt and the +508 nt 
polyadenylated transcripts and the absence of the longer o r shorter transcripts.
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Figure 5-10 Predicted structure of the 3 ’ end of the 340 nt sme2 transcript.
A. Structure prediction was with the RNA Vienna package 1.8.2 at the University of Vienna 
RNA fold server : http://rna.tb i.univie.ac.at/cai-b in/RNAfold.cqi. B. The 3’ end of the 340 nt 
transcript is coincident with the maximum SpELL and SpEAF ChlP-chip MAT scores.
Evidence for stalling and/or premature termination upstream o f the major 
polyadenylation site.
In addition to polyadenylated transcripts, I detected a non-polyadenylated species
with the 3’ end at +340 nt, and future studies will clarify whether this transcript could be
associated with stalled polymerase or result from prematurely terminated transcription.
Curiously, there is a region that is predicted to  form a hairpin structure just upstream of 
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the 3’ end o f this transcript (Figure 5-10 A). This structure could act in a similar fashion 
to  the prokaryotic intrinsic termination sequence, which destabilises the transcription 
elongation complex by forming a hairpin structure just before a poly(U) region in the 
transcript p rio r to  termination (177). The location of the 3’ end of this species is also 
coincident w ith the location of the maximum MAT score associated with chromatin 
enriched by SpELL and SpEAF (Figure 5-10 B). In addition, ChlP-qPCR suggested that this 
site, together with the major polyA sites, falls within the region of highest SpELL/SpEAF 
occupancy. In the future it would be interesting to  investigate pol II transcription through 
this D N A sequence in vitro to see whether the +340 nt site might represent an intrinsic 
pause site o r a premature termination site, and then to  assess the effect of SpELL/SpEAF 
on transcription through this sequence.
How do SpELL and SpEAF affect each other’s recruitment to sme2?
SpELL and SpEAF interact with RNA pol II via the SpELL subunit to  stimulate
transcription in vitro, suggesting a model in which pol II recruits an SpELL/SpEAF complex
to  D N A by binding to  the SpELL subunit. I used ChlP-qPCR to  assess the contribution of
each subunit to  recruitment of the SpELL/SpEAF complex in vivo. The results o f the ChlP-
qPCR experiments confirm results from the ChlP-chip experiments suggesting that SpELL
is localised near to  a region corresponding to  primer set D (+301 to  +473 nt) (Figure
5-5). This is consistent with the ChlP-chip data, which suggests a bias fo r SpELL/SpEAF
towards the 3’ end of sme2. SpELL enriches fo r this region even in cells with the eafl
gene deleted, suggesting that SpELL can be recruited to  this region of the gene in the
absence of SpEAF (Figure 5-7 B). In contrast, SpEAF enrichment at the sme2 locus
depends on SpELL (Figure 5-7 C). These results support a model whereby pol II recruits
an SpELL/SpEAF complex to  sme2 via an interaction w ith the SpELL subunit. 
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This model would also predict pol II localisation at the same locus, and so I asked 
where SpELL/SpEAF was on the gene relative to  pol II. The results of Figure 5-6 indicate 
that like SpELL and SpEAF, pol II enriches fo r the +301 to  +473 region of sme2. The 
characteristics of sme2 transcripts detected by 3’ RACE and Northern blotting do not 
indicate the 5’ ends of transcripts in this region suggesting that the pol II here would be 
transcriptionally engaged and not, fo r example, part of a preinitiation o r early elongation 
complex. Induction of sme2 by oxidative stress leads to an increase in SpELL/SpEAF 
localisation together with increased pol II phosphorylated at serine 2 and serine 5 on the 
CTD in the transcribed region of sme2. Future studies will help to  determine whether 
SpELL/SpEAF localisation is dependent upon o r is affected by the state of pol II CTD 
phosphorylation.
Analysis o f SpELL/SpEAF contribution to sme2 regulation.
Although I had originally chosen to  use sme2 as a model to  investigate recruitment
of the SpELL/SpEAF complex based on the large enrichment of sme2 sequences in ChlP-
chip assays, I considered the possibility that deletion of either the ell I o r eafl genes could
affect either transcription o r processing of sme2. To assess any changes in polyadenylated
and non polyadenylated sme2 transcripts in the ell IA  and eafl A strains, I performed RT-
qPCR analysis with reverse transcription primed w ith either an oligo(dT) primer o r with
gene specific primers ( 176). The results suggest a modest decrease in levels of the
shorter, polyadenylated transcripts both under conditions where sme2 is expressed at
basal levels o r is induced (Figure 5-8). Using an assay which detects both polyadenylated
and non-polyadenylated transcripts, I detected no significant difference between levels of
sme2 transcripts in the different strains used under non-inducing conditions, suggesting
that the presence of the non-polyadenylated transcripts might reduce any apparent 
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difference between transcript levels detected in the oligo(dT) primed RT-qPCR assay 
(Figure 5-9). This would be consistent with the results o f Figure 5-2, which indicate 
similar amounts of +340 (non-polyadenylated) and +438 to  +442 (polyadenylated) 
transcripts fo r unstressed cells in both mutant and wild type strains. Taken together, the
results of Figure 5-2, Figure 5-3, Figure 5-8, and Figure 5-9 indicate:
1. That under conditions where sme2 is transcribed at basal levels, cells 
contain relatively low levels of two species of transcripts, a ~340 nt non- 
polyadenylated transcript and +438 to  +442 n t polyadenylated transcripts.
2. When cells are exposed to oxidative stress, there is a significant increase 
in the levels of the +438 to +442 nt transcripts but not the +340 non 
polyadenylated transcripts.
3. There are slightly lower levels of the +438 to  +442 transcripts in ell IA  
and eafl A strains compared with levels in the wild type strain under both 
conditions where sme2 is expressed at basal levels o r is induced.
The changes in sme2 transcript levels are small but reproducible. There are other genes 
identified by the global genome studies presented in chapter 4 that have greater changes 
in transcript levels in the mutant strains, and these may be more suitable to  use as a 
model to  investigate the causes of these changes in transcript levels in the mutant strains 
in the future.
Possible separate functions for SpELL and SpEAF
As ell IA  cells grow less well in media containing the drug 6AU, whereas eafl A cells grow 
normally, it is likely that an SpELL function that does not require SpEAF causes the 6AU 
growth phenotype. If SpELL recruitment to genes is necessary to fulfil this function, then
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consistent w ith the results of Figure 5-7, SpELL would need to  be recruited in the 
absence of SpEAF. It is not clear whether SpELL/SpEAF recruitment to  this locus affects 
the level of sme2 transcripts.
A  hint that SpEAF might have an independent function comes from the observations of 
Figure 5-8, which suggest that there might be a greater reduction in sme2 transcript levels 
in eafl A cells than in ell IA  cells. One possibility is that there is an SpEAF function that 
does not require the presence o f SpELL and would not depend on SpEAF co-localisation 
with SpELL. The absence of this function might cause the reduced levels of sme2 
transcripts in the eafl A strain. Consistent w ith the idea that SpEAF may have a function 
that does not involve its interaction w ith SpELL, it has been reported previously that EAF 
proteins contain a transactivation domain that is separate from the ELL interaction 
domain (115).
In conclusion, I have used a model gene, sme2, to  answer questions about the recruitment 
of the SpELL/SpEAF complex to  genes in cells and propose a model, consistent with in 
vitro data, that the SpELL/SpEAF is recruited via an interaction between pol II and the 
SpELL subunit.
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CHAPTER 6. GENERAL DISCUSSION
Prior to  this study, the status o f ELL family members in lower, single celled 
eukaryotes had been unclear, with orthologues of ELL not apparent in either of the best 
characterised fungal model organisms S. cerevisiae o r S. pombe. This had led to  speculation 
that transcription elongation factors of this class may have appeared at a later 
evolutionary stage and may have evolved fo r functions specific to  higher, multi-cellular 
organisms, such as the transcription of particularly long genes, o r complex developmental 
programs that require very precise timing of transcriptional activation o r repression. In 
addition, no previous studies had attempted to  define the role of ELL globally -  whether 
ELL is used fo r the regulation of all genes in an organism o r is limited to  regulating 
transcription of only a subset of genes. The function of ELL in vivo had also been unclear. 
Although ELL clearly stimulates transcription elongation in v itro  by reducing transient 
pausing, it had not been known whether ELL functions in this way on genes in cells, 
whether ELL performs alternative functions, and how ELL function might affect the 
quantity and nature of RNA transcripts.
The results presented in this thesis have shed light on a number of these 
questions. First, I have confirmed that a single celled eukaryote, S. pombe, uses ELL, 
confirming that this class of transcription elongation factors did not co-evolve w ith higher 
eukaryotes. Furthermore, ELL does not contribute exclusively to  the transcription of 
genes tens o f kilobases long (as the average gene in S. pombe is 1416 bp with only six 
being annotated as being greater than 10 kb and none longer than 15 kb). Like their 
cousins in higher organisms, the SpELL and SpEAF proteins function together as a
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complex to  stimulate transcription elongation in vitro. SpELL and SpEAF are co-enriched 
on similar regions of chromatin from S. pombe cells, which suggests that they colocalise 
on chromatin. They appear not to  localise to  all genes, and deletion of the ell I and eafl 
genes is not lethal, arguing that the SpELL/SpEAF complex is not universally required. The 
exact function of the complex in cells and how the nature of RNA transcripts might be 
regulated remains unclear although as I will discuss below there are some indications that 
the SpELL/SpEAF complex might function at a pause site at the sme2 gene in cells. Future
experiments will elucidate whether the sequence of the transcribed region of this gene
influences recruitment of the complex to  the 3’ end of the sme2 gene.
6.1 Future Directions
6.1.1 The function of SpELL and SpEAF at sme2
I have demonstrated that SpELL/SpEAF is recruited to  sme2 and colocalises w ith pol 
II near the 3’ end of the gene. This colocalisation appears to  coincide w ith a non- 
polyadenylated sme2 transcript, which could represent a nascent transcript associated 
with paused pol II. Intriguingly, near the 3’-end of the non-polyadenylated transcript is a 
sequence predicted to adopt a hairpin structure, which could influence pausing.
Although my results suggest that the complex is recruited to  the gene through 
the SpELL subunit, it has not been demonstrated whether there is a direct interaction 
with pol II at the 3’ end of sme2, o r indeed whether pol II is required fo r recruitment of 
the SpELL/SpEAF complex. To address this, I propose conducting experiments that would 
change pol II occupancy of sme2 so that I could ask whether there would be 
corresponding changes in SpELL/SpEAF occupancy. Changes in pol II occupancy might be 
achieved by mutating prom oter sequence elements needed fo r pol II recruitment, such as
the TATA box, which has been mapped previously. Alternatively it might be feasible to 
block transcription of pol II specifically with a drug such as a-amanitin. If it is established 
that pol II is required fo r SpELL/SpEAF complex recruitment, one could then ask whether 
pol II CTD modifications correlate w ith SpELL/SpEAF occupancy. The complex appears to 
colocalise w ith pol II with serine-2 and/or serine-5 phosphorylated. It may be possible to 
manipulate phosphorylation of the pol II CTD by mutations in genes involved in CTD 
kinase pathways such as c s k l1, cdk7 o r cdk8. In addition to  asking whether CTD 
phosphorylation is important fo r SpELL/SpEAF localisation in cells, one could ask whether 
the complex is able to bind CTD repeats in vitro and whether phosphorylation of serine 
residues within CTD repeats would affect binding. This could be tested by first mixing the 
purified complex with biotinylated CTD peptides (with o r w ithout phosphorylated serine 
2 and/or serine 5 residues), and then purifying CTD associated complexes with 
streptavidin coated magnetic beads.
The enrichment of a region near the 3’ end o f sm el by SpELL, SpEAF, and pol II 
together w ith the existence of a non-polyadenylated sme2 transcript ending near this 
region, raises the intriguing possibility that there is paused pol II here. To investigate this 
possibility and to determine whether the 340 nt non-polyadenylated transcript results 
from paused pol II, it may be possible to  use a techniques such as permanganate 
footprinting to  test the presence of single stranded D N A representing a transcription 
bubble and nuclear run-on assays to determine whether 340nt transcripts can continue to
1 Cskl is a C D K  activating kinase, which can activate Cdk9 (a subunit o f P-TEFb), which in turn  
phosphorylates the pol II CTD at serine 2. Deletion o f cskl has been reported to  result in a 10 fold 
reduction o f pol II C TD  serine 2 phosphorylation (179).
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be elongated. Previous studies have suggested that pausing at some sites depends, at least 
in part, in sequences within the RNA transcript upstream of the active site and/or 
sequences in the D N A template just downstream of the active site. If there is paused 
polymerase at +340 nt then sequences in the vicinity may be responsible fo r pausing. If so, 
mutations in the coding region here might reduce pausing and reveal the importance of 
any nucleic acid sequences in promoting the pause. This could either involve replacing the 
whole of the transcribed region of sme2 w ith an alternative sequence o r mutating smaller 
regions. There is a particularly promising region just upstream of 340 nt that appears 
capable of forming a hairpin structure that might promote pausing and so I would propose 
investigating this region of the transcript. Mutations that would disrupt the hairpin 
structure might reduce the accumulation of +340 nt transcripts and might affect the 
accumulation of SpELL, SpEAF and pol II in this region. As well as mutating this region in
S. pombe cells, complementary experiments could be done using the sme2 sequence as a 
D N A template fo r reconstituted elongation reactions in vitro. This would not only 
determine whether the hairpin serves as a strong pause site, but in addition the 
transcripts associated with pausing could be characterized and any structures that might 
cause the pause could be investigated. In studies using E. coli RNA polymerase,
Chamberlin and coworkers used nuclease mapping to  provide evidence of secondary 
structure in RNA transcripts from paused complexes (39). Fisher and Yanofsky describe 
using D N A oligomers complementary to  an RNA hairpin associated with a strong pause 
site to  reduce pausing in vitro (42), and similar experiments could be done using DN A 
oligomers complementary to  the predicted hairpin in the sme2 transcript. Experiments 
using S.pombe cells might also elucidate whether sequences within the transcribed region 
are important fo r accumulation of pol II, SpELL and SpEAF at a particular location. For
example, one could ask whether transferring the sme2 transcribed region to  a different 
genomic location w ith a different prom oter would result in recruitment of SpELL, SpEAF 
and pol II to an alternative location.
Many RNA processing reactions are regulated cotranscriptionally. The location of 
SpELL and SpEAF near the 3’ end of the sme2 gene raises the possibility that the complex 
might be involved in processing the 3’ end transcript and so it would be interesting to 
investigate the possibility that sme2 transcripts are not processed correctly in strains 
lacking the ell I gene. For example correct polyadenylation of sme2 could be assessed 
using the assay described by Kusov and co-workers (180) to  determine poly(A) tail 
lengths of specific genes. In this assay, samples of total mRNA are elongated with 
guanosine residues, cDNA is generated using an oligo(dC9T6) primer, which anneals to 
the junction between the 3’ end of the poly(A) tail and the added guanosines, and the 
poly(A) tail fo r a particular gene is amplified using a gene specific sense primer. The range 
of tail lengths can then be estimated by gel electrophoresis o r determined more precisely 
by cloning and sequencing the per products.
Finally, indications that the SpELL/SpEAF complex may be important fo r 
transcription of sme2, a gene required fo r meiosis I, raise the possibility that disruption of 
the SpELL/SpEAF complex may compromise meiosis. It would be interesting to  see 
whether a diploid homozygote ell I deletion strain was capable of progressing through 
meiosis and sporulating. I could also compare levels of sme2 transcripts in wild type and 
ell IA  o r e af/A  cells under conditions, such as nitrogen starvation, which are known to 
stimulate progression into meiosis.
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6.1.2 Analysis of genes other than sme2
To see whether the SpELL recruitment depends on SpEAF at genes other than 
sme2, I propose extending my ChlP-qPCR analysis to  other genes. The candidate genes 
that are involved in cell separation, fo r example oce2 o r eng I, would be suitable for 
further investigation by ChlP-qPCR.
Changes in gene expression in the ell IA  and eaf/ A strains detected by expression 
array analysis were modest. As only a few probes corresponding to  each predicted 
protein coding gene were spotted on the arrays, a more comprehensive picture of 
changes in levels of all transcribed RNA might be achieved if the experiments were 
repeated using Affymetrix tiling arrays. Tiling arrays have a large number of probes 
covering most of the genome with no bias towards predicted ORFs of protein coding 
genes and, fo r example, might detect non-coding RNA transcripts o r changes in transcript 
levels corresponding to  the 3’ end of a gene relative to  the 5’ end of a gene.
6.1.3 Further investigations into the biochemical mechanisms of an 
SpELL/SpEAF I pol II complex
Investigating the biochemical mechanisms controlling pol II pausing.
The results o f this study suggest that SpELL/SpEAF functions via a direct 
interaction w ith pol II. More detailed structural information regarding the interactions 
between the SpELL/SpEAF complex and the ternary complex might give insight into how
the complex functions in modulating pol II pausing. Indeed, the nature of the interactions 
between pol II and other factors involved in regulating pol II pausing has helped in 
developing models to explain how these factors work. In particular, models have been 
proposed to  explain the biochemical mechanisms involved in the control of pol II pausing 
near promoters by DSIF/NELF, and to  explain the control of transcription through arrest 
sites by Sll (TFIIS). During prom oter proximal pausing, a subunit of NELF might bind to 
the pol II clamp domain, and DSIF is thought to  bind Rpb7 (181). This would be consistent 
with the idea that DSIF/NELF complex is positioned near the pol II RNA exit channel. 
Binding of NELF to  the RNA transcript as it emerges from this channel might explain why 
elongation becomes inhibited by DSIF/NELF once the transcript reaches 20 -  30 nt long 
(reviewed in (182)). A fter transcriptional arrest, a region of Sll can enter the funnel 
region of pol II to help position a water molecule at the active site and thus to  help to  
catalyse hydrolysis of the 3’ end of an arrested transcript.
Further investigation into ELL-pol II interactions.
The experiment o f Figure 3 -10 suggests a species specific functional interaction 
between the ELL/EAF complex and its cognate pol II, when equimolar amounts of S. 
pombe and/or human ELL and/or EAF were used to stimulate transcription elongation in 
vitro; however, it is not clear whether this species specificity is absolute. Despite 
conservation of structural domains between S. pombe and human ELL/EAF proteins, the 
amino acid sequences are dissimilar (Figure 3-1) and may result in different characteristics 
between the surfaces of the human and yeast proteins. Nevertheless, it would be 
interesting to see whether higher concentrations of human ELL o r EAF could stimulate 
transcription by S. pombe pol II. The results of Figure 3-10 B lane 8 are consistent with a 
possible very modest positive regulation of SpELL by human EAF I and this experiment 
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could be repeated with increasing concentrations of EAF I. In addition, experiments could 
be conducted in S. pombe cells to  test whether overexpression of the human ELL or EAF 
proteins in ell IA  o r eafl A cells might rescue the altered patterns of gene expression in 
the deletion strains.
To assess which pol II subunits SpELL might bind, I propose coexpressing epitope 
tagged SpELL w ith individual S. pombe pol II subunits (or smaller regions of pol II subunits) 
using recombinant baculoviruses. I have conducted similar experiments with human ELL, 
and preliminary results suggest that human ELL interacts with human pol 11 subunits Rpbl, 
Rpb2 and Rpb3. Another approach might be to  use Far-western blotting, using labeled 
SpELL or SpEAF to  probe for subunits of RNA pol II that have been hybridised to  a 
membrane. More revealing information about SpELL/SpEAF pol II function might come 
from a more precise knowledge of the complex structure, perhaps using X-ray 
crystallography o r electron microscopy. Such studies would involve collaboration with 
groups with expert knowledge in these procedures.
In light of the physical interaction between pol II and SpELL/SpEAF in vitro, it is 
interesting that cells expressing reduced levels of the pol II subunit Rpb4, and cells with 
either ell I o r eafl deleted, have reduced expression of a number of genes in the Ace2 
pathway. This raises the possibility that overexpression of Rpb4 might suppress 
downregulation of these Ace2 pathway genes in the ell I A and eafl A strains, I propose 
expressing the rpb4 gene on a plasmid under the control of the inducible nm tl promoter 
in ell I A  o r eafl A cells and comparing RNA levels of the Ace2 regulated genes before and 
after induction of rpb4.
140
ELL/EAF could enhance elongation in part via interactions with RNA.
It remains unclear whether the complex also interacts w ith nucleic acids. There is 
some evidence that another transcription elongation factor that reduces transient pausing, 
Elongin, does not need to  interact w ith RNA to stimulate elongation (183). Binding of^a 
nascent RNA transcript to SpELL and/or SpEAF could be assessed by performing in vitro 
transcription reactions w ith both radiolabeled CTP and the UV crosslinkable analogue 5- 
bromo-UTP. This method was used recently to  show that the Spt5 subunit of DSIF binds 
the nascent transcript which was +22 nt long (but not + 18 nt long) as it emerged from 
the pol II exit channel (181). Binding o f the complex to  RNA in the absence of pol II and 
DNA could also be assayed, perhaps using a selection of biotinylated RNA oligos, some 
with sequences that might be predicted to form hairpin structures. Complementary 
studies in vivo using RNA immunoprecipitations might establish whether transcripts from a 
set of genes are bound to  the SpELL/SpEAF complex and if so, whether these genes are 
those enriched in SpELL/SpEAF ChlPs.
6.1.4 Why are the el!1 and eafl genes non-essential in S. pombe?
Like many yeast genes, ell I and eafl are non-essential under the conditions in 
which cells are grown in the laboratory. They have a function that is not required for 
haploid cells growing in rich media at optimal temperatures. Perhaps the SpELL/SpEAF 
complex is essential fo r meiosis (sme2 which is highly enriched by SpELL and SpEAF in 
chromatin immunoprecipitations is essential fo r meiosis I) and it would be straightforward 
to  test the ability of homozygous mutant diploids to  sporulate. Homozygote diploids can 
be generated by mixing cells from haploid cells of opposite mating type and incubating on
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malt agar. Diploids from wild type cells generated in this way usually sporulate with 
complete asci after incubation fo r 3 days at 25°C, and sporulation can be visualized by 
exposing plate cultures to  iodine vapour (184). A  reduction in the percentage of viable 
spores in mutant cells might indicate defects in meiosis (185), and, if mutant cells are able 
to  soprulate, the viability of the spores can be analysed. To do this, spores need to  be 
isolated from the mating mixture, which contains both asci (containing spores) and 
vegetative cells. Digestion with glusulase removes the walls of the asci, which releases 
spores. Glusulase also digests the walls of vegetative cells, killing them. Dilutions of spores 
can then be plated and incubated under conditions where viable spores will generate 
colonies of cells. The percentage of viable spores can be calculated from estimates of the 
number of spores plated and the number of colonies formed (185).
Additional experiments might investigate expression of different classes of genes 
involved in meiosis in mutant cells grown in conditions propitious fo r the expression of 
such genes. W ild type and ell IA  o r eafl A cells could be grown in minimal media lacking a 
nitrogen source. RNA prepared from these cells could be analysed either by RT-qPCR 
using primers corresponding to a selection of meiotic genes o r by reverse transcription 
followed by hybridisation to  expression arrays.
SpELL and SpEAF also appear to  be enriched at, and modulate the transcript levels 
of, a number of genes involved in cell separation after cytokinesis. It has been proposed 
that regulation of these Ace2 pathway genes might have evolved to  control whether 
filamentous fungi grow as single cells o r filamentous hyphae in response to environmental 
stimuli (186). Switching from single cellular growth to  hyphal growth may be a mechanism 
that fission yeast use to forage fo r nutrients, and downregulating cell separation might be 
a mechanism used to  promote the formation of filamentous structures. Expression of the
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Ace2 pathway genes changes during the cell cycle (186). So far I have analysed RNA levels 
of Ace2 pathway genes in unsynchronised cells growing in rich media. I might expect to 
see greater variation in levels of Ace2 pathway genes between wild type and mutant cells 
for populations o f cells that are synchronised at a stage in the cell cycle where these 
genes are normally expressed. I propose synchronising cells by centrifugal elutriation 
(187) and allowing the synchronised population of cells to  progress through the cell cycle. 
Expression of Ace2 pathway genes in synchronised cells could then be measured by 
analysing RNA from  samples of cells taken at different times during progression through 
the cell cycle by RT-qPCR.
Alternatively, SpELL and SpEAF might fulfil redundant roles. It is possible that 
other proteins o r complexes take over these roles in the absence of SpELL/SpEAF. To 
investigate this possibility I suggest disrupting the ell I o r eafl genes in the S. pombe 
deletion strain library to  look fo r genetic interactions between ell I /ea fl and other genes. 
Roguev and Krogan have developed a high-throughput platform to  screen fo r genetic 
interactions between genes of interest (188). This technique could be used to identify 
both negative interactions (for example pairs of deleted genes that result in a sick or 
lethal phenotypes), and positive interactions (for example where deletion of ell I /eafl 
suppresses a sick phenotype caused by deletion of another gene, o r where the 6-AU 
sensitivity of the ell IA  cells is suppressed by deletion of a second gene). If I find a meiotic 
o r sporulation phenotype in the ell IA  cells, I could also look fo r genes that when 
disrupted suppress o r enhance that phenotype.
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Appendix A: S. pombe Strains used in this study
S tra in  (p a re n ta l)  G eno type
972 h-
elll A (972 ) elM ::kanMX6 h-
PP138 ade6-M 216 leu 1 -32 ura4-D18 his3-D1 h-
PP1 37 ade6-M 216 leu 1-32 ura4-D18 his3-D1 h+
elll A (PP1 38) e lll ::kanMX6 ade6-M21 6 leu 1 -32 ura4-D l 8 his3-D1
elll A (PP137) e lll ::kanMX6 ade6-M21 6 leu 1-32 ura4-D1 8 his3-D1
eafl A (PP1 38) e a fl ::kanMX6 ade6-M21 6 leu 1 -32  u ra4-D l 8 his3- 
D1 h-
elll -myc (PP1 38) e lll ::ell1 1 3m yc/natM X6 ade6-M21 6 leu 1 -32 ura4- 
D18 his3-D1 h-
elll-myc  (PP1 37) e lll ::ell 1 1 3m yc/natM X6 ade6-M21 6 leu l -32  ura4-
eafl-myc  (PP1 38) e a fl ::eaf1 1 3m yc/natM X6 ade6-M21 6 leu l -32
elll-myc eafl A 
(P P 137 /8 )
ell 1 ::ell1 1 3m yc/natM X6 ea fl ::kanMX6 ade6-M21 6 
le u l-32  ura4-D18 his3-D1
eafl-myc elll A 
(P P 137 /8 )
e a fl ::eaf1 1 3m yc/natM X6 e lll ::kanMX6 ade6-M21 6 
le u l-32 ura4-D18 his3-D1
rpb3-myc (PP1 38) rpb3::rpb3 13m yc/natM X6 ade6-M 216 leu 1-32
tbp 1-myc (PP1 38) tbp1 ::tbp1  1 3m yc/natM X6 ade6-M21 6 leu 1 -32
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p o f4 -m y c  (PP1 37) po f4 ::p o f4  1 3m yc/natM X6 ade6-M21 6 leu l -32
elll rescue (PP1 38) e lll ::kanMX6 ade6-M21 6 leu 1 -32::ell1 / le u l ura4-
CBS354/O Y1*
Sj elll A (CBS354/O Y1) * Sj e lll ::kanMX6
*S. japonicus
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Appendix B: Primers Used in this Study
sme2 ChIP and RT /  qPCR analysis (Chapter 5. )
P rim er Name Sequence
sme2 -1407 fwd (A) TAC CAC GGT AC A ATG GTC GGA GAT
sme2 -1326 rev (A) 
sme2 -530 fwd (B)
CCC ATG GGA GCA TTA TCG GTT GAT 
CGG AGA ACG CAA GCT TGA AAT GGA
sme2 -389 rev (B) TGG TAC CGT ATT GTG AGC GA
sme2 +26 fwd (C) TGT TGG TCA ATC TTC TGC CGT CTT G
sme2 + 105 rev (C) GCG ATC TTG CAT GCA TAT TCC GTC
sme2 +301 fwd (D) CCC AAG TTG GTT TAT GTG AGC CTT GTC
sme2 +473 rev (D) GTG CTT TCA AGG ATA AC A ATG CAG CC
sme2 +640 fwd (E) ACC CGC AGT TTG TTT AAA CGC T
sme2 +738 rev (E) GGG TTT AAC GAA TGG TTT CAG CAC G
sme2 fwd +717 (F) GCT GAA ACC ATT CGT TAA ACC CTG C
sme2 rev +835 (F) CAG CAC AAC CGA AGA CCA ATG CAA
sme2 fwd +1210 (G) TGG TTG GAC TTT GCC GAT TTC ACG
sme2 rev + 1 363 (G) ATG CTG GGA TCT GTC TGT TCT GCT
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sme2 fwd 1839 (H) TTG TTG GTA CGA TGC CCG ACA AGA
sme2 rev 1928 (H) CGC CGG AAG CAA TAC CAT TTA AGC
K region fwd GTT GCG CAA GCG AAG TTA TGG AGT
K region rev ATA CGG TGC TTG GGC TTA GTC CTT
S. pom be  strain construction (Chapter 3. , Chapter 4. and Chapter
5. )
P rim er Name Sequence
elll A MX6 fwd CTT AA A  CAA GCT TCT CCG TTG TGC CAT CTA 
GCT AAT ATA  ATC ATT TTG AG A GGC TTT TAC 
TAT CGA TCT ATT TGG GTT GAC GGA TCC CCG 
GGT TAA TTA A
ellktag MX6 fwd AAG ATG AAC TTA TAT CTC TAC ATT CTC AGC 
TCA AAA GCT GGA AAA ATA CAC TTT ACG ATG 
CTT CCT CGG AGC TAG CCC TCC GGA TCC CCG 
GGT TAA TTA A
ell 1 MX6 rev TTA AAC GAA ACA CTA GCC TTA ACG AAA GCA 
GGA AA A AAC AGC CTG CAC TCG TTG TAG GCA 
CCG TAC AGT ATT GAA ACA ATG AAT TCG AGC 
TCG TTT AAA C
eafl A MX 6 fwd TCT TAC CTT ACG TTA TTT ATT TGA TTT ATA 
TCG AAA TTT CCA ATT TCG TAC AGG CCT GAC 
TTT TAC CAT TAT AAA CAA TCC GGA TCC CCG 
GGT TAA TTA A
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eafl :tag MX6 fwd GGG GTC TAT CTT CGC AAG AGA GGG ATT ATG 
CTT CTT CTG CTC AGG CAG AGG GTA TCA GCA 
GCG CTT CCG AGG ATG AGG ATC GGA TCC 
CCG GGT TAA TTA A
eafl MX6 rev AAA ATG ACA CAG AGT GAA ACG AGT TTA TTA 
CCG CCG ATT CGC TGT CGA GTA GTG ATG GAA 
AAG ACT TGT CTT GCT TTA CTG AAT TCG AGC 
TCG TTT AAA C
rpb3:tag MX6 fwd TTT CTG CTA ACG AAC TG A ATA TGG AGG AGA 
ATG CAG AAA TG A ACT GGT CTC CCT ATC AAA 
ATG GTG AAG AA A AC A CGT GGC GGA TCC 
CCG GGT TAA TTA A
rpb3 MX6 rev ATC TAA AGC TAT AAT AAA TCC AAG TGA AGA 
AGA ACA AAA TTA TGA TAT GAG GGA GGA ATA 
TAT ATC TCT ATA TAT GCA TAG AAT TCG AGC 
TCG TTT AAA C
tbp 1 :tag MX6 fwd TAA CTG GTG CGA AAG TCC GTG AGG AAA TTT 
ACC AAG CTT TTG AAG CCA TTT ATC CAG TAT 
TGT CTG AAT TTC GAA AAC ATC GGA TCC CCG 
GGT TAA TTA A
tbp 1 MX6 rev AGG ATG TCT CTA TCA TCT GCA TCA TAT AAA 
AAT ACT CAT AAA TGA TGA CTT ACA GTG AAG 
GGG ATT CTC CGG AAA GCT TTG AAT TCG AGC 
TCG TTT AAA C
pof4A MX6 fwd GCA CTC TTC CAA TTG AAG AC T ATA GAG CTC 
TAA TTC GAT CGT TTT CTT TGA AAT TTT TAA 
AAA TTA CTA TCA TAT GAG CGC GGA TCC CCG 
G G TTA A  T T A A
pof4 MX6 rev CCT CGA AGG ATT TGG AAA AAA GGA CAT GGG
AAA AGA CGT AGG GCG AGA GAT TGA TGG AGA 
GGA GGA AGA TGA AGG TTG AGG AAT TCG AGC 
TCG TTT AAA C
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Sj elll A MX6 fwd TCT GCA TCC TTC AAA CTT CTC GTT GCG TTT 
GCT GTT TGA CCT GAC GTT GAA TTT GTC TGT 
GCT CAA GTG CTG CTG CTG GAC GGA TCC CCG 
GGT TAA TTA A
Sj ell 1 MX6 rev AAG AGT AAG AAA AAG GGG ACT AGG TGG TGG 
ACG AAT AGC AGA ACG AAT GGA CAA ACC GTC 
CAA GGG GCG GAG AAG GAA AGG AAT TCG 
AGC TCG TTT AAA C
PCR confirm ation o f strains (Chapter 3. , Chapter 4. and Chapter 5. )
P rim er Name Sequence
pFA6A PTEF rev CTC CAT GTC GCT GGC CGG GTG AC
ell 1 coding fwd CCC AAA CCT TCC CGT CTC GCA ACC GTC TGC 
ATC ACC
ell 1 coding rev GAG GGC TAG CTC CGA GGA AGC ATC GTA AAG TG
ell 1 upstream fwd CTG GTC CCG TAA CCC TAT TCC GCC GC
eafl coding fwd GAT CTC GAG ATG AAT TCA TTA CAG AAG GGA TCA TAC AAA GTT ATT CCC GGG TCC AGC
eafl coding rev CAT GGT ACC TTA ATC CTC ATC CTC GGA AGC GCT GCT GAT ACC CTC
eafl upstream fwd CAG GCT AGC GTT GTC AAT AGC AGC AAT AAA TCT AAC AGT CAT CAT ACT C
rpb3 fwd ACA CCC TAT TCT CGC CGA TCC AAA
tbpl fwd ATG CGT ATC CGT GAA CCC AAG TCT
149
pof4 upstream fwd ACT CGC A CT TAG A TT CTC CGC GTT
pof4 coding fwd CAG CTC GAG ATG TAT TCT TTA AAA GAT TTG TGC ATC CAA GTC GCG
pof4 coding rev CAC GGT ACC TTA AAT TCG TTT AGG AAC TTG ACT AGA AAA CCT CGA AGG
Sj ell 1 coding fwd AGT GGG AGC TTC GTC CTG AAA TGT
Sj ell 1 coding rev TGC ATC AGG CGG AAG AGA AAG AGA
Sj ell 1 upstream fwd TTA TGC ACC ACC GAC AGT CTC CTT
Primers used to  confirm  changes in RNA levels in elll A and eafl  A 
strains by RT /  qPCR (Chapter 4. )
P rim er Name Sequence
abp2 fwd AGA GCG TCC CAT CAC ATG TCT GAA
abp2 rev ATG TGA ATT GTT GGC TGC GGA AGG
ace2 fwd ATG GCT AGC TTA TAT TGC GGC CCT
ace2 rev CCA GCT TTG CAT AAG TCA CAG CGA
actl fwd ACT GCT GCT CAA TCT TCC TCC CTT
actl rev ACT GCT GCT CAA TCT TCC TCC CTT
adgl fwd TCA AGC TCT GAA GTC ACC TCC CAA
150
adgl rev ACC GGC AGT CTC AGT AAC AGT GAA
adg3 fwd GAT GGT GTG GCA GTC AAG CCA TTT
adg3 rev ATT ACC CGG GAG AAC CGT TTG ACA
agnl fwd GCA CTG GAA GAA AGC GTT GCA GAT
agnl rev AGG CGA GAC TGG TGC AAC ATA CAA
atsl fwd GTT CAG TTC GCA TTC GCT CTG TCA
atsl rev ATG CCA CAG GAG TAA CCT CGT CAA
cdc45 fwd CGC CTT GGA CGA TGT CGA TTC ATT
cdc45 rev GGT GAT TCC AGT ACG AAC AAT GGC
chrl fwd TTG GCC AAT GAC AAG GGT AAT GCG
chrl rev TTC CCG AGG ACA TAA CAA GCA GGA
engl fwd TTC GCA A TA  TGG CTG CGA CAA TGG
engl rev ATG CCA GTT GAC TGT GCG GTA GTA
fio l fwd AGC AG T GCA TGT TGG ATG GTG TTC
fio l rev AC A GGC TGA AAT CAC AC A TGC TGC
1 ,  
gpdl fwd AAG TTG CCC GTG AGC AAT TCT GTG
gpdl rev AAC GTC GTC AAC GGA GAC AAC TGA
mak 10 fwd GAC GGT GCT TTG TAT GCG GTT GAA
151
mak 10 rev AGC TTC  CGA ACG AAG TAG TGG CTT
mei2 fwd ATT CAG TTA GCA CCT CTT CGG CCT
mei2 rev TAG CAG CAG TGG GAG TTT CTT GGT
mfm2 fwd GCC TAC AAC AAC AAT CCT ACC GAT G
mfm2 rev ACA CAC ATA TAA GGA ACC TTT GGA GT
mid2 fwd ATC CAC CTA AGG TTC GCA CTC GTT
mid2 rev AGT GCG GTT CGG CTT AC A GAA TCA
pex7 fwd ATT AGG CGG AAG CGG ACG TCT TTA " . '
pex7 rev AAA GAA CCA TCA CCA CAG CAA GCG
phol fwd GCT TTC GAT GCT GTT GGA ATC GCT
phol rev AAT AAC TCG AC A CGG CCA CTG CTA
SPAPBIAIO. 14 fwd ACC TTG TC T CGT TCT TCC TGC GAT
................ ..........................................  . ____________________ _ _ ............... I
SPAPBIAIO. 14 rev TCC AGG AGC AGC ATC AAC TCT TGT
SPAC1002.19 fwd TGG TAT TGA GGA AGC TGC CAA GGA
SPAC1002.19 rev AGT CAC CAG TAC GCT TAC GCT TGT
SPAC 1039.02 fwd ATG GTT GAC ACC GGT GAT TTG CAC
. . .  . .  1
SPAC 1039.02 rev AAT GGC GGC TTG GTA CAA TTC GTG
SPAC I5E 1.02c fwd AGT CGT ACT CGA TCG CTG CAT TGT
152
SPAC 15E 1.02c rev CGG GCA ATC CAG ATG CAC CAA ATA
SPAC27D7.09c fwd CAC TGT TG A AGG CAG CAA TGG TGT
SPAC27D7.09c rev ATC GCA ACC AGA GCT AG A GCA GTT
SPAC27D7.10c fwd AAT GGC ACT GGC CGA TTC ATT CTC
SPAC27D7.10c rev ATC GCA ACC AGA GCT AG A GCA GTT
SPAC2EI P3.05c fwd TCT AG T GCT GCT TCT TCC ACC AC A
SPAC2EI P3.05c rev ACT GCT TGT CGA CAC ACT GGA AG A
SPAC2H 10.01 fwd TTC ACC TTC TCT TGA CGC AG A CGA
SPAC2H 10.01 rev GCA ATT GGC TTC CAC TTC CTT GGT
SPBCI289.I4 fwd CCA TAT GCT GCT GGC GTT TC A TGT
SPBC1289.14 rev TGT GAC AGG ACC AGA TTG GTG TGA
SPBC 1861.01c (cnp3) fwd ACG CGA AGA AGA TGT CCA ACG AGA
SPBC 1861.01 c (cnp3) rev TAC GTT TCG ACC TTC GGA CAC CAA
SPBC 1 E8.04 fwd CGC TGG AAA TGG ACA CCA AC A CAA
SPBC 1 E8.04 rev ATC AAA GTG TCG TAG CAC CGG AGA
SPBC215.06c fwd AGC TGT ATG ACA GAA GCT CAA CGC
SPBC215.06c rev TCG TCA AGC GAG TGT TTA GTG GGA
SPBC8E4.01 c fwd
--  .
AC T GGT ACG AAC GAA TAC CGC ACA
153
SPBC8E4.01 c rev TA T C C A  GGA ACA TAG CCG G CA ACA
SPBPBI0D8.0I fwd AAA CCA AAG TGC CTT TCA CGG AGC
SPBPBI0D8.0I rev TGT GTA TCC AGC ACA AG A GGC TGT
SPBPB7E8.01 fwd TAC TGG CGA GTC TGT TTG TTC CCA
SPBPB7E8.0I rev AC T GCA AGC CAT GGG AAT TTC ACG
SPBPB7E8.02 fwd CAA GCA ACG CAT TGA CTT CCG TGA
SPBPB7E8.02 rev TGT ACC ACT GAC AGC AC A CAT CCA
s trl fwd TGT CAC AGC CCT TGT TAG TAC CGT
s trl rev TTT CTA AAC GCT TGG GCA TCA CGC
str3 fwd GAC CAA ATT TCG CGG CTA CAG GAA
str3 rev ACC AC A CTG AAG GAA CCA CCC ATA
tlh 1 /2 fwd GGC GCA CTA TGG AC A AC T TGC ATT
tlh 112 rev TGG GTG CTT TGT TTC CAC CAA CAG
154
Appendix C: Gene Lists
Genes identified by microarray analysis with a greater than 1.40 fold 
change in RNA levels in elll A or eafl A strains (Figure 4-1)
G ene
abp2
ell 1A /  w t  
(RT /  qPCR*)
0.59
eafl A /  w t  
(RT /  qPCR*]
0.44
ace2 0.60 0.62
adgl 0.67 0.67
adg3 0.67 0.71
agnl 0.69 0.56
atsl 1.25 1.33
cdc45 0.95 0.95
chrl 0.73 0.71
engl 0.65 0.56
fio l 1.68 1.74
gpdl 0.70 0.68
maklO 0.99 0.92
mei2 0.41 0.31
mfm2 0.67 0.63
mid2 0.85 0.81
pex7 0.52 1.10
phol 0.44 0.39
SPAPBIAIO. 14 0.67 0.92
SPAC 1002.19 0.75 0.85
SPAC 1039.02 0.67 0.81
SPAC I5E 1.02c 1.75 1.50
SPAC27D7.09c 1.79 1.81
SPAC27D7.10c 1.03 1.25
SPAC2EIP3.05c 0.44 0.37
P ro d u c t178
ARS binding protein Abp2; phenotype aberrant septa
transcription factor Ace2; transcriptionally regulates 
cell separation during cytokinesis 
sequence orphan; cell surface glycoprotein 
transcriptionally regulated by Ace2 
beta-glucosidase Adg3 (predicted); cell surface 
glycoprotein transcriptionally regulated by Ace2 
glucan endo-1,3-alpha-glucosidase Agn I ; 
transcriptionally regulated by Ace2 
N-acetyltransferase Ats I (predicted)
DNA replication pre-initiation complex subunit 
Cdc45 (Cell division control protein 45) 
chitin synthase regulatory factor Chrl (predicted); 
transcriptionally regulated by Ace2 
endo-l,3-beta-glucanase Engl; transcriptionally 
regulated by Ace2
iron transport multicopper oxidase Fiol
glycerol-3-phosphate dehydrogenase Gpd I
NatC N-acetyltransferase complex subunit MaklO 
(predicted)
RNA-binding protein involved in meiosis Mei2
M-factor precursor Mfm2 (M-factor is a mating 
pheromone produced by M-type mating cells.) 
anillin homologue Mid2; septin ring organizing 
protein transcriptionally regulated by Ace2 
peroxin-7 (predicted); peroxisomal targeting signal 2 
receptor
secreted acid phosphatase Pho I 
F-box protein
GTP cyclohydrolase II (predicted)
phosphoprotein phosphatase (predicted)
DUFI76I family protein
But2 family protein (Ubiquitin 3 binding protein 
But2)
But2 family protein
fungal cellulose binding domain protein
* mean value of three independent experiments
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SPAC2H 10.01 0.34 0.41
SPBC 1289.14 2.72 2.07
SPBC I86 l.0 lc
(cnp3)
0.59 0.49
SPBCIE8.04 1.39 1.30
SPBC215.06c 0.92 0.90
SPBC8E4.01 c 0.55 0.53
SPBPBI0D8.0I 0.49 0.80
SPBPB7E8.0I 0.55 0.80
SPBPB7E8.02 0.95 0.91
s trl 1.35 1.81
str3 3.34 3.37
t lh 1 2.67 8.96
transcription factor, zf-fungal binuclear cluster type
(predicted). Adjacent to adgl
adducin
centromere protein CENP-C 
pseudogene
human LYHR.T homolog (zinc finger protein)
inorganic phosphate transporter (predicted); 
adjacent to pho I
cysteine transporter (predicted)
sequence orphan
PSPI family protein
siderophore-iron transporter Strl
siderophore-iron transporter Str3
RecQ type DNA helicase (sub-telomeric helicase)
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SpELL enriched genes (identified as described in section 4.5.1
aar2 cox 18 hht2 m mm l p tn l rps60l SPACI 3G6.06c SPAC24811.09
ace2 cox5 hht3 msal publ rps602 SPACI3G6.IOc SPAC24811.12c
adgl cpdl his2 msh6 pvgl rps801 SPACI 3G6.13 SPAC24811.13
adg3 cpyl his3 mug 142 pvg3 rrn l 1 SPACI 44.12 SPAC24H6.I3
adhl csn2 hmgl mug5 pvgS rrn5 SPACI 44.18 SPAC2588.03
adh4 csn4 hmt2 mug80 pykl rrn7 SPAC 1565.07c SPAC2588.il
adkl csxl hobl myhl pypl rsc58 SPACI 687.09 SPAC2588.12c
agnl ctr4 hsfl nda3 pyrl rsdl SPACI6E8.0I SPAC2588.19c
ogsl cu tl hspIO nedl pzh l rst2 SPACI 705.03c SPAC25G 10.09c
alg2 cwf22 hsp90 nep2 qcrl rsv2 SPACI 782.05 SPAC26FI.05
alg3 cyrl hst4 n ifl qcr2 sapl SPACI 782.06c SPAC26FI.07
am tl cys2 hta l nntl qcr7 sa tl SPACI 786.02 SPAC26F1,08c
amt2 dakl hta2 nop 12 qcr8 sce3 SPACI 7A2.05 SPAC26H5.03
an d dbp2 h tb l nrdl rad26 scrl SPAC 17A 2.12 SPAC26H5.04
apel dbp3 hxk2 ofd l rad8 scwl SPACI 7AS.05c SPAC26H5.09c
app l d fp l idh l ogml ran i sdh2 SPACI 7AS.09c SPAC27D7.1 Ic
apsl d id id p l orc4 ravl sdh4 SPAC 17AS. 10 SPAC27E2.04c
ap t1 d ld l ip k l p23fy red1 sebl SPACI 7G6.I Ic SPAC2 7E2.11 c
arc1 drsl isp4 pac2 recIO sec 10 SPACI 7G6.18 SPAC27E2.I3
arc 15 eco39 isp6 pap l rep2 sec26 SPACI 7G8.07 SPAC27FI.07
arg l2 e f la < isp7 pasl rest sec3l SPACI7G8.08c SPAC29A4.03c
arg5 efc25 isul pchl rga3 sec62 SPAC I7H 9.il SPAC29A4.09
arol egd2 its3 pexl3 rga7 sec74 SPACI 7H9.12c SPAC29812.05c
arp9 e lfl iwsl pgkl rg fi senl SPAC 1805.16c SPAC2C4.17c
a tfl e lll ka p l2 3 php2 rhp23 setl SPACI8G6.09c SPAC2EIP3.04"
a tll engl klp2 phxl rpa2 set8 SPAC 19812.02c SPAC2EIP3.05c
atp2 eno101 kspl pka l rpbl s fil SPACI 9GI 2.05 SPAC2F3.09
aurl erg! Ieu2 p la l rpb9 sfp l SPACI 9GI 2.09 SPAC2F3.I0
bem46 erg 12 Ieu3 p lb l rp d sgol SPAC I9 G 12.16c SPAC2F7,02c
b frl erg7 Ikh l p lr l rpc40 sgtl SPACIA6.I0 SPAC2F7,05c
bgl2 esc/ Iskl pm al rpc53 shk2 SPACI 83.02c SPAC30.l0c
bgsl esf2 lysl pmo2 rpllOO l sid2 SPACI 83.04c SPAC30.II
bgs2 exgl tys3 pm p3l rp llO I sir2 SPACI FI 2.03c SPAC30.I3
bgs3 fba l Iys4 pmt3 rp ll 101 sks2 SPACI FI 2.04c SPAC30.l4c
b ip l fep l m a d p o fl4 rp ll5 slp l SPACIF5.02 SPAC30DI1.14c
b irl fkh l mad3 pof4 rp ll 603 slu7 SPACI F7.09c SPAC3 IA2.04c
bpbl fma2 mae2 pofB rp l2 IO I smbl SPACI F8.07c SPAC3IG5.04
b rfl fm n l m a fl po ll rpl24 snf30 SPACI F8.08 SPAC3IG5.05c
btf3 for3 m agi pop3 rpl26 SPAC 1002.18 SPAC20G8.07c SPAC3 IG 5 .I5
but2 fur4 mal3 p p il rpl302 SPAC1002.20 SPAC2IEI 1.07 SPAC3IG5.2I
cbhl got! mam3 p pk l rpl3 703 SPACI 006.07 SPAC222.13c SPAC328.04
ccsl g & l m bxl p p k l 1 rp l401 SPAC1039.02 SPAC22 7.17c SPAC3AI 1.07
cctl ght2 mcp60 ppk32 rpl402 SPAC 1093.02 SPAC22AI 2.06c SPAC3 A 12.06c
cdal ' ght8 mcs4 ppk4 rp l430 l SPACI 093.03 SPAC22AI2.I6 SPAC3AI2.I9
cdcl 7 gln l mde3 p r ll 2 rpl4302 SPAC 10F6.03c SPAC22F8.08 SPAC3F 10.03
cdcl8 gpd l mde 7 p r ll3 rpl502 SPACI0F6.04 SPAC23AI.02c SPAC3H1.05
cdc22 gpd2 met26 prl32 rpp203 SPACI 0F6.07c ■ SPAC23AI.I4c SPAC3H1,06c
cdc25 gpm l m eu l4 prl39 rps002 SPACI 142.06 SPAC23AI. 17 SPAC3HI.07
cdc48 gP& m eu l5 prl42 rpsl 01 SPACI ID 3 .13 SPAC23CI 1.01 SPAC3H 1.08c
cdc5 gsal m fm l prlS2 rps 1401 SPACI ID3.14c SPAC23CI 1.03 SPAC4C5.05c
cdr2 gst2 mfm3 prl53 rpsl 502 SPACI IE3.13c SPAC23CI 1.05 SPAC4FI0.1 Oc
cekl hal4 mgr2 p rp l rps220l SPACI IG7.01 SPAC23D3.I2 SPAC52I.03 .
cfh4 h h fl mid2 prp22 rps23 SPACI 250.07 SPAC23H3.09c SPACS21.04c
de l hhf2 mis4 p rr l rps260l SPACI 2BI 0.18 SPAC23H3.11 c SPAC56E4.03
cnxl hhf3 mlo3 psil rps3002 SPACI 3F5.05 SPAC23H3.12c SPAC56F8.03
cox 17 hh tl m m fl psul rps403 SPACI 3G6.05c SPAC24811.07c SPAC56F8.12
SPAC57A7.02c SPBC 119.10 SPBC21 C3.08c SPBC609.03 SPCCI 442.12 SPCC736.I5 tp il
SPAC57A7.04c SPBCI 198.06c SPBC2I H7.06c SPBC646.15c SPCCI 442 .13c SPCC757.I2 tp p l
SPAC57A7.0S SPBCI IB I0 .03 SPBC23G7.07c SPBC646.I6 SPCCI 442 .16c SPCC794.I5 tp r l
SPAC5H 10.03 SPBCI IB I0 .04c SPBC24C6.04 SPBC660.06 SPCCI 450.09c SPCC830.I0 tpsl
SPAC5H 10.04 SPBCI 1 C l 1.05 SPBC25B2.03 SPBC660.I0 SPCCI 62.01c SPCC962.05 tp x l
SPAC5HIO.I2c SPBCI 1 C l 1.06c SPBC25H2.06c SPBC6BI.I2c SPCCI 62.02c SPCC965.I3 trm l
SPAC630.08c SPBCI 1 C l 1.10 SPBC27.05 SPBC713.06 SPCCI 672.01 SPCC970.06 trx l
SPAC630.IS SPBCI IG I 1.01 SPBC27BI2.l2c SPBC713.07c SPCCI 6C4.02c SPCC970.08 trx2
SPAC637.06 S P BC I27I.I3 SPBC29A 10.08 SPBC7I3.I3c SPCCI 739.10 SPCP3IBI0.06 tub l
SPAC683.02c SPBCI 271.14 SPBC29A3.09c SPBC725.I0 SPCCI 795.10c SPCPBICI 1.03 ubcl 4
SPAC694.02 ' SPBC1289.06c SPBC29A3.I9 . SPBC83.I7 SPCCI 8.02 SPCPBICI 1.04c ubc8
SPAC6C3.02c SPBCI 2C2.03c SPBC29A3.2I SPBC839.I6 SPCCI 8.03 SPCTRNASER.07 ub il
SPAC6C3.08 SPBCI 347.11 SPBC29B5.04c SPBC887.l5c SPCCI 8 .17c spf30 ubi3
SPAC6C3.09 SPBCI 34 7 .13c SPBC2A9.04c SPBC8D2.15 SPCCI 840.07c SPNCRNA .103 ubrl
SPAC6F 12.04 SPBC1347.14c SPBC2D 10.04 SPBC8D2.16c SPCCI 88.10c SPNCRNA.I08 ubx2
SPAC6G 10.03c SPBCI3A2.02 SPBC2F 12.02c SPBC8D2.18c SPCCI 906.05 SPNCRNA.il 4 ucp6
SPAC6GI0.07 SPBCI3A2.04c SPBC2F 12.03c SPBC8E4.0lc SPCCI 91.05c SPNCRNA. 120 ural
SPAC6GI0.09 SPBCI 3E7.03c SPBC2G5.05 SPBC8E4.02c SPCC297.05 SPNCRNA. 122 ura3
SPAC6GIO.IOc SPBC I3G  1.09 SPBC30B4.02c SPBC947.0I SPCC297.06c SPNCRNA. 133 ura4
SPAC6G9.03c SPBCI4C8.02 SPBC30B4.03c SPBPI6F5.08c SPCC306.08c SPNCRNA. 129 urgl
SPAC6G9.I4 SPBCI4C8.04 SPBC30B4.I0 SPBPI8G5.02 SPCC306.11 SPNCRNA.80 usplO I
SPAC7D4.08 SPBCI4F5.IOc SPBC30D10.17c SPBPI8G5.03 SPCC320.06 SPNCRNA.90 vhtl
SPAC7D4.12c SPBCI 4F5.1 Ic SPBC3IA8.0lc SPBP23A 10.09 SPCC330.06c SPNCRNA.92 vip l
SPAC806.02c SPBCI 539.07c SPBC32F 12.07c SPBP23AI0.I Ic SPCC4I7.I5 SPNCRNA.93 vphl
SPAC824.04 SPBCI5D4.02 SPBC32F12.10 SPBP23A 10.12 SPCC4B3.02c SPNCRNA.99 vps24
SPAC8C9.04 SPBCISD4.05 SPBC32FI2.l2c SPBP35G2.02 SPCC4B3.07 spot 5 vps35
SPAC8E ll .0 9 c SPBCI 5D4.08c SPBC32F 12.13c SPBP35G2.I4 SPCC4B3.08 spp42 vps5
SPAC8EI 1.10 SPBCI 5D4.09c SPBC32FI2.I5 SPBP4H 10.14c SPCC4FI 1.03c sre2 vps902
SPAC9.07c SPBCI 685.13 SPBC336.11 SPBP4H 10.15 SPCC4G3.0I srpl vrp l
SPAC9.08c SPBCI 6A3.02c SPBC337.02c SPBP8B7.15c SPCC4G3.13c ssal weel
SPAC959.04c SPBCI 6A3.19 SPBC337.07c SPBP8B7.17c SPCC4G3.I4 sso2 wisl
SPAC959.06c SPBCI 6C6.04 SPBC36.02c SPBPB2B2.0S SPCC4G3.I6 sscl wis2
SPAC977.l3c SPBCI 6C6.05 SPBC365.04c SPBPB2B2.06c SPCC4G3.17 ssn6 wos2
SPAC977.l4c SPBC I6 D  10.08c SPBC365.16 SPBPB7E8.0I SPCC550.07 sspl wscl
SPAC9E9.0I SPBCI 6E9.16c SPBC3B8.03 SPBPB7E8.02 SPCC550.08 ssr2 wspl
SPAC9E9.05 SPBCI 703.13c SPBC3B8.09 SPBPB7E8.03 SPCC550.09 ssr4 yak3
SPAC9E9.06c SPBC1711.04 SPBC3B9.0I SPBPJ4664.02 SPCC550.11 ste l 1 yam8
SPAC9E9.09c SPBCI 711.05 SPBC3D6.01 SPBTRNAHIS.02 SPCC550.I4 ste20 ybtl
SPAG9G I.IOc SPBCI 711.08 SPBC3D6.16 SPBTRNAPRO.06 SPCC553.10 stil ypt2
SPACUNK4.I0 SPBCI 7 11.09c SPBC3E7.1 Ic SPCCI 020.08 SPCC553.l2c sts5 zfs l
SPACUNK4.IS SPBCI 711.12 SPBC3H7.02 SPCCI020.09 SPCC576.04 sual z ip 1
SPACUNK4.16c SPBC 1734.04 SPBC3H7.03c SPCCI 183.07 SPCC576.0S suc22
SPAPI1 E l 0.01 SPBCI 734.11 SPBC4.03c SPCCI 259.02c SPCC576.12c sum3
SPAPBI 5E9.02c SPBCI8E5.07 SPBC428.11 SPCCI 259.08 SPCC576.13 sup45
SPAPBI7E 12.06 SPBCI9C2.08 SPBC428.12c SPCCI 26.07c SPCC584.0lc ta ll
SPAPBI8E9.06c SPBCI 9C7.04c SPBC428.I4 SPCCI 26.08c SPCC594.0I tas3
SPAPBIAIO.OS SPBCI 9F5.04 SPBC428.I5 SPCCI 2 8 1.03c SPCC594.02c tb p l
SPAPBIA 10.06c SPBCI 9G7.04 SPBC4C3.0I SPCCI 2 8 1.06c SPCC5E4.05c tcgl
SPAPBIAI0.08 SPBCI 9G7.07c SPBC4C3.03 SPCCI 322.02 SPCC5E4.05c tdh l
SPAPBI A 10.14 SPBCI 9G7.17 SPBC4F6.17c SPCCI 322.03 SPCC5E4.1 Oc tef3
SPAPBI A 10. IS SPBCIA4.04 SPBC530.0I SPCCI 322.04 SPCC622.12c tif224
SPAPBI E7.04c SPBCIA4.05 SPBC530.02 SPCCI 322.05c SPCC63.IOc t if5 l2
SPAPBI E7.07 SPBCIA4.09 SPBC530.08 SPCCI 322.10 SPCC63.I4 tim40
SPAPB24D3.03 SPBCIE8.05 SPBC56F2.08c SPCCI 322.16 SPCC645.09 tnr3
SPAPB2B4.04c SPBC2I5.I3 SPBC56F2.12 SPCCI 393.02c SPCC645.I0 tom40
SPBCI 19.05c SPBC21 C3.07c SPBC577.il SPCCI 393.08 SPCC70.I0 top2
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SpEAF enriched genes (identified as described in section 4.5.1)
aar2 e lfl mis 16 rp d  1 SPACI 1 £ 3 .13c SPAC2F7.05c SP8CI347.l3c
abp2 engl mlo3 rpc40 SPACI 2 8 ! 0.18 SPAC30.l0c SP8CI347.l4c
oce2 eno101 m ok l2 rpc53 SPACI 3G6.IOc SPAC30.II SP8CI3A2.04c
actl erg 12 m rp ll 6 rp llO I SPACI 3G 6.13 SPAC3IG5.I5 SP8CI5D4.05
adgl esd mugS r p ll lO I SPAC 144.01 SPAC31 G5.21 SP8CI604.06c
adg3 exgl nep2 rp llS SPAC 144.12 SPAC3HI.07 SP8CI685.I3
adhl fasl n ifl rpl24 SPAC 144.18 SPAC3H 1.08c SP8CI6D 10.08c
agnl fba l nntl rpl26 SPAC1556.08c SPAC4C5.03 SP8CI711.04
agsl fep l npp l06 rpl3202 SPAC1565.07c SPAC4FI0.1 Oc SP8CI711.05
a lg l2 m n rfl rp l40 l SPACI 635.01 SPAC4F 10.21 SP8CI711.08
alg2 fma2 nsel rpl402 SPACI 705.02 SPAC4F8.06 SP8CI7 11.09c
alg3 fta5 nup l0 7 rpp202 SPACI 705.03c SPAC4H3.09 SP 8C I734 .il
alp 16 gar2 om al rpp203 SPACI 782.05 SPAC589.09 SP8CI9C2.08
an d gcvl P23fy rps002 SPACI 782.06c SPAC589.1 Oc SP8CI9C7.04c
apel ght2 pac2 rpslO I SPACI 786.02 SPAC5H 10.03 SP8CI9G7.04
app l ght8 pap l rps 102 SPACI 7A2.15 SPAC5H 10.04 SP8CI9G7.I7
apsl g lnl pchl rps 1201 SPACI 8G6.13 SPAC664.12c SP8C2 IC3.07c
arol gpdl pex l3 rps 1401 SPAC 19812.02c SPAC6C3.02c SP8C21 C3.08c
arp9 gpm l pex7 rps 1402 SPACI9G 12.05 SPAC6FI2.04 SP8C23G7.11
atp2 g p ti p fk l rps 1502 SPAC I9 G 12.16c SPAC6GIO.IOc SP8C23G7.I4
b frl hh fl PgH rps220l SPAC 183.02c SPAC6G9.08 SP8C2582.08
bgl2 hhf2 pgkl rps23 SPAC 183.04c SPAC7D4.08 SP8C25H2.04c
bgs3 hhf3 phol rps260l SPACI FI 2.03c SPAC806.02c SP8C27.05
bgs4 hhtl pka l rps3002 SPACI FI 2.04c SPAC806.11 SP8C27812.12c
bipl hht2 p lb l rps402 SPACI F5.02 SPAC82I.05 SP8C29A 10.08
bosl hht3 Plg7 rps403 SPACI F8.07c SPAC824.04 SP8C2985.04c
but2 his3 p lrl rps60l SPACIF8.08 SPAC8EI1.10 SP8C2G5.05
cbhl hmt2 pm al rps7 SPAC222.08c SPAC9.07c SP8C3084.02c
cdc22 hspIO p o fl4 rps80l SPAC222.13c SPAC9.08c SP8C3084.03c
cdc48 hsp90 PPH rpt6 SPAC227.17c SPAC922.04 SP8C32F 12.07c
cfh4 hsrl p pk l r rp l 6 SPAC22A12.16 SPAC926.05c SP8C32FI2.I0
c hsl hst4 prIOl rsd l SPAC22F8.08 SPAC959.04c SP8C32FI2.l2c
cnxl h ta l prl03 saml SPAC22F8.08 SPAC959.05c SP8C32FI2.I5
cox 17 hta2 p r ll 2 sapl SPAC22H/ 2.05c SPAC959.06c SP8C32H8.08c
csn2 h tb l prl32 scwl SPAC23A 1.02c SPAC977.l4c SP8C359.03c
csn4 hxk2 prl39 sdh2 SPAC23AI.09 SPAC9E9.0I SP8C36.03c
csxl ip k l prl42 sebl SPAC23CI 1.01 SPAC9E9.09c SP8C36S.I6
ar4 isul prlS3 sec26 SPAC23CI 1.03 SPACUNK4.15 SP8C388.03
ctr5 iwsl prl63 sec3l SPAC23D3.I2 SPACUNK4.16c SP8C389.0I
cut! 1 kap 109 p rp l2 sec62 SPAC23H3.09c SPAP8I SE9.02c SP8C3D6.0I
cut2 ka p l2 3 psil sent SPAC24811.07c SPAP8l8E9.06c SP8C3E7.I Ic
cwf28 Ieu2 pssl set8 SPAC24811.13 SPAP8IAI0.05 SP8C3E7.I3C
cwf7 lysl psul s fil SPAC24H6.I3 SPAP8IA 10.06c SP8C3H7.02
cyrl Iys3 psyl s fp l SPAC2588.11 SPAP8IAI0.I4 SP8C409.08
cys2 Iys4 ptc2 sgtl SPAC2588.12c SPAP8 IA I0 .I5 SP8C428.11
dbp2 m a d pvgl sir2 SPAC26A3.17c SPAP8I E7.04c SP8C4F6.17c
d fp l m ael pvg3 sks2 SPAC26FI.05 SPAP8IE7.07 SP8C530.08
d id mae2 pykl s lp l SPAC26FI.07 SP8CI 19.10 SP8C56F2.08c
dldl m afl pypi sm bl SPAC26F 1.08c SP8CI 198.06c SP8C56F2.I2
dpm2 mal3 rad26 snzl SPAC27E2.04c SP8CIIC I 1.05 SP8C646.I5C
eafl mcp60 rad8 sodl SPAC2 7E2.11 c SP8CI1 C l 1.06c SP8C646.I6
eca39 mde3 ravl SPAC1002.20 SPAC27E2.I3 S P 8C I27 I.I3 SP8C7I3.09
e fl a-b mep33 red! SPACI 006.07 SPAC27FI.07 S P 8C I27 I.I4 SP8C83.I7
efla-c met26 r id SPACI0F6.07c SPAC29812.05c SP8CI289.06c SP8C839.I6
efc25 mgr2 rpb9 SPACI 142.06 SPAC2C4.17c SP8CI 2C2.03c SP8C887.I5C
egd2 mid2 rp d SPACI ID 3 .13 SPAC2F3.09 S P 8C I347 .il SP8C8D2.I8C
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SPBC8E4.0lc SPCCI 322.10 SPCC550.14 SPNCRNA.I22 s trl t rx l
SPSC8E4.02c SPCCI 322.16 SPCC553.I0 SPNCRNA. 129 sual tub l
SPBP23AI0.I Ic SPCCI 393.02c SPCC553.11 c SPNCRNA. 133 suc22 ubil
SPBP4H10.15 SPCCI393.08 SPCC576.04 SPNCRNA 134 sum3 ubi3
SPBP8B7.17c SPCCI672.0I SPCC576.l2c SPNCRNA. 136 sup45 ubx2
SPBPB2B2.04 SPCCI 682.15 SPCC594.02c SPNCRNA.80 sxal ura l
SPBPB2B2.05 SPCCI 795.10c SPCC622.1 Oc SPNCRNA.90 tbp l ura4
SPBPB7E8.0I SPCCI 8.02 SPCC645.08c SPNCRNA.92 tdh l vhtl
SPBPB7E8.03 SPCCI 906.05 SPCC645.I3 SPNCRNA.99 tef3 vi p i
SPBTRNAHIS.02 SPCC24BI0.22 SPCC70.I0 spp42 tifS I vps24
SPCCI 223.13 SPCC297.0S SPCC736.I5 sre2 tnr3 vps901
SPCCI 259.08 SPCC297.06c SPCC757.I2 ssal tom40 wis2
SPCCI 2 8 1.06c SPCC306.il SPCPBICI 1.03 ssa2 tp il wos2
SPCCI 322.02 SPCC330.06c . SPCTRNAASN.06 sscl tp p l wscl
SPCCI 322.03 SPCC417.15 SPCTRNAILE09 ssn6 tpsl yb tl
SPCCI322.04 SPCC4G3.I6 SPNCRNA.I03 ste20 tp x l ypt2
SPCCI 322.05c SPCC4G3.17 SPNCRNA. 117 stil trm l
(SpELL OR SpEAF enriched genes) n (genes with altered RNA levels 
in el/1 A OR eaflA arrays)
These are the first 16 genes depicted in Figure 4-8 (in order from left to  right on 
the figure)
abp2
ace2
engl
adg3
adgl
agn1
mid2
SPAC2E1 P3.05C
phol
pex7
SPBPB7E8.01 
SPBC8E4.01c 
SPAC1039.02 
gpdl
SPBPB7E8.02
strl
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Appendix D: Sequence of the eaf1 mRNA 
(characterised by RACE and submitted to genbank)
S. pombe EAF (eaf7) mRNA, g ill 22934794I gbIEFI 92607.11
ACTTTTAC CATTATAAAC AA T CAT G AATT C ATTAC AG AAG G G AT CAT AC AA 
AG TT ATT CCCGGGT CCAGCTT CT CAAAG AATT CAAATGG ACTTTTAT CTATTAAA 
T AC AATTTTAT ACCAG AAAG T GTG G ACCCTT CTCGT CG AG GT GTTTT AG AAAAG 
GCTCAGGAAGCCTATCGTCTACGTCTTCCTTCAACTTTTGATGATGACAGGCCT 
CATATATTTGAAGGCTCATGCCAACGAGCCAGGAATGTGGACTGTGTACTAATT 
TTT AACG CT AAAAC AAAG AC ATT C AC ACT G G AG CATATT GAT GAG ATT G CTCG A 
TTAAATGCTTTACG CAATCCAAAAG TCTCTAAAACTGTACCTTCTAATG CCATCA 
CT CAAT CT GAT AATT CCCAAAT CT CT G AAT CCAAAT CG AC CT CT CAAAGTGCGG 
T CACG ACT AATT CCACG AG ACGT AAAG AAAGG AATTGG AAGCTT CAAAGG AT G 
G AAAAATAAAACCTTCATCGAGCAATACTCGATATCCTGCCATATCTAGCAAGG 
G AC CAATCACCACCG ATACCAACGATGAGCCTG ACATGG AGGTCATGGAGTTG 
GATGACTTTGCCAAAGAGTTAGAGCTAGGATTTGATCAGGAATTTAATTCCATA 
GACGACCCCT CTACAGTAT CCCAAACGGCCAGC AAAC CAAT CT CTTT G AGGGG 
T CT AT CTT CG C AAG AG AG G GATTATG CTT CTT CT G CT C AG G C AG AG G G TAT C AG 
CAGCGCTTCCGAGGATGAGGATTAAGTATGCTTTATGCTGTGTTTCGTATACAC 
TTT CC AAACACG AT AAT G AG AAAAT CT GTT AAT G AACG ACTT G CAACG AAATT C 
C AG G G AGTAAAGTAAAG C AAG ACAAGTCTTTT CCAT C AC T AC T CG AC AG CG AA 
TCGGCGGTAATAAACTCGTTTCACTCTGTGTCATTTTTTTAATTATATACGAACG 
TGTCT ACG CC AAG G G AAAAAC A T AT A T  CGTTTT AAAAT GTTTT CAT CTTTTT ATA 
TTT CTTTTTATT ATT ATT AATT CAT AAT G ACT ATAAAAAACAT G G CTT GT CTT AAA 
AAAAAAAAAAAAAAAAAAAA
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